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ABSTRACT 
 
Despite the decreased rate of HBV horizontal transmission in South Africa (SA) due to the 
HB vaccine, the risk of perinatal transmission remains of concern, especially in HIV/HBV 
co-infected women. Loss of HBV immune control, resulting in higher HBV replication and 
thus increasing the risk of transmission is described in HIV/HBV co-infected women. 
Chronic hepatitis is a well-recognized risk factor for hepatocellular carcinoma (HCC). The 
presence of specific HBV mutations has been reported in chronic and HCC patients and is 
used in algorithms for the prediction of HCC in CHB patients in Asia. While these mutations 
are extensively described in male patients, little is known regarding the antenatal and 
paediatric populations. This study aimed to determine the prevalence of HBV infection in 
HIV-exposed infants and to investigate the presence of HCC-related mutations in pregnant 
women and HIV-exposed children in SA. 
Residual samples of infants born to HIV-infected mothers were collected from the P1041 
study previously conducted in SA. HBV markers (HBsAg, anti-HBs and anti-HBc) were 
tested on the Architect (Abbott). HBsAg positive samples were tested for HBV DNA to 
determine HBV viral loads. HBV strains were characterised by sequencing of the HBsAg 
gene and genotypes were determined by phylogenetic analysis using HepSEQ 
(www.hepseq.org.uk). For the HCC-related mutations investigation, samples and data were 
collected from three HBV-related studies: the NHLS Paediatric Study, an Antenatal Study 
and the current study. Pre-S, basal core promoter (BCP) and pre-core data was collected from 
all samples. Multiple alignments were formed and the nucleotide sequences of these extracts 
were translated into protein sequences. These protein sequences were compared manually to 
the HBV reference genes to identify HCC-related mutations. 
Of 850 HIV-exposed infants tested, three infants were positive for both HBsAg and HBV 
DNA. Two samples show evidence of past, but cleared HBV infection. Sequence analysis 
showed that the infants were infected with a subgenotype A1. At follow up, only one infant 
and mother were able to be traced and contacted. The infant was HIV-infected and had been 
on an ART regimen, including lamivudine for two years. HBV testing showed that the infant 
was HBsAg positive and had an undetectable viral load. Core sequence analysis showed 
clustering between mother and infant sequences. Transmission of mutant HBV previously 
associated with HCC prompted the question of what the prevalence of mutations in the 
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antenatal and paediatric population is. In this investigation of HCC-related mutations study, a 
higher prevalence of combined pre-S, BCP and pre-core mutations was found in HIV-
infected as compared to HIV-uninfected women.  
This study shows that vertical transmission is occurring in HIV-exposed infants in SA despite 
HB vaccination. Data described in this study suggests the importance of HB vaccination 
closer to the time of birth in SA. Moreover, data on the higher prevalence of HCC-related 
mutations in HIV-infected pregnant women provide a background for further longitudinal 
studies to confirm these findings and their implications in SA. 
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OPSOMMING 
 
As gevolg van die beskikbaarheid van die Hepatitis B virus (HBV) entstof , het horisontale 
transmissie van die virus drasties in Suid-Afrika (SA) verminder. Ten spyte hiervan, is daar 
steeds ‘n hoë risiko van perinatale transmissie van swanger vroue na hulle babas, dit word 
veral gesien met MIV/HBV positiewe vroue. Dit is wyd beskryf dat vroue wat mede-besmet 
is met MIV/HBV gewoonlik beheer verloor oor hulle immuunstelsel, wat lei tot ‘n hoër mate 
van HBV replikasie en dus ‘n hoër risiko van virus oordrag. Kroniese hepatitis is wel bekend 
as ‘n hoë risiko faktor vir HCC. Die teenwoordigheid van spesifieke HBV mutasies in 
kroniese en HCC pasiënte word alreeds in Asië gebruik in sekere algoritmes en formules om 
infeksie aan te dui en te voorspel. Hierdie mutasies is omvattend  beskryf in manlike pasiënte, 
maar baie min is bekend in voorgeboorte en pediatriese gevalle. In hierdie studie het ons die 
teenwoordigheid van HCC-verwante mutasies in swanger vroue en MIV-blootgestelde 
kinders in Suid-Afrika ondersoek. 
 
Monsters is verkry van babas gebore van MIV-positiewe moeders van die P1041 studie wat 
voorheen in SA gedoen is. Die HBV merkers (HbsAg, teen-HBs en teen-HBc) was op die 
Architect (Abbott) getoets. HBsAg positiewe monsters was getoets vir HBV DNA om die 
virale lading te bepaal. Die verskeidenheid HBV stamme was gekarakteriseer deur die virus 
se nukleïensuur volgordes te bepaal. Die verskillende genotipes is bepaal deur filogenetiese 
analises te doen met behulp van die HepSEQ (www.hepseq.org.uk) program. Vir die HCC-
verwante mutasie studie is monsters en data vergelyk met 3 HBV-verwante studies: die 
NHLS pediatriese studie, ‘n voorgeboorte studie en hierdie spesifieke studie. Voor-S, basale 
kern promoter en voor-kern data was van alle monsters bekom. ‘n Veelvoudige belyning was 
gedoen met die nukleïensuur volgordes van die verskeie DNA ekstrakte, wat daarna vertaal is 
in proteïen volgordes. Hierdie proteïenvolgordes translasie was by hand vergelyk met 
verwysings gene om die relatiewe HCC mutasies te probeer identifiseer. 
 
Van die 850 blootgestelde MIV babas wat getoets is, het 3 positief getoets vir beide HbsAg 
en HBV DNA. Twee monsters het bewys van verlede , maar vrygestelde HBV infeksie. Data 
analise bewys dat die babas met subtipe A1 besmet was. Ons kon slegs een moeder en baba 
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paar opvolg en kontak vir verdere toetse. Die baba was MIV-positief en was op 
antiretrovirale behandeling , insluitend lamivudine, vir ten minste 2 jaar. HBV toetse het 
gewys dat die baba HbsAg positief is en ‘n onopspoorbare virale lading gehad het. Kern 
nukleïensuur volgorde analise het groepering getoon tussen  die ma en baba se virus monsters 
. Die transmissie van die mutante HBV wat geassosieer is met HCC het gelei tot die vraag 
wat die voorkomssyfer is van hierdie spesifieke mutasies in die voorgeboorte en pediatriese 
populasies in SA. In hierdie studie het ons ‘n hoër gekombineerde voorkomssyfer gevind van 
die voor-S, basale kern promoter en voor-kern mutasies in MIV-positiewe vroue, in 
vergelyking met MIV-negatiewe vroue. 
 
Hierdie studie bewys dus dat vertikale transmissie van HBV in blootgestelde MIV babas 
steeds plaasvind, ten spyte van HBV inenting. Die data wat in hierdie studie beskryf was dui 
daarop dat die belangrikheid van HBV inenting nader aan die tyd van die geboorte in SA 
gegee moet word.As gevolg van die hoë voorkomssyfer van HCC-verwante mutasies in 
swanger vroue, is daar verdere longitudinale studies nodig om hierdie bevindinge en hul 
implikasies in SA te bevestig.  
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CHAPTER 1: INTRODUCTION 
 
Hepatitis B virus (HBV) infection is a major global public health problem and remains one of 
the most important causes of cirrhosis and hepatocellular carcinoma (HCC) internationally. 
HBV-related HCC accounts for approximately 55% of global HCC cases and around 80% of 
Sub-Saharan Africa cases (SSA) (Kew, 2010). According to the World Health Organisation 
(WHO), the virus is responsible for around 2 billion infections worldwide with 250 million 
chronic carriers, despite the availability of a safe and effective vaccine for more than 20 years 
(Bertoletti & Gehring, 2013).  The prevalence of chronic hepatitis B (CHB) varies from 
regions: a low rate (0.1 – 2%) in the USA and Western Europe, an intermediate rate (2 – 8%) 
in Mediterranean countries and Japan and a high rate (8 – 20%) in Southeast Asia and SSA 
regions where infections are the most common (Liaw & Chu, 2009). HBV-infected children 
are most at risk to develop CHB, putting them at high risk of developing the complications of 
chronic infection. 
 
Rationale of the study 
Prior the implementation of the Hepatitis B (HB) vaccine in South Africa (SA) in 1995, 
studies had reported high prevalence of Hepatitis B surface (HBs) antigenemia in the 
population, with a rate ranging from 1% to 20% in children of a young age. One study from 
the early 70s reported a 54% (34/63) hepatitis B surface antigen (HBsAg) prevalence among 
children of 14 years old or younger and a 65% (55/84) prevalence among adults aged 
between 15 and 70 years old (Kew et al., 1974). Prozesky et al. compared different age 
groups when describing the epidemiology of HBV in children. They found the highest 
prevalence of HBsAg among 3 to 5 years old children (10/85(11.8%)) and the lowest 
prevalence in aged less than 6 months old (1/103 (1%)) (Prozesky et al., 1983). In 1988, 
Abdool Karim et al. reported 51 infants less than a year old who tested negative for HBsAg, 
but 136 infants aged less than two years old had an HBsAg seroprevalence of 1.5% and 
HBeAg prevalence of 0.7% (Abdool Karim et al., 1988). These studies showed that the 
highest rate of HBV infection was found among children older than a year, indicating that 
horizontal transmission was the major mode of HBV transmission. These observations 
provided a background for the implementation of the HB vaccine in the local Expanded 
Programme on Immunization (EPI) in 1995. The first dose of the vaccine is delivered at six 
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weeks of age rather than within the 24-hours of birth as is recommended by the WHO. 
Although the rate of mono-infection decreased, an increased rate of infection in HIV-infected 
individuals varying from regions was observed (National Department of Health, 2009). 
HIV/HBV co-infection is associated with higher HBV viral loads, which increases the risk of 
HBV mother to child transmission (MTCT) (Burnett et al., 2005). Paganelli et al. explained 
that HIV could induce immune suppression in HIV/HBV co-infected patients, resulting in a 
delay in the seroconversion to anti-HBe, reactivation of HBe antigenemia and seroreversion 
to HBsAg positivity (Paganelli, Stephenne & Sokal, 2012). The prevalence of HBV 
carriage in HIV infected individuals in SA was reported to range between 3% and 22% in 
adults (Mphahlele et al., 2006; Firnhaber et al., 2008; Hoffmann et al., 2008; Lukhwareni 
et al., 2009). However, little is known regarding the prevalence of HBV in children in the 
HIV era. This study will thus be reporting on the epidemiology of HBV among HIV-exposed 
children.  
The Mother to Child Transmission Prevention program (PMTCT) guidelines recommended a 
routine HIV testing for all pregnant women with an unknown HIV status and a CD4 count 
test if found HIV positive. At the time of recruitment for this study, women with CD4 counts 
less or equal to 200cells/mm
3
 were started immediately on antiretroviral therapy (ART) 
including stavudine (d4T), lamivudine (3TC) and nevirapine (NVP) (National Department 
of Health, 2008). Antenatal screening for HBV is not routinely practiced. Whilst Burnett et 
al. reported HBsAg prevalence rates of 7.4% to 8.3% in pregnant women in Limpopo 
Province, SA (Burnett et al., 2005), recent data from an antenatal Western Province cohort 
showed an HBsAg prevalence of 2.9% to 3.4% (Andersson et al., 2013). Epidemiological 
data showed that approximately 30% of women attending antenatal clinics are now living 
with HIV (National Department of Health, 2009) hence with a high risk of perinatal 
transmission. 3TC is active against both the reverse transcriptase (RT) enzyme of HIV and of 
HBV. However, prolonged used of the drug causes a high rate of HBV antiviral resistance 
(Yuen et al., 2009). Due to the compact organisation of HBV, mutations selected in the 
presence of 3TC which arise in the viral polymerase (pol gene) will alter the overlapping 
surface (HBsAg) gene and this, in the face of a failing immune system, may lead to the 
selection of mutated viruses potentially resistant to both vaccine and nucleoside antiviral 
drugs (Toressi, 2002). It remains unknown whether the potentially increased infectivity of 
maternal HBV due to HIV could result in perinatal transmission and whether the transmitted 
viruses are wild type or drug driven/immune escape mutant viruses. This study has 
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investigated whether either antenatal screening for HBV or an alteration of immunization 
schedules are now needed to prevent perinatal transmission and whether the nature of any 
transmitted viruses is such that they may escape from vaccine control because of the altered 
HBsAg antigenicity.  
The introduction of ART has brought about a decreased mortality and morbidity rate in the 
HIV-infected population globally. However, an increase in liver-related diseases mortality 
and morbidity is observed in HIV/HBV co-infected individuals. These individuals present 
with increased liver fibrosis brought about by hepatic flares caused by the increased levels of 
HBV replication (Puoti et al., 2006). The latter is recognized as an increasing risk factor for 
HCC (Dwevedi et al., 2011). Furthermore, specific HBV mutations such as basal core 
promoter (BCP), pre-core and pre-S mutations, are well recognized as risk factors for HCC in 
Asia thus the suggestion that the detection of these mutations may help in the early 
identification of HBV chronic patients at high risk of developing liver malignancy (Chen et 
al., 2008). These mutations have been previously described in both chronically infected HBV 
and HCC patients in SA (Baptista et al., 1999; Mayaphi et al., 2013). An epidemiology 
study on antenatal women in the Western Cape Province revealed a high presence of some of 
these HCC-related mutations, among HIV-infected as compared to HIV-uninfected women 
(Andersson et al., 2013). This suggested that HIV could be an important risk factor in the 
development of these HBV mutations. Considering the risk of peripartum HBV transmission 
in HIV co-infected women, we were wondering if these mutations are transmitted to HIV-
exposed children. Additionally, given the association of these mutations to HCC, it would be 
important to assess if they could be used as markers of prediction of HCC development in 
HBV-infected children and pregnant women. 
Chapter 2 describes the organization of the HB viral genome and its diversity. A detailed 
report on the epidemiology of HBV infection, HIV/HBV co-infection and HBV-related HCC 
in SA are also presented. 
Chapter 3 describes the prevalence of HBV in a large cohort of HIV-exposed infants. The 
reasons for doing the study included (1) the scarcity of studies on HBV in HIV-exposed and 
infected children, (2) the high prevalence of HBV in HIV-infected women with loss of HBV 
immune control, (3) the drug-resistance caused by 3TC in HIV-infected individuals raised the 
importance of describing the epidemiology of HBV infection in children born of HIV-
infected mothers. The primary aim was to describe infant HBV epidemiology and to 
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investigate the mode of transmission of HBV in SA in the era of HIV. In this chapter, the 
sample population and the methodology used to answer our research question are elaborated 
on. Results on the prevalence of HBV infection in our cohort are also presented. 
Having identified important HBV mutations in the mother-to-child transmission study 
described in chapter 3, coupled with a previous study conducted in the Division of Medical 
Virology which found a high prevalence of HCC-related mutations (BCP and pre-core 
mutations) in HIV-infected as compared to HIV-uninfected pregnant women (Maponga, TG, 
MSc thesis, Stellenbosch University, 2012), we investigated the prevalence of these 
mutations in HIV-exposed children and pregnant women. This is described in chapter 4.  
In chapter 5, the significance of these findings and the impact these results could have in 
addressing the problems of HBV in SA and perhaps beyond are discussed.  
The concluding remarks from this work are found in chapter 6. 
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CHAPTER 2: LITERATURE REVIEW 
 
HBV was discovered in 1965 in Australia, by a scientist named Blumberg and his colleagues. 
They discovered a ―new‖ antigen in leukaemia sera from transfused patients. This newly 
discovered antigen was called the ―Australian antigen‖. After being associated with type B 
hepatitis, this new antigen was named Hepatitis B surface antigen (Blumberg & Alter, 
1965). From the Hepadnaviridae family (hepatotropic DNA viruses) and further grouped in 
the Orthohepadnavirus genus. HBV was found to infect only mammals and be highly 
infectious to humans. Other members of this virus family have been found to infect mammals 
and birds but are not infectious to humans. These are the Woodchuck Hepatitis Virus (WHV) 
and Beechey Ground Squirrel Hepatitis Virus (GSHV) affecting mammals and the Avian 
Virus Pekin Duck Hepatitis B Virus (DHBV). As the name of the family suggests, these 
viruses target the liver with viral replication occurring predominantly in hepatocytes (Collier 
& Oxford, 2006).  
 
2.1 Hepatitis B structure and genomic organization 
Morphologically, HBV under an electron microscope (EM) appears as three distinct particles 
of different size and shape of which only one is the virus itself. It is a 42 nm particle, also 
referred to as the Dane particle. This is, an icosahedral nucleocapsid core surrounded by the 
hepatitis B surface proteins (HBsAg) embedded in a lipid bilayer and contains the following: 
the DNA genome, a DNA-dependent DNA polymerase, the hepatitis B core antigen (HBcAg) 
and the hepatitis B e antigen (HBeAg). Associated with the Dane particle, are tubular and 
spherical particles of 20-22 nm in diameter, which make up the excess HBsAg. 
As shown on Figure 2.1, HBV is encoded by a circular double-stranded DNA genome of 
about 3200 base pairs with one strand shorter than the other one by about 700 nucleotides, 
and associated with a DNA polymerase enzyme similar to the retroviral reverse transcriptase 
(RT) enzyme found in retroviruses. The complete strand has been identified as the ―minus 
strand‖ and the incomplete one is the ―plus strand‖ (Collier & Oxford, 2006). The 5‘ends of 
both strands are repeated by an eleven nucleotides (nt) motif named DR1 and DR2 
respectively involved in the switching of templates during viral DNA synthesis. This genome 
codes for four overlapping ORFs (S, C, P and X) with the polymerase gene overlapping the 
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surface gene, situated on the incomplete or ―plus‖ strand. These genes encode for seven 
essential viral structural and functional proteins named the small, middle and large surface 
proteins (HBsAg), the pre-core (HBeAg) and core (HBcAg) proteins, the polymerase enzyme 
and the X protein (HBx) respectively (Chen & Chen, 2011). Additional acting elements 
being enhancers, promoters, polyadenylation and replication signals involve in the initiation 
and termination of both genomic replication and translation are found within these ORFs.  
 
Figure 2. 1: Schematic representation of the HBV genome and its transcripts. The genome of 3.2 kbp of 
length is made of two DNA strands: the complete minus (-) strand and the incomplete plus (+) strand. The latter 
is made up of four overlapping genes: S, C, P and X with P being the longest gene and X the smallest gene.  At 
the 5‘end of the (-) and (+) stands are found two repeat motifs of 11 nucleotides each named DR1 and DR2 
respectively (Locarnini & Zoulim, 2010 Reproduced with permission). 
The S or surface gene 
The surface gene is divided into three domains - pre-S1, pre-S2 and S - encoding for the 
small (S), middle (M) and large (L) surface glycoproteins or HBsAgs. The latter are 
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translated from three different start codons (AUG) situated at the beginning of each region of 
the complete S ORF; hence they possess a common C-terminus but different N-terminus.  
Unlike the middle (M) and large (L) surface glycoproteins, the small (S) surface protein is 
found abundantly in the complete virion. The gene coding for this protein is of 226 base pairs 
in length and is translated from the third of the three-in frame initiation codons, situated at the 
beginning of the S domain. An antigenic determinant called group specific antigen or ‗a’ is 
attached to the protein, forming a region of the S gene. HBV vaccination aims for the 
formation of anti-a antibodies to conferred protective immunity (Harrison, 2008). As 
represented on Figure 2.1, there is overlapping between the surface gene and the polymerase 
gene. Consequently, mutations generated through viral replication or prophylaxis in the 
polymerase gene can affect the nucleotide sequence of the S domain on the surface gene. 
Similarly, changes occurring in the surface gene could affect the nucleotide sequence of the 
polymerase gene (Torresi, 2002; Locarnini, 2003).  
The M protein is translated from two of the three-in frame initiation codons situated in  the 
pre-S2 and S regions and thus, has an additional 55 amino acids (aa) added to 226 aa at its N-
terminus.  
Complete translation of the surface reading frame (pre-S1 + pre-S2 + S) results in the 
formation of the large surface protein (L) with an additional 125 base pairs, the pre-S1 
domain. A region within this domain is thought to be involved in the attachment of the virus 
to its receptor on the hepatocytes (Harrison, Dusheiko & Zuckerman, 2009). 
 The C or core gene 
This gene contains two domains – the pre-core and the core – with two in-frame initiation 
start sites (AUG) at the beginning of each domain. Thus translation of this gene yields two 
different proteins. The core protein (HBcAg), serological marker of the presence of an HBV 
infection, is the end result of translation of the second initiation codon situated in the core 
domain of the C ORF. Translation of the upstream initiation codon in the pre-core domain 
results in the synthesis of a precursor polypeptide and a signal sequence. The latter directs 
further processing of the formed polypeptide in the endoplasmic reticulum (ER) at its C-
terminus. Secretion of the HBeAg, serological marker of an active viral replication, follows. 
HBeAg has been thought to be an immune tolerogen hence its role in facilitating persistent 
HBV infection (Lee, 1997). Moreover, HBeAg has been demonstrated to be able to cross the 
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placenta during pregnancy, increasing the risk of transmission of HBV infection in the foetus 
and inducing a T-cell tolerance in the newborn against HBeAg (Wang & Zhu, 2000). 
The P or polymerase gene 
The polymerase gene codes for the viral polymerase enzyme. The ORF is divided into three 
functional domains: at the N-terminus is the protein terminal (TP), followed by the reverse 
transcriptase (RT) domain, and the RNaseH domain at the N-terminus. A spacer domain links 
the TP domain and the RT domain of the gene. 
 The TP domain primes the initiation of the minus-strand synthesis during viral 
replication via a tyrosine residue used as a primer for reverse transcription. Hence it is 
covalently bound at the 5‘end of the minus strand during reverse transcription. 
 The RT domain encodes the RT enzyme involved in the reverse transcription process 
during viral replication. This domain is further divided into seven conserved 
subdomains named A through G (Kim, Lee & Ryu, 2009). 
 The RNaseH domain codes for the RNaseH enzyme. Reverse transcription involves 
formation of the minus DNA strand using an mRNA as a template. At the end of the 
process, the mRNA is degraded from the RNA-DNA hybrid by the RNaseH enzyme 
(Harrison, Dusheiko & Zuckerman, 2009). 
The X gene 
This gene encodes a 154 aa long protein termed the X protein. The term ―X‖ was associated 
to this protein because of its unknown function at the time it was discovered. Today the 
protein is considered to be a transactivator of viral replication and is critical to a number of 
cellular functions such as signal transduction of cytoplasmic pathways, cell apoptosis and 
regulatory effects on the cell. The protein is also thought to have a role in HBV-induced liver 
carcinogenesis (Bouchard & Schneider, 2004). 
 
2.2 Hepatitis B virus replication 
Figure 2.2 illustrates the HBV replication cycle, characterized by reverse transcription. It 
starts with the binding of the viral particle to receptors found on the lipoid plasma membrane 
of hepatocytes. Binding is thought to be mediated by a segment of the pre-S1 region 
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(Neurath et al., 1986). Following membrane fusion, the viral core is released in the cytosol 
where uncoating occurs. The genome then translocates into the nucleus of the liver cell, and 
is converted into a covalently closed circular form (cccDNA) forming a ―minichromosome‖. 
Formation of the cccDNA involves completion of the incomplete (+) strand, repair of the (-) 
strand and ligation of the 5‘ ends of the two complete strands through superhelical turns. The 
formed cccDNA is used as template for the formation of four polyadenylated 3‘ co-terminal 
RNAs of different length (0.7kb, 2.1kb, 2.4kb and 3.5 kb), initiated by four viral promoters 
and two enhancers (Enh1 and Enh2) (Harrison, Dusheiko & Zuckerman, 2009). 
Transcription of the core promoter results in the 3.5 kb RNA. The latter comprises the pre-
core RNA and the pregenomic RNA (pgRNA) whose translation yield HBeAg, HBcAg and 
the polymerase respectively. The 2.4 kb RNA is transcribed from the surface promoter 1 
(SP1), encoding the L surface protein. The pre-S1, encoding for the M and S surface proteins, 
is transcribed into the 2.1 kb RNA, and the 0.7 kb RNA is transcribed from the X promoter 
which encodes the X protein (Nassal & Schaller, 1993).  
The pgRNA is used as template for reverse transcription by the viral polymerase enzyme for 
synthesis of the (-) DNA strand. The N-terminal domain of the polymerase, made of a 
tyrosine residue covalently attached through phosphodiester bonds to a dGTP residue, acts as 
a primer for reverse transcription (Karayiannis & Thomas, 2008). Binding of the viral 
polymerase to a bulge on the pgRNA termed epsilon (ε), a packaging signal, initiates 
encapsulation of the complex with the viral products produced from translation of the viral 
mRNAs, forming an immature core particle. Subsequent events of replication occur in the 
nucleocapsid. This process is followed by the translocation of the polymerase-primer 
complex to a complementary DR1 sequence on the 3‘ end of the template and then the 
pgRNA is reverse transcribed while simultaneously degraded by the RNaseH enzyme 
(Nassal & Schaller, 1993; Harrison, 2008). The completed (-) DNA strand is left at the 
DR1 position with a capped oligoribonucleotide (the not degraded 5‘end of the template) 
(Loeb, Hirsch & Ganem, 1991). The latter translocates to the 5‘ end of the (-) strand and 
hybridizes with a copy of DR1 being DR2, priming synthesis of the (+) DNA strand. As the 
(+) strand is being synthesized, the genome is folded in a circular configuration, allowed by 
the short (eight nucleotides) terminal redundancy of the (-) strand (Harrison, Dusheiko & 
Zuckerman, 2009).  
As mentioned above, viral replication occurs in the nucleocapsid with the entry of 
deoxynucleotide triphosphates (dNTPs) through its pores. Some cores will not be completed 
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while others will be. The incomplete ones, containing the mature HBV genome, will be 
transported back into the nucleus for further cccDNA synthesis (Ganem & Prince, 2004). 
The complete cores get finalised before completion of the (+) strand synthesis, causing a lack 
of dNTPs for the polymerase; hence the characteristic incomplete (+) strand of the HBV 
genome. The mature cores then bud through the internal membrane already embedded with 
the surface proteins, forming mature viral particles delivered out of the cell via exocytosis 
(Harrison, 2008; Karayiannis & Thomas, 2008).  
 
 
Figure 2. 2: HBV life cycle. HBV targets the hepatocytes to establish infection. The viral particle binds to 
unknown receptor on the surface of the hepatocytes. Membrane fusion is followed by entry of the nucleocapsid 
containing the viral genome in the cytosol. The nucleocapsid is uncoated, releasing the viral genome which 
translocates into the nucleus. The viral genome is converted into cccDNA through repair of the (-) DNA strand 
and completion of the (+) DNA strand. The cccDNA is used as template for the formation of four viral mRNAs 
of different lengths and whose transcription leads to the formation of the viral proteins. The longest RNA 
formed from the transcription of cccDNA, called pgRNA, is used as template for reverse transcription for the 
formation of the (-) DNA strand. The polymerase binds to a packaging signal (ε) on the pgRNA template, 
resulting in RNA packaging and core assembly. This is followed with synthesis of the (-) DNA strand using the 
N-terminal domain of the polymerase and concomitant hydrolysis of the RNA template. The newly synthesized 
(-) DNA strand is then used as template for (+) DNA strand synthesis.  Some core particles are transported back 
into the nucleus for further formation of cccDNA. Other cores bearing the complete genome will be finalised in 
the endoplasmic reticulum and transported to the internal membrane embedded with HBsAg, forming a 
complete viral particle ready for exocytosis out of the cell (Ganem & Prince, 2004 Reproduced with 
permission, Copyright Massachusetts Medical Society). 
2.3 Molecular HBV diversity distribution and clinical significance 
HBV has been classified into eight major HBV genotypes, named A to H.  Classification is 
done based on a divergence of >8% or more in the entire genome and 4 % in the S gene 
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(Kramvis, Kew & Francois, 2005). Recently, two additional genotypes named I and J have 
been described based on these divergence criteria. However, they are not well characterized 
yet (Huy et al., 2008; Tatematsu et al., 2009). Genotypes are further subdivided into 
subtypes or subgenotypes named from 1, 2, 3 etc., with a 4 – 8% difference in their 
sequences. These genotypes have been well described and distributed globally (Figure 2.3).  
Genotype A is subdivided into 7 subgenotypes (A1 to A7) and is responsible for most HBV 
infections in Cameroon. The subgenotype A1 is mostly found in SSA but has also been 
reported in Asia and America (Lin & Kao, 2011) and was described in SA for the first time 
in 1997 (Bowyer et al., 1997). Unlike A1, the subgenotype A2 is mainly found in Northern 
Europe. However, the strain has also been detected in SA, suggesting a possible introduction 
of the virus subgenotype in Europe by Europeans travelling to SA (Kramvis & Kew, 2007). 
The subgenotype A3 was found to be restricted to Western Africa with an origin from 
Cameroon (Lin & Kao, 2011). Subgenotype A4 and A5 were reported in Mali, Gambia and 
the Southeast part of Nigeria respectively (Olinger et al., 2006) but were also described to be 
present in SSA (Kimbi, Kramvis & Kew, 2004). Subgenotype A6 was characterized as a 
mixture of three strains originating from African-Belgian individuals originating from Congo 
and Rwanda (Pourkarim et al., 2010). A new subgenotype, referred as A7, has been so far 
described in only Cameroon and Rwanda. However, this new subgenotype has yet to be fully 
characterized (Hübschen et al., 2011). Genotype B is divided into two groups: the ―pure‖ 
group originating from Japan (also called Ba) and the ―recombinant‖ group from Asia (also 
called Bj). The genotype was further classified into 6 subgenotypes, named B1 to B6. 
Subgenotypes B2 – B5, whose sequences consists of recombination of a part of the core 
region of genotype C added to the core ORF of genotype B, form the ―recombinant‖ group. 
These subgenotypes dominate East Asia. The ―pure‖ group is made up of subgenotypes B1 
and B6, found in Japan and the Artic respectively. Another HBV genotype common in Asia 
is genotype C. The latter includes subgenotypes C1 – C5, found in East and Southeast Asia 
(Lin & Kao, 2011). Genotype D is subdivided into 5 subgenotypes and is widespread in 
Africa, India, and Europe and is the predominant genotype in Mediterranean regions. 
Genotype E is constrained in West Africa and spans the region going from Mali to Namibia 
referred to as the ―genotype E crescent‖ (Kramvis & Kew, 2007). Genotype F is subdivided 
into subgenotypes F1, F2, F3 and F4. Genotype G, unlike the others, needs to be in the 
presence of another genotype to establish an infection. Few reports of this genotype are 
available from France and the United States (Stuyver et al., 2000). Genotype H, is 
Stellenbosch University  http://scholar.sun.ac.za
 
30 
 
genetically quite close to genotype F because of the little divergence of their sequences (less 
than 8%), and is predominant in Central America (McMahon, 2009a). In 2008, a new HBV 
variant was isolated for the first time in Vietnam. This new variant was suggested to be 
genotype I. This genotype, originating from Southern China, was shown to be the end result 
of recombination between genotypes A, C and G (Huy et al., 2008; Fang et al., 2011). The 
tenth genotype, Genotype J, was discovered in a Japanese man. Phylogenetic analysis of the 
sequence showed a close clustering with gibbon and orangutan genotypes and the human 
genotype C (Tatematsu et al., 2009).  
HBV diversity has been shown to have an influence on disease progression and in the pattern 
of transmission of the virus. Genotype C was observed to be predominant in regions of the 
world where perinatal transmission predominates (Livingston et al., 2007; McMahon, 
2009a). Also, HBeAg seroconversion was demonstrated to occur at a later age in individuals 
infected with HBV genotype C as compared to the other genotypes, hence the increase risk of 
developing HCC (Chan et al., 2004), liver fibrosis and cirrhosis (LC) (Chen et al., 2004). 
Genotype A is associated with high replication of HBV DNA thus high viral load, facilitating 
horizontal transmission in adults. Subtype A1 is linked to high rate of HCC in SSA as 
compared to subtype A2 which play a role in the development of HCC in older people. 
Genotype B is related to acute and fulminant hepatitis with high viral load. However HBeAg 
seroconversion occurs at a younger age in subtype B1 or Bj than in subtype Ba. Genotype D 
is found in HBeAg- negative chronic infection and, subtype D3 is responsible of occult 
infection. Very little is known about disease progression related to the other genotypes (Cao, 
2009; McMahon, 2009a). Table 2.1 shows a summary of the liver disease progression 
related to HBV genotypes. 
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Figure 2. 3: Worldwide geographical distribution of HBV genotypes. This distribution shows a mixture of 
genotypes in SSA with a higher prevalence of genotype E in Namibia and genotype A in SA. The Northern part 
of Africa is dominated by genotype D, and as the literature suggests, genotype E is predominant in West Africa. 
Recombinants are shown to be mostly occurring in Asia (Kramvis, Kew & François, 2005 Reproduced with 
permission). 
Recombination between HBV genotypes has been described in some regions where more 
than one genotype is circulating. It can happen either through co-infection or superinfection 
of an individual with more than one strain. Time at which the process occurs during 
replication is unknown but it has been thought to happen during template switches for the 
synthesis of the (+) and (-) strands (Kramvis, Kew & François, 2005). A/D recombinants 
were described in SSA (Owiredu, Kramvis & Kew, 2001) and B/C recombinants are 
popular in Asia (Bowyer & Sim, 2000). This mechanism could result in immune escape of 
the virus or change in the viral replication but its impact on the disease outcome remains 
uncertain (Owiredu, Kramvis & Kew, 2001). 
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Table 2. 1: Liver disease progression associated with HBV genotypes (Modified Lin & 
Kao, 2011 Reproduced with permission).  
Genotype C B A D E – J 
Characteristics      
Modes of 
transmission 
Perinatal/ 
Vertical  
Perinatal/ 
Vertical 
Horizontal Horizontal/Perinatal  Horizontal  
Tendency of 
chronicity 
Higher Lower Higher Lower ND 
Positivity of 
HBeAg 
Higher Lower Higher Lower ND 
HBeAg 
seroconversion 
Late Earlier Earlier Late ND 
HBsAg 
seroclearance 
Less More More Less ND 
Histologic 
activity 
Higher Lower Lower Higher ND 
Response to 
interferon alpha 
Lower Higher Higher Lower Lower in 
Genotype G 
Response to 
nucleos(t)ide 
analogues 
ND No significance difference between genotype A to D 
Virologic 
characteristics 
     
Serum HBV 
DNA levels 
Higher Lower ND ND ND 
Frequency of 
pre-core A1896 
mutation 
Lower Higher Lower Higher ND 
Frequency of 
basal core 
promoter 
T1762/A1764 
mutation 
Higher Lower Higher Lower ND 
Frequency of 
pre-S deletion 
mutation 
Higher Lower ND ND ND 
ND = No Available data 
 
2.4 HBV-associated mutations 
The HBV genome evolves at a rate of 1.4-3.2 x 10
-5
 nucleotide substitution per site per year, 
owing to the viral error-prone reverse transcriptase used during reverse transcription as a 
mechanism of evolution for the virus. Mutations in overlapping genes tend to affect proteins 
in both genes, and the removal of an epitope of a protein due to a mutation can result in either 
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the addition of an epitope to the other protein or harming the protein functionality (Maman et 
al., 2011). This leads to the circulation of a population of genetically different, but related 
viruses called quasispecies.  Although these mutations could be harmful to the viral particles, 
some could also be beneficial to them by either enhancing replication or easing immune 
escape (Karayiannis & Thomas, 2008). 
2.4.1 Mutations in the core gene 
Two types of mutations have been described in the pre-core/core gene which affects HBeAg 
expression. The first functionally characterized was the pre-core stop mutation G1896A at 
nucleotide (nt) 1896 (or codon 28: TGG), located in the encapsidation signal (ε) structure of 
the pre-core. This mutation, as the name suggests, causes a stop codon in the pre-core gene 
(TGG to TAG; TAG: stop codon) hence blocking HBeAg production (Locarnini, 2004). The 
ε structure is critical during viral replication and is stabilized by the base paring between nt 
G1896 and nt 1858 forming a T – A. The occurrence of the G1896A mutation depends on the 
base present at nt 1858. Genotypes B, D E, G and some C and F strains have a T1858 
mutation enabling the stabilization of the ε structure by the stop codon mutant. However, 
genotypes A, H and some C and F strains have a C1858 instead hence the rare occurrence of 
the stop codon mutant. The presence or absence of C or T at nt 1858 explains the difference 
in prevalence of this mutation geographically (Kramvis & Kew, 2005; Tong, Wands 
&Wen, 2013). The second mutation, rather common in chronic carriers, affects the BCP at nt 
1762 and 1764. This mutation, referred to as the double BCP mutation A1762T/G1764A, 
leads to a 70% decrease in the HBeAg production and the increase of viral replication 
(Jammeh et al., 2008). Other mutations such as T1753C, C1766T and T1768A occurring in 
the BCP regions have also been associated to increased viral replication and decreased 
HBeAg expression (Quarleri, 2014). 
2.4.2 Mutations in the X gene 
Due to the overlapping between the pre-core domain of the Core gene from nt 1742 to 1802 
and the X gene seen on Figure 2.1, mutations occurring in the X gene could have an impact 
on the pre-core, specifically on the BCP and Enhancer II regions and vice versa. This 
explains the double mutation K130M/V131I on the X gene caused by the double BCP 
A1762T/G1764A mutation. Moreover, any deletions or insertions in the BCP could cause a 
shift of the X gene, hence producing truncated X proteins (Locarnini, 2004). 
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2.4.3 Mutations in the surface gene 
Numerous mutations occurring in the surface gene have been described. These mutations are 
considerably clinically important in a context of HBV prevention (through vaccination) and 
of diagnosis (HBsAg serology testing) (Hunt et al., 2000). Pre-S mutants form the largest 
group of mutations occurring in the surface/envelope region of the HBV genome. They are 
more frequent among genotypes B and C than other genotypes and range from deletions, 
insertions, point mutations to genetic recombination (Kramvis & Kew, 2005). The pre-S1 
and pre-S2 contain several epitopes for T and B cells demonstrating their importance for the 
interaction between the immune system. Mutations in the pre-S region have been found to 
appear in late stage CHB patients, and also in fulminant hepatitis and HCC patients (Shen & 
Yan, 2014). As HBV chronicity persists, a progression of pre-S deletions is observed leading 
to an accumulation of two types of large HBV surface antigens (LHBs) being S1-LHBs and 
S2-LHBs and viral particles in the hepatocytes. Patients exhibiting pre-S mutations and core 
mutations had higher incidences of HCC than those without or with single mutations (Chen 
et al., 2006; Qu et al., 2013).  
2.4.4 Mutations in the polymerase gene 
This gene is the main target of HBV treatment and contains the error prone RT enzyme, the 
cause of mutations occurring in this region of the genome. Because of the overlap of the P 
gene with the S gene, mutations in the RT domain could potentially result into changes in the 
coding sequence of the HBsAg region (Cento et al., 2013). These mutants have the ability to 
escape serological diagnosis and evade vaccine protection. Polymerase mutants have been 
identified in patients on ART such as 3TC, adefovir (ADV) and entecavir (Locarnini, 2004). 
The most common mutation reported from 3TC therapy is referred to as the tyrosine-
methionine-aspartate or YMDD mutation. The latter may cause changes in the S ORF leading 
to the formation of mutants HBs proteins (Clements et al., 2010). The mutant HBs antigens 
failed to be recognized by immune anti-HBs antibodies hence maintaining the replication of 
the virus. This phenomenon could also be seen through HB vaccination. The latter is based 
on the induction of antibodies against the antigenic epitope found on the HBsAg protein 
called the ―a‖ determinant. However in some cases, the immune pressure brought about by 
these anti-HBs proteins causes the selection of immune HBV escape mutants. The most 
common mutation causing this evasion is the substitution of a glycine to an arginine at 
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position 145 (sG145R) (Cooreman , Leroux-Roels & Paulij, 2001; Sheldon & Soriano, 
2008). 
 
2.5 Natural history and pathogenesis of the virus 
As the name ―hepatotropic‖ suggests, HBV targets the liver and results in either a transient or 
chronic infection. A transient infection can cause serious illness and terminates with acute or 
fulminant hepatitis. Developing chronicity is highly dependent on the age at which primary 
infection occurred. A chronic infection can produce serious problems with a 25% risk of 
primary liver cancer or HCC and a 2-3% risk of liver cirrhosis annually (McMahon, 2009b).  
2.5.1 Acute hepatitis 
Acute HBV infection can be symptomatic or asymptomatic depending on the age at which 
infection occurs. The infection is characterized by complete recovery at the end of its course 
with formation of anti-HBs antibodies, lowering the risk of developing liver cirrhosis or HCC 
(Shepard et al., 2006). Acute hepatitis is not common in neonates unless born from HBeAg-
negative mothers. These infants develop fulminant hepatitis characterized by liver failure and 
a strong immune response against HBV which leads to rapid recovery (Liaw & Chu, 2009). 
However symptomatic acute hepatitis occurs in about 10% of young children aged between 
one to five years, in most cases of infections in younger children, adolescents and adults. 
Incubation period is around three to six months before onset of symptoms which include 
nausea, vomiting, abdominal pain, anorexia, malaise, jaundice and changes in stool and urine 
colour (Chang, 2007). Diagnostic of an acute infection involves serological testing for 
HBsAg, total anti-HBc antibodies and immunoglobulin M antibodies to HBcAg (IgM anti-
HBc). The first marker to appear in the blood is HBsAg, followed by IgM anti-HBc two 
weeks later. Figure 2.4 shows that as the disease progresses, HBsAg and IgM anti-HBc 
become undetectable in the blood, leaving only anti-HBc (total) and anti-HBs antibodies. 
Anti-HBc (total) antibodies persist for life whereas anti-HBs antibodies tend to wane with 
time. Anti-HBs antibodies are also considered as markers of previous HBV active 
immunization, inducing protective immunity against HBV (Lee, 1997; Liaw & Chu, 2009).  
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Figure 2. 4: Serological changes in acute HBV infection. The first serological marker released in the 
circulation is HBsAg between 0-3 weeks after infection followed by IgM anti-HBc and total anti-HBc 
antibodies which persist for life. The production of anti-HBs antibodies from week 32 marks the point at which 
resolution of the infection starts (Paar, 2001 Reproduced with permission). 
 
2.5.2 Chronic hepatitis 
Chronic hepatitis infection (CHB) is confirmed with the presence of HBsAg for more than six 
months. It affects around 90% of infants born from both HBeAg and HBsAg-positive 
mothers (Beasley et al., 1977), 25-30% of children infected between one to five years, and 5-
10% of adults unless immunocompromised (McMahon et al., 1985). Chronicity may persist 
for life and leads to severe hepatic damage such as liver cirrhosis or HCC. In countries with 
common childhood infection, there is high seroprevalence (80-85%) of HBsAg and HBeAg 
in children below the age of 15 years than in adults carriers (Harrison, Dusheiko & 
Zuckerman, 2009). Developing chronicity is inversely proportional to the age at which 
infection was acquired. CHB is divided into four phases illustrated on Figure 2.5: (1) the 
immune tolerant phase, (2) the immune clearance phase, (3) the non-replicative phase, and 
(4) the reactivation phase which may be seen in some patients (Karayiannis &Thomas, 
2008). 
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Figure 2. 5: Natural course of chronic HBV infection. This diagram shows the course of a chronic HBV 
infection with time. A chronic HBV infection is divided into four phases being the (1) the immune tolerant 
phase characterized with high HBV DNA and HBeAg levels, normal ALT levels and asymptomatic; (2) the 
immune clearance phase is characterized by a decrease of HBV DNA, HBeAg levels and ALT flares causing 
acute liver damage which may lead to cirrhosis, (3) the inactive residual or non-replicative phase characterized 
with complete HBeAg seroconversion and undetectable levels of HBV DNA levels. At this stage liver cirrhosis 
could develop and lead to HCC and accumulation of pre-core HBV mutants occur, and (4) the reactivation 
phase characterized with HBeAg seroreversion due to either HBeAg- negative hepatitis which developed from 
the accumulation of pre-core mutations or immunosuppression. Here the ALT flares and active hepatitis occur 
again (Liaw & Chu, 2009, Reproduced with permission).   
 
Immune tolerant phase 
This phase is characterized by a seropositive status of all HBV serological markers with high 
viral load (2x10
6
 to 2x10
7
 IU/mL) levels, normal alanine aminotransferase (ALT) levels and 
liver histology with no apparent symptoms. CHB patients can remain in this phase for two to 
three decades if infected perinatally or during childhood, but for two to four weeks if the 
infection is acquired during adulthood (Wright, 2006; Chen & Chen, 2011). There is no 
evidence of immune response against HBV, explained by the HBeAg-specific helper T 
lymphocytes tolerance induced by the maternal transplacental transfer of HBeAg during 
pregnancy. Hence the tolerogenic function attributed to HBeAg. The immune system fails to 
recognize HBeAg as a foreign particle, leading to high viral replication and high viral load. 
However in case of mutations in the pre-core or core promoter, HBeAg production is 
Stellenbosch University  http://scholar.sun.ac.za
 
38 
 
decreased, reducing immunotolerance and leading to an increase in the ability of the immune 
system to react against the infected hepatocytes (Paganelli, Stephenne & Sokal, 2012). This 
event could be a participant of the transition from the immune tolerant phase to the immune 
clearance phase. 
Immune clearance phase 
Here HBeAg seroconversion is accompanied by an increase of ALT values exceeding 1000 
IU/L, and a decrease in HBV DNA levels below 2000 IU/mL. The stronger the immune 
response, the higher the ALT flares. The higher the ALT levels, the higher the liver damage - 
resulting in liver cirrhosis and/or fibrosis. However there is insufficient data on the risk of 
liver disease progression in children (Nebbia, Peppa & Maini, 2012).  
Seroconversion to anti-HBe depends on many factors such as age, HBV genotype, maternal 
HBsAg status and the geography. Children born from HBeAg positive mothers tend to have a 
lower rate of HBeAg seroconversion (<2% annually in children less than 3 years of age and 
4-5% after 3 years) (Jonas, 2013) than older children or those born from HBeAg-negative 
mothers. Also, individuals infected with genotype B tend to seroconvert to anti-HBe earlier 
(less than 20 years of age) than genotype C carriers (over 40 years of age) (Chu, Hussain & 
Lok, 2002; Livingston et al., 2007). In relation to geography, there is a higher HBeAg 
seroconversion rate observed in the Euro-Mediterranean region and Africa as compared to 
Southeast Asia annually (Ott et al., 2012). Little data is available concerning this issue in 
SSA. 
Spontaneous clearance of HBsAg also occurs but at a very low rate depending on the age of 
infection. Rate of incidence is estimated to be 0.4% to 2% if infection occurred in adulthood 
and 0.1% to 0.8% if infection occurred via MTCT or during childhood (Huo et al., 1998).  
Non-replicative phase 
As the word ―non-replicative‖ suggests, there is absence of HBV replication. Complete 
HBeAg seroconversion, normalization of ALT levels, very low level of HBV DNA 
(undetectable with hybridization methods) and improvement of liver histology are observed 
at this stage of the infection. The patient is said to be an HBeAg- negative inactive carrier. 
Although HBV replication is absent, permanent liver damage accompanied by development 
of cirrhosis and/or HCC may occur in childhood (Liaw and Chu, 2009). Most CHB carriers 
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could remain in this phase indefinitely. However, a small proportion could serorevert to 
HBeAg or could develop HBeAg-negative active hepatitis (Chang, 2007). The latter results 
from a pre-core mutation, also called G → A mutation, leading to a lack of HBeAg 
formation. Loss of the tolerogen HBeAg activates the immune system leading to HBV 
reactivation or to the immune clearance phase of the disease.  
Reactivation phase 
This phase is characterized by reactivation of HBV viral replication leading to seroreversion 
to HBeAg. This phase is mostly seen in patients undergoing chemotherapy, on 
immunosuppressive treatment, and HIV-immunosuppressed. As the immune system 
weakens, it loses its control over the low rate of viral replication. This results in an increase 
of ALT levels, HBV DNA levels higher than 20,000 IU/mL and a high risk of developing 
liver cirrhosis, fibrosis and/or HCC (McMahon, 2009b). 
2.5.3 Occult infection 
Considered as the fifth phase of CHB by some, occult HBV infection (OBI) is defined by the 
presence of HBV DNA in the liver in individuals with a negative HBsAg and a positive anti-
HBc (total) antibodies status. However in some cases all HBV serological markers are absent. 
This distinguishes between seropositive and seronegative OBI respectively (Conjeevaram 
&Lok, 2001). The presence of the HBV genome in the liver could be explained by: the 
integration of the viral genome in the form of cccDNA in the genome of the host hepatic 
cells, immunosuppression, mutations in the S gene infection caused by a HBV unable to 
synthesize the S antigen, insensitive serological assays in the detection of HBsAg 
immunological markers, presence of immune complexes hiding HBsAg (Ramezani et al., 
2011). However in most OBI cases, the virus shows mutations in its genome‘s sequence but 
has full ability of replication in the host (Hu, 2002; Raimondo et al., 2013). OBI has been 
implicated clinically in scenarios such as the occurrence of transfusion-transmitted HBV 
hepatitis through blood transfusions or liver transplantation (Chazouilleres et al., 1994), 
development of chronic liver disease and fulminant hepatitis  (Cacciola et al., 1999) and was 
presented to play a role in the development of HCC (Pollicino, Saitta & Raimondo, 2011). 
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2.6 HBV-related hepatocellular carcinoma 
Liver cancer is one of the leading causes of cancer deaths in Africa. As mentioned earlier, 
early childhood infections is the main risk factor of chronic HBV. Chronic HBV infection is 
the leading cause of HCC in SSA. The association between CHB and the development of 
HCC was first established in 1975 (Blumberg et al., 1975). The geographical prevalence of 
the tumour is determined by the geographical distribution of HBV. Thus, the highest 
incidence of the tumour is found in highly HBV endemic regions such as Asia and SSA. In 
low endemic regions, where the HBV carriage is low, factors other than HBV are the main 
risk factors. A range of risk factors have been associated to the increased risk of malignancy 
in HBV chronic patients. These are host genetic, viral and environmental factors. 
Host genetic factors 
The important aspects concern gender and age.  In regard to gender, African and Asian 
studies have shown that males are at greater risk of malignant transformation as compared to 
females (Beasley et al., 1981; Beasley et al., 1984; Kew et al., 1983). While HCC is 
common among old individuals with an increasing risk as the age increases in most 
populations and in Taiwanese (Beasley et al., 1984), black Africans show a highest 
prevalence of HCC in patients younger than 30 years old and a decreasing prevalence in older 
than 60 years old (Kew et al., 1983).  
Although mostly common in adults and uncommon in children (0.5% - 2% of paediatric 
malignancies worldwide), liver tumours have been previously reported in the South African 
paediatric population (Moore et al., 1997; Moore et al., 2004). The latest audit from Moore 
and colleagues reported an increase in the epidemiology of HBV-related HCC among 
children in Southern Africa, which differs from the rest of the world (Moore et al., 2008). 
The increased prevalence of liver malignant formation may be caused by perinatal HBV 
infection, an underestimated mode of transmission in SA.  
Viral factors 
These concern characteristics of the virus such as viral load, genomic mutations and 
genotypes. A high HBV viral load is synonymous with active HBV replication. Studies have 
demonstrated that patients with high HBV viral load and HBeAg positive are exposed to a 
quicker progression to liver cancer (Tang et al., 2004; Yang et al., 2002; Yu et al., 2005). 
Yu et al. also described that a high viral load is associated with genotype C. Thus genotype C 
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carriers are at a greater risk of malignancy than genotype B carriers (Yu et al., 2005). In 
Southern Africa, genotype A has been reported to present a 4.5-fold increased risk of HCC as 
compared to genotype D carriers (Kew et al., 2005).  
Over time and due to immune pressure, HBV has developed mechanisms to escape immune 
recognition through mutations in specific regions of its genome. These are BCP, pre-core 
(Baptista et al., 1999) and pre-S mutations (Shen & Yan, 2014) which are well recognized 
risk factors for the development of HCC in Asia. Prospective studies have observed an on-
going combination of pre-S deletions in the 3‘end of the pre-S1 and 5‘end of the pre-S2 
domains in chronic patients who eventually developed liver cancer (Chen et al., 2006; Qu et 
al., 2013). The pre-S1 and pre-S2 domains contain several epitopes for T and B cells thus 
their important role in the interaction with the immune system (Ferrari et al., 1992). The 
accumulation of pre-S deletions leads to the accumulation of two types of ground glass 
hepatocytes (GGHs) containing two different types of mutant LHBs (Wang et al., 2003). The 
accumulation of these LHBs in the endoplasmic reticulum (ER) causes a cascade of ER stress 
signalling pathways which leads to oxidative DNA damage (Hsieh et al., 2004). The latter 
may cause genomic instability resulting in mutation of liver cells thus liver malignancy 
formation (Wang et al., 2006). In addition to pre-S mutations/deletions, the double BCP 
mutation A1762T/G1764A is also commonly found in CHB and HCC patients. This mutation 
leads to a decreased HBeAg production and increased in viral replication, according to 
transfection studies, (Parekh et al., 2003; Liang et al., 2013) and causes a double mutation 
in the overlapping X gene at position 130 and 131. These combined mutations on the X gene 
have been shown to induce an increase activity of NF-ĸB activity through unknown pathways 
(Lee et al., 2011). The NF-ĸB protein is an important gene transcriptor involved in many 
features of cell regulation including oncogenic transformation, regulating immune activation 
and apoptosis. HBeAg, a tolerogen, acts as an inhibitor of immune clearance of infected 
hepatocytes. The loss of this tolerogen, brought by either of the two above mentioned 
mutants, leads to the recognition of HBV-infected hepatocytes by the CD8
+
 cytotoxic T cells 
therefore causing hepatocytes apoptosis hence liver damage (Hunt et al., 2000). Liver 
damage could trigger wound healing responses that in the long run promote the development 
of hepatic fibrosis and HCC (Luedde and Schwabe, 2011). An increase in NF-ĸB proteins 
brought about by the upregulation could result in increased inflammation or insufficient 
protection from cell death (Luedde and Schwabe, 2011). Other BCP mutations such as 
T1753C and the double C1766T/ T1768A have also been associated to the formation of liver 
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tumours (Qu et al., 2011). Although these mutations are independent risk factors for HCC, 
Qu et al. observed that the risk factor is greater when these mutations are combined than 
single (Qu et al., 2013). 
Environmental factors 
Repeated dietary exposure to the mycotoxin produced by fungi of the Aspergillus species 
(flavus and parasiticus) named aflatoxin B1 (AFB1) has been reported as an important cause 
of HCC in HBV endemic regions (Bressac et al., 1991a; Bressac et al., 1991b). This toxin is 
found in food such as peanut, corn and rice stored in moist conditions contaminated by the 
fungus. A product of metabolization of AFB1, AFB1-exo-8, 9-epoxide, has the ability to bind 
to DNA causing impairment of DNA, RNA and protein synthesis. The toxin is also thought 
to cause a mutation at serine 249 (guanine to thymine transversions), also known as the 
R249S point mutation, in the tumour-suppressor p53 gene. This mutation has been described 
in a majority of HCC patients who are HBV-infected (Bressac et al., 1991b) but has not yet 
been found in non-HBV related HCC cases. 
 
2.7 HBV epidemiology in Sub-Saharan Africa 
HBV and HIV are major public health problems with HIV causing the highest number of 
infectious diseases deaths worldwide and viral hepatitis the second most common cause of 
deaths from infectious diseases. SSA carries a high burden of both these diseases. The two 
viruses share similar routes of transmission and were shown to cause co-infection in about 5 -
15% of the worldwide population, with a high association rate in highly endemic regions 
such as SSA. The rate of co-infection depends on many other factors such as the geographic 
areas and their differences in CHB prevalence, the route of transmission and the age at which 
infection is contracted.  
About two-thirds of the worldwide 33 million HIV infections are found in SSA (Hogan et 
al., 2012). HBV is the main cause of chronic liver disease ranging from minor disorders to 
cirrhosis and liver cancer (Botha et al., 1984; Kew, 2012). Since HBV is able to remain 
viable on dry surfaces for extended periods of time, the virus is considered to be more 
infectious than HIV (Alter, 2006). Prevalence of hepatitis B infection, illustrated on Figure 
2.6, is defined according to the percentage of the population seropositive for HBsAg. The 
highest prevalence of HBV is shown to be found in intermediate and highly endemic (4 – 8% 
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HBsAg seroprevalence and >8% HBsAg seroprevalence respectively, according to the WHO) 
areas such as Southern Africa and West Africa respectively (Modi & Feld, 2007).  
HBV studies conducted in SSA have shown a higher prevalence of the virus in HIV-infected 
individuals than in HIV-uninfected ones, with a prevalence of 1% to 19% co-infection in 
children (Mutwa et al., 2013). SSA countries such as Senegal (Diop-Ndiaye et al., 2008), 
Nigeria (Adewole et al., 2009), Ghana (Geretti et al., 2010) and, Zambia (Kapembwa et al., 
2011) reported HBV- HIV co-infection rates of 16.5%, 11.5%, 16.7% and 9.9% respectively 
in adults. In the North of Namibia, Brandt et al. revealed an 8.7 % occurrence of HIV/HBV 
co-infection in 1057 chronic hepatitis children (>18 years old) in the immune-tolerant phase 
of the disease (Brandt et al., 2012). A recent study in the North of Tanzania also showed a 
9.7% prevalence of HBV in 157 HIV-infected children (Muro et al., 2013).   
 
 
Figure 2. 6: Hepatitis B virus prevalence in Africa. Sub-Saharan Africa harbours the highest number of 
hepatitis B virus infections compared to the Northern part of Africa (Modi & Feld, 2007 Reproduced with 
permission). 
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2.7.1 Epidemiology in South Africa 
In Johannesburg, Firnhaber et al. confirmed a high prevalence of HBV in HIV-positive 
persons with a total HIV/HBV co-infection rate of 5% (Firnhaber et al., 2008).  Two other 
serosurveys conducted in the rural areas of SA had the same results but with a higher rate of 
co-infection being around 16.2 % and 17%, respectively (Mphahlele et al., 2006; Hoffmann 
et al., 2008).The prevalence of hepatitis B in the South African obstetrics population is also 
of concern. Pre-HBV immunization data have described a low HBV prevalence (1.21%) in 
pregnant women (Guidozzi et al., 1993). A decade later, Burnett et al. reported antenatal 
HBsAg prevalence rates of 7.4% to 8.3% in the Limpopo province of SA. Recent data from 
an antenatal Western Province cohort described a hepatitis infection rate of 2.9% whilst of 
3.4% among HIV/HBV co-infected pregnant women with high HBeAg prevalence and loss 
of immune control of HBV (Andersson et al., 2013). This determines the risk of 
transmission of hepatitis to infants.  
Prior to the introduction of the HB vaccine, a 10.4% HBsAg prevalence rate had been 
described among children, with high HBsAg positivity rate of 8.1% and 8.9% in children 
aged 0 – 6  and 7 – 12 months, respectively (Vardas et al., 1999). Post immunization data 
described considerate decrease of the HBV infection rate among children (Hino et al., 2001; 
Tsebe et al., 2001). A recent analysis of pre- versus post-HBV immunization reported (1) 
increased immunity to HBV infection from 13% to 57%, decreasing as age increased, and (2) 
a decrease of HBV chronic carriage from 4.2% to 1.4% (Amponsah-Dacosta et al., 2014).  
Although much is known on hepatitis in mono-infected children, data on HBsAg prevalence 
rate among HBV-HIV co-infected children in SA are sparse.  
2.7.2 HBV occult infection in HIV-infected patients 
Occult infection prevalence varies in different geographical regions, depending on the 
prevalence of HBV in the area. The frequency has been shown to be quite high in SA. 
Firnhaber et al. found a prevalence of 88.4% of OBI in 43 individuals positive for HIV and 
anti-HBc (Firnhaber et al., 2009). The same year, Lukhwareni et al. detected HBV DNA in 
34 of 148 HBsAg negative HIV-positive patients (Lukhwareni et al., 2009). Although OBI 
seems to be common in HIV/HBV co-infected patients, insights in the natural history of the 
disease and risk of developing liver disease in HIV/HBV co-infection are unknown. 
However, patients with occult HIV/HBV infection tend to respond equally well to HAART as 
those HIV/HBV co-infected with HBsAg positivity (Chadwick et al., 2013). 
Stellenbosch University  http://scholar.sun.ac.za
 
45 
 
2.8 Hepatitis B virus transmission routes 
HBV has the ability to survive for extended periods of time on dry surfaces thus its high 
infectivity. The viral protein HBsAg is found in high quantities in the blood and other body 
fluids such as saliva, sperm, menstrual and vaginal discharge, breast milk and serous 
exudates. Contact with any of these fluids from an HBsAg positive individual leads to 
transmission of the virus. Two main routes of transmission of the virus have been established: 
vertical and horizontal transmission (Harrison, Dusheiko & Zuckerman, 2009).  
Vertical or perinatal transmission 
 Also referred as MTCT, vertical transmission is the main factor of HBV chronicity 
development in infants (Ott, Stevens & Wiersma, 2012), especially in Asia (Stevens et al., 
1975), and the main HBV mode of transmission in high endemic areas (>8% HBsAg 
seroprevalence). Child-bearing women positive for both HBeAg and HBsAg with a high viral 
load have a 90% rate of transmission compared to a 25% rate of transmission for HBeAg 
negative mothers and a 12% transmission rate for HBeAg negative and anti-HBe positive 
mothers (Umar et al., 2013). HIV co-infection could also be a risk factor for MTCT because 
co-infected mothers show higher levels of HBeAg and HBV DNA as compared to HBV 
mono-infected mothers (Modi & Feld, 2007). Vertical transmission can occur through three 
different patterns: (1) intrauterine, (2) intrapartum, and (3) postpartum (Pol, Corouge & 
Fontaine, 2011).  
(1) In utero or intrauterine transmission: As mentioned above, HBeAg was demonstrated to 
be able to cross the placenta during pregnancy and infect the foetus. Evidence of an in utero 
transmission is shown by the detection of HBsAg in a newborn 24 hours after delivery. 
Studies have been contradictory on whether this type of transmission is related to the 
infiltration of maternal blood into the placenta and not to HBV replication, maternal HBsAg 
titre or viral load (Ohto et al., 1987); or if not the other way around (Zhang, Han and Yue, 
1998).  Further researches performed on the Asian population on this issue showed that the 
infection occurs through a cellular transfer process, from the placental decidual cells to the 
villous capillary endothelial cells reaching the foetal circulation through a Fc gamma receptor 
III- mediated entry of HBsAg – anti-HBs immune complexes mechanism into the placenta; 
hence the decrease in viral load from the maternal side to the foetal side (Xu et al., 2001). 
However, this mechanism has not yet been reported in any other continent than Asia (Xu et 
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al., 2002). Studies have also presented high maternal HBV DNA titres to be strongly 
associated with in utero transmission (Pande et al., 2008; Wiseman et al., 2009).  
(2) Intrapartum transmission was shown to be associated with the duration (>9 hours) of the 
first stage of labour (Wong, Lee & Ip, 1980). Transmission of maternal HBsAg can also 
occur during delivery from the mixture of maternal and foetal blood due to placental leakage 
or instrumentation-induced trauma (Umar et al., 2013). 
(3) Postpartum: On this pattern of transmission, very little convincing evidence is available. 
HBsAg and HBV DNA have been detected in breast milk and in infant‘s gut born from 
HBeAg mothers. However, many studies have not shown breastfeeding as a risk factor for 
HBV MTCT transmission (Chen et al., 2013).  
Horizontal transmission 
This is the common HBV mode of transmission in intermediate and low endemic areas 
(Alter, 2006). However, it was found to be the predominant mode of transmission in the 
highly endemic area SSA, where childhood infection is common (Botha et al., 1984). 
Horizontal transmission may occur either during childhood or in adulthood. Although the 
mechanism behind the spread of the virus is not well understood, a few risk factors, including 
the use of unsterile needles during ritual scarification by traditional healers (Kew, Reis & 
Macnab, 1973), contact of bodily fluids such as saliva and blood through skin abrasions, 
(Kiire, 1996), weeping sores (Mphahlele et al., 2002) and human bites (Hui et al., 2005) 
have been associated with this mode of transmission.  
In childhood, transmission may occur postpartum, through the usage of infected medical 
instruments in hospitals often happening in resource-limited settings, virus spread among 
siblings and parents referred as intra household transmission and multiple intramuscular 
injections (Kourtis et al., 2012). Infection in adults occurs often through risky behaviours 
such as unprotected sexual activity, having more than one partner, and injection drug use; but 
could also happen from person-to person of a household via infectious body fluids. 
Transplantation and blood transfusions are other routes through which infection could be 
contracted. These two are being eradicated in developed countries through the 
implementation of testing donors for HBsAg or HBV viral nucleic acid but is still seen in 
developing countries (Alter, 2006). 
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2.9 Prevention and management of Hepatitis B virus infection in children 
2.9.1 HBV immunization in children 
Preventive measures implemented by public health organizations and governments have been 
established to reduce the incidence of this disease. Since infants are most likely to develop 
chronic HBV infection as compared to adults, ensuring children are protected is a cost 
effective way to prevent on-going infection.  
Passive immunization 
Passive immunization was introduced in 1974 and involves the preparation of hepatitis B 
immunoglobulin (HBIG) using pools of plasma with high titres of anti-HBs proteins. The 
latter form immune complexes with HBsAg and bring about neutralization of the viral 
particles. HBIG provides passive protection only in case of acute exposure to HBV but isn‘t 
used as pre-exposure prophylaxis because of its high cost and short period efficiency 
(Harrison, Dusheiko & Zuckerman, 2009). This method has been proven to reduce HBV 
intrauterine infection in pregnant women (Li et al., 2004) and to reduce the chance of HBV 
infection in newborns born of HBeAg and HBV DNA positive mothers. However, this 
prophylactic measure should be coupled with active immunization to ensure long term 
protection (Lee et al., 2006a; Zuckerman, 2007). Passive immunization is also used as a 
preventive measure for reinfection in liver transplant patients (Shouval & Samuel, 2000), in 
post exposure prophylaxis in those who are non-responsive to the vaccine and after sexual 
exposure to the virus. 
Active HBV immunization 
An effective and safe vaccine, the first vaccine to prevent cancer, was developed and has 
been available for nearly 30 years. It was recommended by the WHO to be part of the EPI of 
every country by 1997. By 2007, 71 (89%) of the 193 states member of the WHO had 
introduced a hepatitis B vaccination program (Chen, 2009). The vaccine was designed to 
reduce the incidence rate of infections and subsequent eradication of the virus. It was 
launched for the first time in Taiwan in 1984 (Hsu et al., 1988) and then followed the 
establishment of HBV immunization programs in most of the countries with an HBsAg 
prevalence >8%. Even though mass immunization of children was shown to be quite 
effective in controlling the HBV epidemic in many regions of the world (Luo, Li & Ruan, 
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2012; Ni et al., 2012), coverage is still not optimal in many countries where HBV prevalence 
is high. 
First generation HBV vaccine was made from plasma-derived HBsAg purified from chronic 
carriers, but was replaced with the second generation recombinant vaccine made of HBsAg 
expressed in yeast (Chen, 2009). The latter lacked the pre-S epitopes and thus only contained 
the small or major S protein. The recombinant third generation vaccines were improved by 
inserting the pre-S epitopes (pre-S1 and pre-S2) in addition to the S domain, which expressed 
the complete HBsAg protein. These vaccines although appearing to be more effective are not 
widely available. This vaccine was developed based on evidence suggesting that the pre-S 
epitopes could (1) enhance the HBs antibodies response and the cellular immune response, 
and (2) also prevent the docking of the viral particles to their receptors on hepatocytes 
(Harrison, Dusheiko & Zuckerman, 2009). Guidelines were produced by the WHO on how 
to administer the vaccine. According to the EPI, newborn infants should receive their first 
dose within 24 hours of birth regardless of the maternal HBV or HIV status followed by two 
additional doses at one and six months of age. In case the child is born from an HBsAg 
positive mother, the vaccine should be combined with HBIG, inoculated at different sites. 
This measure is of great importance in areas of high HBV endemicity where HBV is 
transmitted from mother-to-child. This strategy, low of cost, was implemented for the reason 
that screening mothers for HBsAg was highly costly and developing countries could not 
afford such expenses. The need for booster doses in the routine immunization program has 
not yet been established (Broderick & Jonas, 2004; WHO, 2010). To the high-risk 
populations such as young children or adolescents, individuals requiring blood transfusions or 
organ transplantation, dialysis patients, immunocompromised patients, health care workers or 
any individual exposed to blood products at his/her work place, injecting drug users, 
individuals with multiple sexual partners and HIV infected individuals, administration of the 
vaccine was also recommended (Harrison, Dusheiko & Zuckerman, 2009; WHO, 2010). 
Though efficient in infants born from HBV mono-infected mothers, recent data demonstrated 
the low effectiveness and response of HBV immunization in infants born from HIV/HBV co-
infected mothers (Mutwa et al., 2013). 
In SSA, infant HBV vaccine is given six weeks postnatal rather than within the 24 hours of 
delivery (Kiire, 1996; Mutwa et al., 2013). Also, it was shown in SA that infants born of 
HIV mothers had less probability of receiving childhood vaccinations (Ndirangu et al., 
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2009). More data acquired from other studies on this topic led to the suggestion that HIV 
maternal status was associated with children‘s immunization status. Unfortunately, this leaves 
the HIV-exposed infant with a high viral load vulnerable to acquire an HBV infection with 
high chances of becoming a chronic carrier (Healy, Gupta & Melvin, 2013). 
2.9.2 HBV drug treatment 
Hepatitis B viral replication is crucial in the progression of the hepatic disease; hence 
suppression of the virus to achieve HBeAg seroconversion, genome clearance and 
improvement of liver injury are the main objectives of antiviral agents. Long term goals 
include reducing the chances of developing liver cirrhosis and HCC and subsequent survival 
extension of the patients (Puoti et al., 2002). However, currently available ARTs do not 
achieve complete eradication of the cccDNA incorporated into the human genome in chronic 
infections (Thio, 2009). As mentioned above, most cases of acute infection are resolved and 
patients do not need treatment. However this is not the case for chronic carriers and 
HIV/HBV co-infected patients who do not clear the infection. Therefore, the need of 
treatment for these groups becomes crucial to control the disease. To date, little data on the 
treatment of HBV in co-infected children are available but ARTs, summarized in Table 2.2, 
are available and recommendations on how to monitor CHB children have been established 
(See Figure 2.7). These ARTs include the interferon based therapy (interferon alpha) and the 
nucleos(t)ides analogues drugs lamivudine, adefovir dipivoxil, entecavir, telbivudine, and 
tenofovir (Healy, Gupta and Melvin, 2013). 
Interferon-based therapy 
This includes interferon alpha-2b (IFNα-2b) and pegylated interferon, both shown to be 
effective in treating chronic patients. Yet, only IFNα-2b has been approved to be used in 
infants. Early seroconversion to anti-HBe and long-term seroconversion in patients with 
elevated ALT levels above baseline are observed in infants treated with IFNα-2b (Kurbegov 
& Sokol, 2009; Paganelli, Stephenne & Sokal, 2012). 
Using IFN over nucleos(t)ide drugs has the advantage of avoiding emergence of resistance 
(Chang, 2007). However, this treatment is not without disadvantages. Patients on IFN 
treatment tend to develop undesired effects such as flu-like symptoms, fatigue, anorexia, 
weight loss, hair loss, hyperthyroidism, depression, and thrombocytopenia. However these 
side-effects are less severe in children than in adults (Liaw & Chu, 2009). 
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Tenofovir 
This therapy was recently approved for usage in the treatment of HBV mono-infected 
children older than 18 years of age and of HIV/HBV co-infected children older than 2 years 
of age with concerns of renal and bone toxicity if used at long-term in younger children. Like 
3TC and entecavir, tenofovir (TNF) is not recommended to be used as monotherapy in 
HIV/HBV co-infected individuals to avoid emergence of resistance strains but has significant 
activity against 3TC-resistant strains (Paganelli, Stephenne & Sokal, 2012; Healy, Gupta 
& Melvin, 2013) hence it can be used as a rescue option in 3TC and ADV-resistant patients 
(Van Bömmel et al., 2006). 
 
Lamivudine 
Lamivudine (3TC), a product of 2, 3-dideoxy-3 –thiacytidine, is a nucleoside analogue with 
antiviral effects on both HBV and HIV and a safety profile in children. The drug competes 
for cytosine during viral DNA synthesis resulting in suppression of viral replication. The first 
published data on the effects of 3TC on chronic children showed a significant decrease of 
HBV DNA levels associated with HBeAg seroconversion after a year of treatment in patients 
with ALT levels at least two times above the baseline, but only 2% had an HBsAg 
seroconversion (Jonas et al., 2002). To children, a dosage of 3mg/kg per day with a 
maximum dose of 100 mg per day is recommended (Lok & McMahon, 2007). 
Although efficient, long term 3TC monotherapy have been associated with the occurrence of 
HBV mutations, often called YMDD motif mutations, leading to a decrease in virological 
response. 3TC-induced mutations happen to be occurring in the catalytic domain of the P 
gene, which, because of its overlap with the S gene result in changes in the ‗a‘ determinant of 
the HBsAg protein (Lok et al., 2000; Harrison, Dusheiko & Zuckerman, 2009). This 
causes the formation of drug resistant strains which may have the potential to induce vaccine 
escape and nucleos(t)ide antiviral drug resistance (Clements et al., 2010). Incidence of 
YMDD mutations was found to increase with the duration of the therapy (19% after 12 
months of treatment, 49% at 24 months and 70% after 48 months) (Liaw et al., 1999; 
Locarnini, 2004;  Sokal et al., 2006).  
 
Adefovir dipivoxil 
Antiviral effect of this purine analogue compound involves direct incorporation in 
competition with the substrate deoxyadenosine triphosphate (dATP) to cause chain 
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termination to bring about the inhibition of both the viral RT enzyme and DNA polymerase 
(Harrison, Dusheiko & Zuckerman, 2009). No report of drug-resistance was shown to arise 
from this therapy in children but resistance is reported in adult patients after five years of 
therapy. Nephrotoxicity is known as the main side effect of this drug if used at high doses 
(Paganelli, Stephenne & Sokal, 2012). Studies have demonstrated that therapy with ADV is 
more efficient as compared to 3TC.  
The first study working on the effect of ADV in chronic HBV children had its results 
reported in 2008. It demonstrated that children with chronic HBV and positive for HBeAg 
aged between 12 and 17 years showed significant virological response (HBV DNA <1000 
copies/mL, seroconversion to anti-HBe, and normalization of ALT levels) as compared to 
children younger than 12 years (Jonas et al., 2008). ADV was then approved as an antiviral 
therapy for children from 12 years of age (Paganelli, Stephenne & Sokal, 2012).  
 
Entecavir 
Entecavir, a carbocyclic analogue of 2-deoxyguanosine, was proven to be more efficient than 
both 3TC and ADV in decreasing HBV DNA levels and HBeAg seroconversion (Lai et al., 
2006; Leung et al., 2009). It is prescribed in children older than 16 years of age (Paganelli, 
Stephenne & Sokal, 2012). Furthermore, entecavir possesses antiviral effects against HIV 
but because of its possibility to induce resistance; this therapy should not be used alone in 
HIV/HBV co-infected patients (Healy, Gupta & Melvin, 2013).  
The drug targets three specific events occurring during HBV replication: DNA polymerase 
priming, negative strand reverse transcription and synthesis of the HBV DNA (+)strand 
(Harrison, Dusheiko & Zuckerman, 2009). 
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Figure 2. 7: Recommendations in the monitoring of chronic hepatitis B children. AFP: alpha-fetoprotein; 
ALT: alanine aminotransferase; 
a
ALT level and white blood cell/platelet (WBC/Plt) count are generally 
included in the baseline evaluation as part of a hepatic function panel and complete blood count, respectively. 
b
The ALT level should be considered elevated if greater than the testing laboratory ULN or _40 IU/L, 
whichever is lower (Jonas, 2013 Reproduced with permission). 
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Table 2. 2: Antiviral therapies of chronic HBV in children (Healy, Gupta & Melvin, 2013) 
Generic Name Trade Name US FDA labelled 
indications and ages 
HIV-1 
activity† 
HBV resistance 
mutations 
IFN-α-2B Intron A® HBV: ≥1 year No  
Lamivudine Epivir® 
Epivir–HBV® 
HIV: birth and older 
HBV: ≥2 years 
Yes M204I/V 
L180M 
A181T/V 
V173L 
Adefovir Hepsera® HBV: ≥12 years No‡ N236T 
A181T/V 
Telbivudine Tyzeka® HBV: ≥16 years No M204I 
A181T/V 
Tenofovir Viread® HIV: ≥2 years 
HBV: ≥18 years 
Yes A194T§ 
A181T/V 
N236T 
Entecavir Baraclude® HBV: ≥16 years Yes¶ M204I/V# 
L180M 
T184I/A/G/L 
S202I/G 
I169T 
IFN-α-2b Intron A® HBV: ≥1 year No  
PegIFN-α-2a Pegasys® HBV: ≥18 years No  
†Agent also has activity against HIV-1 and can lead to development of HIV resistance 
mutations if used as monotherapy in an HIV/HBV-coinfected individual. Additional 
antiretrovirals should always be included in a treatment regimen. ‡While adefovir does have 
minimal HIV-1 activity, development of HIV-1 resistance mutations has not been 
demonstrated. §Tenofovir mutations have not been clearly associated with decreased anti-
HBV efficacy. ¶Entecavir does not have sufficient antiretroviral activity to be used for HIV-1 
therapy. #Presence of several mutations is necessary to decrease efficacy for entecavir. 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
54 
 
CHAPTER 3: EPIDEMIOLOGY OF HEPATITIS B VIRUS INFECTION IN HIV-
EXPOSED INFANTS 
 
This chapter aims to describe the prevalence of active HBV infection in a cohort of children 
born of HIV-infected women. Although horizontal transmission is considered the common 
mode of HBV transmission in children in SSA, this chapter also reports on the rate of vertical 
transmission in HBV-infected children. 
 
3.1 Introduction 
The implementation of the HB vaccine in SA was based on the finding that horizontal 
transmission was the main HBV route of transmission in SA. Following the implementation 
of the HB vaccine, comparative studies have shown a decrease in the prevalence of HBV 
infection as evidenced by the decrease in chronic HBV carriage from 4.2% to 1.4% as 
described by Amponsah-Dacosta et al. (Amponsah-Dacosta et al., 2014) and the increased 
immunity to the infection  (Hino et al., 2001; Tsebe et al., 2001). Its prevalence in HIV-
infected adults has been extensively explored but little is known concerning the HIV-infected 
paediatric population.  
A relatively high prevalence of HBsAg in HIV-infected pregnant women has been described 
in SA (Burnett et al., 2007; Andersson et al., 2013; Thumbiran et al., 2014). A proportion 
of these women presented with high HBV viral load and HBeAg positivity hence were at 
high risk of transmitting the HB infection to their babies (Andersson et al., 2012; Hoffmann 
et al., 2014). HIV, on its own, has an impact on the natural history of HBV through a delay in 
HBeAg seroconversion. Additionally, the retrovirus was reported to reduce vaccine efficacy 
in babies born from HIV-infected women (Zuccotti et al., 1994; Arrazola et al., 1995). This 
is, thus, of concern in SA where active immunization is given post 6-weeks of birth. The 
infant is left in that perinatal period with a high risk of infection through vertical 
transmission. 
Few studies have looked at the contribution of MTCT to the chronic HBV carriage in infants 
born of HIV-infected women. Therefore, in the current study, a large population of infants 
born of HIV-infected women in SA was investigated for HBV infection. The primary aim 
Stellenbosch University  http://scholar.sun.ac.za
 
55 
 
was to describe the prevalence of HBV infection in these HIV-exposed infants and the route 
of transmission of infection.   
 
3.2 Materials and Methods 
3.2.1 Ethical aspects 
The study received ethical approval from the Health Research Ethics Committee (HREC) of 
the Faculty of Health Sciences, Stellenbosch University. The ethics reference number is: 
N10/04/115. 
3.2.2 Sample and data collection 
3.2.2.1  Study population 
This a retrospective cohort study making use of a repository of banked samples from the 
P1041 study, part of International Maternal Pediatric Adolescent AIDS Clinical Trials Group 
(IMPAACT). P1041 was a multi-centred, Phase II-III randomized, double blind, placebo 
controlled trial to determine the efficacy of isoniazid (INH) in preventing tuberculosis (TB) 
disease and latent TB infection among South African infants with perinatal exposure to HIV. 
The enrolment of participants took place during the period of 13 December 2004 to 26 June 
2006. Data collection on the infants took place at study entry (approximately 12 weeks from 
birth), and together with blood sampling at ~25 weeks of age (hence designated ―Week 12 on 
study‖) and ~60 weeks of age (hence designated ―Week 48 on study‖).  
A total of 1354 infants born of HIV-infected mothers in Johannesburg, Durban and Cape 
Town, SA were enrolled for the PACTG P1041 study. Among these infants, 548 were HIV-
infected and 806 were HIV-uninfected.  Nine hundred and ninety six infants had plasma 
samples of at least 0.1 ml at ―Week 48‖.  Among the 916 infants with ―Week 48‖ plasma 
samples, there were 388 infants with ―baseline‖ samples (―Week 0‖ or ―Week 12‖) from all 
study sites.  
All plasma and serum samples available at ―Week 48‖ were tested in order to determine the 
overall prevalence of HBV in P1041. This was done in order to ensure all cases infected by 
―week 48‖ were identified in the most cost effective way.  All samples that tested positive for 
HBsAg and anti-HBc (total) were identified and contacted for follow up through the health 
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facilities where sample collection was performed. Blood samples were collected from the 
children and their mothers to identify whether the infection was of maternal origin. Samples 
collected at point of entry of the study i.e. 12 weeks of age of the infant and at ―Week 12‖ i.e. 
24 weeks of age of the infant were requested, using the patient ID number (PID), from the 
laboratories where study samples were stored in the cities of origin. The minimum volume 
requirement was 0.1 ml for both sample types.  
3.2.2.2 Data collection 
Data collection and blood sampling were performed together on infants at study entry. Blood 
sampling was performed at ~25 weeks of age designated ―Week 12‖ on study and ~60 weeks 
of age designated ―Week 48‖ on study.  
3.2.3 Serology procedures 
Samples collected at ~60 weeks of age (―Week 48‖ on study) were tested for HBV 
serological markers using the ARCHITECT system (Abbott Diagnostics, Delkenheim, 
Germany).  
3.2.3.1  Validation of the ARCHITECT assays 
The samples were of a low volume; therefore validation of low volume samples was required. 
The ARCHITECT i2000SR required a minimum volume of 400µL to execute the required 
serology assays. Samples were diluted to the required volume to complete the assays. The 
aims of the validation were (1) to determine the limit of detection and, (2) determine the 
appropriate diluent for the dilution of the samples. A total number of 37 HBsAg positive 
samples, previously tested neat on the AxSYM platform were retrieved from the NHLS 
diagnostic laboratory situated at the Division of Medical Virology. These samples were 
diluted to 1:10 with normal human plasma (NHP). The latter was received from the Western 
Cape Province Blood Transfusion Service (WPBTS) and known to be HBV, HIV and HCV 
negative on serological and molecular assays. The neat and diluted samples were tested on 
the ARCHITECT for HBV markers including HBsAg, anti-HBs and anti-HBc (total) in 
duplicates on two different days. The dilutions and neat samples were tested on ARCHITECT 
and results were compared to each other.  
Following individual testing, pooled sample testing was performed. A series of samples with 
different HBsAg profiles were screened. (1)Three samples (STY5017776, STY5018481 and 
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STY5051715) with HBsAg S/N > 200 on AxSYM and anti-HBc (total) S/CO >10 on 
ARCHIECT were pooled with 200µL of each sample. Two separate 10-fold serial dilutions 
from 1:10 to 1:1,000,000 of the pooled specimen using NHP and 50% fetal bovine serum/ 
phosphate buffered saline (FCS/PBS) were performed. Additionally, a 1:10 dilution of each 
of the NHP serial dilutions was made in 50% FCS/PBS. The dilutions and neat pools were 
tested on the AxSYM and ARCHITECT for HBsAg, anti-HBs and anti-HBc (total). (2) 
Additionally, a sample with a known HBsAg titre of 431,000 IU/ml (quantification done at 
the Public Health England (PHE)) was also diluted with NHP and 50%FCS/PBS at a range of 
1:10 to 1:10,000,000 and tested on both the AxSYM and ARCHITECT. (3) One sample 
(sample 4) with anti-HBs titre >1,000mIU/mL on the ARCHITECT was diluted from 1:10 to 
1:10,000 using NHP and 50%FCS/PBS. Furthermore, 1:10 dilutions of each of the same 
NHP dilutions were made using 50% FCS/PBS as the diluent. These dilutions, summarized in 
Table 3.1, were tested on the ARCHITECT. 
Table 3. 1: Summary of sample dilutions 
 Pooled sample Anti-HBs> 1000mIU/mL 
 NHP 50% 
FCS/PBS 
10% of NHP 
dil in 50% 
FCS/PBS 
NHP 50% 
FCS/PBS 
10% of NHP 
dil in 50% 
FCS/PBS 
D
ilu
tio
n
 
1:10 1:10 1:10 1:10 1:10 1:10 
1:100 1:100 1:100 1:100 1:100 1:100 
1:1,000 1:1,000 1:1,000 1:1,000 1:1,000 1:1,000 
1:10,000 1:10,000 1:10,000 1:10,000 1:10,000 1:10,000 
1:100,000 1:100,000 1:100,000 1:100,000 1:100,000 1:100,000 
1:1,000,000 1:1,000,000 1:1,000,000 1:1,000,000 1:1,000,000 1:1,000,000 
1:10,000,000 1:10,000,000 1:10,000,000 1:10,000,000 1:10,000,000  
1:100,000,000 1:100,000,000 1:100,000,000 1:100,000,000 1:100,000,000  
 
3.2.3.2  Validation of the ARCHITECT results 
Validation of the HBsAg assay using diluted samples 
As previously mentioned in Section 3.2.3.1, 37 samples were retrieved from the NHLS 
diagnostic laboratory and were diluted in NHP for the testing of HBV markers being HBsAg, 
anti-HBs, anti-HBc (total) on the ARCHITECT. The neat samples were tested in parallel for 
comparison.  Table 3.2 shows a summary of the results.  
Of these 37 neat samples, 11 samples were positive for HBsAg, 6 were negative and 21 
samples were low positive on the AxSYM platform. Out of the 11 HBsAg positive 
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specimens, 9 were found positive and 2 negative when tested neat and at 1:10 dilution during 
both runs on the ARCHITECT. The 2 samples had the lowest positive S/N values as 
compared to the 9 other positive samples on the AxSYM. Only 14 of the 21 low positive 
samples tested positive on the ARCHITECT. Eight of those 14 positives specimens were re-
tested and were repeatedly positive. The remaining 6 could not be re-tested due to low sample 
volume. 
The 21 low positive samples detected on the AxSYM were neutralized to confirm HBsAg 
positivity. As represented on Table 3.3, 13 of these samples were confirmed as true HBsAg 
positive and 7 were negative, indicative of likely false positive results in these samples. One 
sample had an inconclusive result.   
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Table 3. 2: ARCHITECT validation of HBsAg testing on 1:10 diluted samples 
 Run 1 Run 2 
Lab Number AxSYM (S/N) Architect (neat) 
(S/CO) 
Architect 10x 
dilution (S/CO) 
Architect (neat) 
(S/CO) 
Architect 10x 
dilution (S/CO) 
STY4768186 2.26 LP 1.54 POS 0.47 NEG ins ins ins ins 
STY4809997 4.35 LP 0.36 NEG 0.28 NEG 0.25 NEG 0.38 NEG 
STY4827077 4.05 LP 10.39 POS 1.99 POS ins ins ins ins 
STY4857857 2.54 LP 1.23 POS 0.35 NEG ins ins ins ins 
STY4870304 5.28 LP 12.77 POS 2.10 POS ins ins ins ins 
STY4898134 3.03 LP 0.23 NEG 0.36 NEG ins ins ins ins 
STY4904507 2.99 LP 4.34 POS 0.93 NEG ins ins ins ins 
STY5017776 270.9 POS 5234.05 POS 5674.02 POS 5293.96 POS 4749.55 POS 
STY5018481 258.36 POS 4537.47 POS 4439.07 POS 4838 POS 4996.25 POS 
STY5023527 19.65 POS 0.23 NEG 0.26 NEG 0.25 NEG 0.2 NEG 
STY5023934  NA POS 29.83 POS 5.48 POS 27.55 POS 5.43 POS 
STY5028983 15.12 POS 0.28 NEG 0.19 NEG 0.22 NEG 0.23 NEG 
STY5030810 28.1 POS 88.90 POS 13.49 POS 90.61 POS 14.1 POS 
STY5051715 246.09 POS 4792.26 POS 1603.23 POS 4880.53 POS 1733.07 POS 
STY5051766 86.8 POS 554.25 POS 87.16 POS 554.25 POS 87.16 POS 
STY5056302 83.05 POS 499.35 POS 72.27 POS 643.09 POS 93.1 POS 
STY5085522 88.79 POS 432.48 POS 72.15 POS 374.03 POS 58.55 POS 
STY5020925  NA POS 21.57 POS 3.78 POS 27.08 POS 4.21 POS 
NHP NA NEG 0.27 NEG  NA NA  0.3 NEG  NA NA  
STV0544934 3.02 LP 3.56 POS 0.82 NEG 3.35 POS 0.81 NEG 
STV0543722 3.38 LP 3.79 POS 0.74 NEG 3.64 POS 0.78 NEG 
STV0543515 2.24 LP 0.22 NEG 0.25 NEG 0.26 NEG 0.21 NEG 
STV0551517 6.81 LP 15.82 POS 2.73 POS 66.56 POS 2.84 POS 
STV0540956 5.77 LP 5.11 POS 0.86 NEG  NA NA  0.84 NEG 
STV0549516 2.3 LP 0.24 NEG 0.22 NEG 0.38 NEG 0.55 NEG 
STV0546706 3.81 LP 0.59 NEG 0.27 NEG 0.65 NEG 0.28 NEG 
STV0547150 4.02 LP 6.10 POS 0.79 NEG 5.49 POS 0.79 NEG 
STV0549277 5.95 LP 11.51 POS 1.11 POS 8.91 POS 1.08 POS 
STV0556621 2.24 LP 0.29 NEG 0.24 NEG 0.3 NEG 0.24 NEG 
STV0556546 3.57 LP 80.07 POS 7.18 POS 78.47 POS 7.3 POS 
STV0556462 8.13 LP 0.24 NEG 0.19 NEG 0.2 NEG 0.24 NEG 
STV0554000 3.18 LP 10.72 POS 1.25 POS 10.93 POS 1.16 POS 
STV0566338 4.39 LP 4.21 POS 0.62 NEG 3.94 POS 0.61 NEG 
LP:  Low positive 
POS:  Positive 
NEG:  Negative 
Ins:  Insufficient 
NA: Not Available 
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Table 3. 3: Neutralization assay of low HBsAg positive samples 
 Neutralization (neat sample) 
Lab number AxSYM (S/N) NHP OD  Anti-S OD  Result 
STY4768186 2.26 LP 0.070 0.060 NEG 
STY4809997 4.35 LP 0.053 0.054 NEG 
STY4827077 4.05 LP 0.278 0.059 POS 
STY4857857 2.54 LP 0.116 0.059 POS 
STY4870304 5.28 LP 0.320 0.072 POS 
STY4898134 3.03 LP 0.052 0.057 NEG 
STY4904507 2.99 LP 0.263 0.111 POS 
STV0544934 3.02 LP 0.326 0.066 POS 
STV0543722 3.38 LP 0.415 0.170 POS 
STV0543515 2.24 LP 0.053 0.056 NEG 
STV0551517 6.81 LP 1.422 0.285 POS 
STV0540956 5.77 LP 0.235 0.094 POS 
STV0549516 2.3 LP 0.115 0.089 POS 
STV0546706 3.81 LP 0.056 0.054 NEG 
STV0547150 4.02 LP 0.164 0.061 POS 
STV0549277 5.95 LP 0.189 0.066 POS 
STV0556621 2.24 LP 0.054 0.057 NEG 
STV0556546 3.57 LP 1.411 0.091 POS 
STV0556462 8.13 LP 0.054 0.056 NEG 
STV0554000 3.18 LP 0.231 0.060 POS 
STV0566338 4.39 LP 0.169 0.072 POS 
NHP:  Normal Human Plasma 
OD:  Optical density 
LP: Low positive 
 
Further testing on diluted samples was performed using (1) three pooled samples and, (2) a 
sample with known HBsAg titre. Tables 3.4 and 3.5 show the results obtained from those 
assays. (1) On the ARCHITECT, HBsAg positivity was detected to a dilution of 1:100,000 
with 50% FCS/PBS. However, positivity was lost at a dilution of 1:10,000 with NHP and 
10% of NHP diluted in 50% FCS/PBS. On the other hand, HBsAg positivity is not lost until a 
dilution 1:1,000,000 for all three dilutions on the AxSYM. At further dilutions (1:10,000,000 
and 1:100,000,000), the system gave an error code for unknown reasons. These results are 
graphically confirmed on Figure 3.1. The latter also shows the cut off value of both platforms 
ARCHITECT and AxSYM being 1 and 2, respectively. All points situated above those cut 
off values are considered positive and the ones below are considered negative. The graph 
representing results on the ARCHITECT shows no difference in the behaviour of the results 
obtained from diluting the pool sample with either NHP or 50% FCS/PBS. However the 10% 
NHP diluted in 50% FCS/PBS dilution affected the results adversely hence was not an 
adequate method of dilution for the samples. On the other hand, a difference is observed 
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between the dilution with NHP and 50% FCS/PBS on the AxSYM graph and result with the 
10% NHP dilution in 50% FCS/PBS is similar to what is observed on the ARCHITECT. (2) 
The sample with known HBsAg titre appears to be still detected as positive until diluted out 
to 1:10,000,000 dilution with both NHP and 50% FCS/PBS, the highest S/CO values being 
obtained with NHP. This observation is graphically depicted on Figure 3.2.   
Table 3. 4: HBsAg testing on Architect (S/CO values shown) 
 High HBsAg+  (431 000 
IU/ml) 
Pooled sample 
Dilution 50% 
FCS/PBS 
NHP NHP 50% 
FCS/PBS  
10% of NHP dil in 
50% FCS/PBS 
1:10 3349.00 2894.62 3839.81 3892.48 840.56 
1:100 6612.18 6505.56 681.89 766.56 88.48 
1:1,000 5350.76 6332.22 71.80 78.86 12.14 
1:10,000 1118.02 1946.28 7.49 8.09 1.27 
1:100,000 121.17 239.54 0.93 1.13 0.44 
1:1,000,000 10.74 23.21 0.25 0.35 0.67 
1:10,000,000 2.50 2.52 N/A N/A N/A 
1:100,000,000 0.53 0.47 N/A N/A N/A 
Neat high HBsAg+: 590.43 S/CO  
Neat Pool:  5740.72 S/CO 
Dil:    Diluted 
 
Table 3. 5: HBsAg testing on the AxSYM (S/N values shown) 
 
 High HBsAg sample (431 000 
IU/ml) 
Pooled sample 
Dilution 
50% 
FCS/PBS 
NHP NHP 
50% 
FCS/PBS  
10% of NHP dil in 
50% FCS/PBS 
1:10 301.45 433.45 245.24 211.13 123.56 
1:100 427.13 569.06 130.66 118.81 24.73 
1:1,000 363.53 459.24 24.61 26.40 6.31 
1:10,000 237.98 265.83 10.29 4.08 1.98 
1:100,000 81.48 73.81 1.15 1.76 1.22 
1:1,000,000 60.02 9.21 1.34 1.27 1.27 
1:10,000,000 8.91 2.09 N/A N/A N/A 
1:100,000,000 1.98 1.34 N/A N/A N/A 
Neat high HBsAg+: insufficient 
Neat pool:  279.25 S/CO 
Dil:    Diluted 
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Figure 3. 1: Plot of HBsAg positive pool on the ARCHITECT and AxSYM. The X axis represents the S/CO 
and S/N readings respectively and the Y axis represent the dilutions. All points situated above the cut-off line 
are considered as positive whereas points situated below are considered as negative. The three samples that were 
pooled had HBsAg S/N>200 on the AxSYM. 
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Figure 3. 2: Plot of high HBsAg positive sample on the ARCHITECT and AxSYM. Sample quantified at 
431,000 IU/ml at PHE. The X axis represents the S/CO and S/N readings respectively and the Y axis represent 
the dilutions. All points situated above the cut-off line are considered as positive whereas points situated below 
are considered as negative.  
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Validation of the Anti-HBs assay using diluted samples 
The samples used for the HBsAg screening were also used for the anti-HBs assay. As Table 
3.6 below illustrates, 5 neat samples were found anti-HBs positive on the ARCHITECT. Of 
these 5 samples, 4 had low S/CO values as compared to 1 sample with a high S/CO value. 
The latter was also found anti-HBs positive at a 1:10 dilution. Three of the four samples with 
low S/CO values were insufficient for testing at the 1:10 dilution and the other sample was 
found anti-HBs negative when diluted to a 1:10 concentration. Same results were observed on 
the second run. NHP tested negative for this marker on both platforms, confirming the true 
results of these diluted samples. 
Table 3.7 and Figure 3.3 illustrate detailed results obtained on the dilutions of Sample 4 with 
anti-HBs>1.000mIU/mL on the ARCHITECT. Table 3.7 shows that at dilution 1:1,000,000, 
quantification is still possible but positivity is detected up to 1:100 with NHP. With 50% 
FCS/PBS, the same observations were made although the values obtained with NHP are more 
accurate. With the 10% NHP diluted in 50% FCS/PBS, anti-HBs positivity is lost after the 
1:10 dilution. Beyond that point, the sample appeared anti-HBs negative. These observations 
are confirmed on Figure 3.3 showing the cut off value of the assay and the behaviour of the 
assays using diluted samples. The graph also shows no linearity with the data plotted.  
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Table 3. 6: ARCHITECT validation of anti-HBs testing on 1:10 diluted samples 
 Run 1 Run 2 
Lab Number AxSYM Architect 
(neat) 
Architect 10x 
dilution 
Architect 
(neat) 
Architect 10x 
dilution 
STY4768186 NT 17.73 POS 3.61 NEG ins  ins  
STY4809997 NT 0.00 NEG 0.99 NEG 0.00 NEG 1.40 NEG 
STY4827077 NEG 3.05 NEG 1.43 NEG ins  ins  
STY4857857 NT 22.63 POS 5.51 NEG ins  ins  
STY4870304 NT 14.27 POS 1.20 NEG ins  ins  
STY4898134 NEG 0.10 NEG 1.00 NEG ins  ins  
STY4904507 NEG 0.89 NEG 1.23 NEG ins  ins  
STY5017776 NEG 0.56 NEG 0.26 NEG 0.41 NEG 8.19 NEG 
STY5018481 NT 0.13 NEG 0.23 NEG 0.00 NEG 0.00 NEG 
STY5023527 NEG 0.00 NEG 1.17 NEG 0.00 NEG 1.99 NEG 
STY5023934 NT 0.00 NEG 1.15 NEG 0.00 NEG 0.85 NEG 
STY5028983 NT 0.00 NEG 1.16 NEG 0.00 NEG 0.98 NEG 
STY5030810 NEG 0.00 NEG 1.11 NEG 0.00 NEG 0.25 NEG 
STY5051715 NT 0.02 NEG 0.69 NEG 0.00 NEG 1.04 NEG 
STY5051766 NEG 0.04 NEG 1.14 NEG ins  ins  
STY5056302 NT 0.00 NEG 1.03 NEG 0.00 NEG 0.48 NEG 
STY5085522 NEG 5.78 NEG 2.18 NEG 5.10 NEG 1.18 NEG 
STY5020925 NEG 0.00 NEG 1.10 NEG 0.00 NEG 1.24 NEG 
NHP NEG 1.48 NEG NA NA NA NA NA NA 
STV0544934 NEG 0.00 NEG 0.96 NEG 0.00 NEG 0.95 NEG 
STV0543722 NT 15.47 POS 2.70 NEG 14.31 POS 2.85 NEG 
STV0543515 NEG 4.03 NEG 1.31 NEG 4.27 NEG 1.19 NEG 
STV0551517 NEG 8.80 NEG 1.92 NEG 9.60 NEG 2.08 NEG 
STV0540956 NEG 0.00 NEG 0.97 NEG 0.07 NEG 0.95 NEG 
STV0549516 NT 7.15 NEG 1.79 NEG 6.94 NEG 1.70 NEG 
STV0546706 NEG 0.00 NEG 0.99 NEG 0.00 NEG 0.93 NEG 
STV0547150 NT 1.72 NEG 1.16 NEG 1.65 NEG 1.14 NEG 
STV0549277 NEG 0.98 NEG 1.23 NEG 1.01 NEG 1.34 NEG 
STV0556621 NEG 5.82 NEG 1.50 NEG 6.48 NEG 1.54 NEG 
STV0556546 NEG 0.00 NEG 0.95 NEG 0.00 NEG 0.93 NEG 
STV0556462 NT 668.43 POS 60.50 POS 644.84 POS 61.28 POS 
STV0554000 NT 0.00 NEG 0.95 NEG 0.00 NEG 1.02 NEG 
STV0566338 NT 0.23 NEG 1.02 NEG 0.29 NEG 1.05 NEG 
NT:  Not tested 
POS:  Positive 
NEG:  Negative 
Ins:  Insufficient 
NA: Not Available 
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Table 3. 7: Anti-HBs testing of Sample 4 on Architect   
  Sample 4 (>1000 mIU/ml) 
Dilution NHP 50% 
FCS/PBS 
10% of NHP in 50% 
FCS/PBS 
1:10 555.91 546.01 49.62 
1:100 75.49 66.42 8.53 
1:1,000 9.70 7.60 1.98 
 1:10,000 2.06 0.68 1.09 
1:100,000 1.10 0.00 1.10 
1:1,000,000 1.08 0.00 0.97 
NHP:  1.09 
50% FCS/PBS:  0.00 
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Figure 3. 3: Anti-HBs testing on the ARCHITECT. The neat sample used to make the dilutions had anti-HBs 
>1,000mIU/mL on the ARCHITECT. The X axis represents anti-HBs titres calculated for each dilution which 
are represented on the Y axis.  
 
Validation of the anti-HBc (total) assay using diluted samples 
Seventeen neat samples which tested positive for anti-HBc (total) on the AxSYM also tested 
positive on the ARCHITECT and at the 1:10 concentration with the exception of one sample. 
The latter had low anti-HBc (total) positivity when tested neat. 
An additional 13 specimens not tested on the AxSYM, were tested neat on the ARCHITECT. 
Ten of these samples tested anti-HBc (total) positive and three were anti-HBc (total) negative 
on the ARCHIECT. Among the 10 anti-HBc (total) positive samples, two had low anti-HBc 
(total) S/N values as compared to the eight other samples. At a 1:10 dilution, these two 
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samples tested anti-HBc (total) negative. The other 8 specimens were still positive at the 1:10 
dilution.  These observations are detailed on Table 3.8 below.   
Table 3. 8: ARCHITECT validation of anti-HBc (total) testing on 1:10 diluted samples 
  Run 1 Run 2 
Lab number AxSYM Architect 
(neat) 
Architect 
10x dil 
Architect 
(neat) 
Architect 10x 
dil 
STY4768186 NT 2.50 POS 0.63 NEG ins   ins   
STY4809997 NT 0.14 NEG 0.29 NEG 0.13 NEG 0.27 NEG 
STY4827077 POS 12.72 POS 8.72 POS ins   ins   
STY4857857 NT 14.07 POS 11.96 POS ins   ins   
STY4870304 NT 14.27 POS 14.48 POS ins   ins   
STY4898134 NEG 0.09 NEG 0.29 NEG ins   ins   
STY4904507 POS 10.73 POS 10.76 POS ins   ins   
STY5017776 POS 13.79 POS 14.34 POS 13.97 POS 13.28 POS 
STY5018481 NT 13.27 POS 14.35 POS 13.90 POS 13.54 POS 
*STY5023527 NEG 0.12 NEG 0.29 NEG 0.20 NEG 0.39 NEG 
STY5023934 POS 14.41 POS 13.50 POS 13.32 POS 12.54 POS 
STY5028983 NT 0.35 NEG 0.36 NEG 0.32 NEG 0.51 NEG 
STY5030810 POS 10.69 POS 6.45 POS 10.63 POS 6.11 POS 
STY5051715 NT 14.88 POS 14.66 POS 14.31 POS 13.58 POS 
STY5051766 POS 12.94 POS 13.18 POS ins   ins   
STY5056302 NT 11.27 POS 4.10 POS 10.89 POS 3.97 POS 
STY5085522 POS 14.56 POS 15.01 POS 13.58 POS 13.97 POS 
STY5020925 POS 12.92 POS 13.01 POS 12.62 POS 12.00 POS 
NHP NEG 0.36 NEG  NA  NA NA  NA  NA  NA  
STV0544934 POS 10.48 POS 9.79 POS 10.57 POS 9.81 POS 
STV0543722 NT 9.54 POS 8.31 POS 9.82 POS 8.71 POS 
STV0543515 POS 2.05 POS 0.43 NEG 1.94 POS 0.42 NEG 
STV0551517 POS 10.02 POS 9.82 POS 9.86 POS 9.59 POS 
STV0540956 POS 11.71 POS 11.45 POS 11.91 POS 10.80 POS 
STV0549516 POS 7.85 POS 1.39 POS 7.87 POS 1.42 POS 
STV0546706 POS 9.84 POS 2.58 POS 10.17 POS 2.66 POS 
STV0547150 NT 7.50 POS 1.20 POS 7.05 POS 1.19 POS 
STV0549277 POS 7.31 POS 1.14 POS 7.28 POS 1.16 POS 
STV0556621 POS 10.21 POS 4.15 POS 10.37 POS 4.10 POS 
STV0556546 POS 11.83 POS 10.18 POS 12.05 POS 9.96 POS 
STV0556462 NT 1.06 NEG 0.35 NEG 1.17 POS 0.34 NEG 
STV0554000 NT 3.23 POS 0.59 NEG 3.17 POS 0.62 NEG 
STV0566338 NT 12.60 POS 11.92 POS 13.26 POS 12.41 POS 
NT:  Not tested 
POS:  Positive 
NEG:  Negative 
Ins:  Insufficient 
NA: Not Available 
Dil: Diluted 
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The neat pooled sample had an S/CO value of 13.95 on the ARCHITECT and an S/N value 
of 0.080 on the AxSYM. These two values have two different interpretations given the 
difference in nature of the assay on each platform. On the AxSYM, the assay is competitive 
hence all values below the cut off value of 1.00, are considered positive for anti-HBc (total). 
The opposite is applied on the ARCHITECT on which the assay is not competitive, all values 
above the cut off value of 1.00 are considered positive.  
On ARCHITECT, anti-HBc (total) in the pooled sample was detected up to a dilution of 
1:10,000 when using either NHP or 50% FCS/PBS as the diluent. However S/CO values are 
higher when using NHP. With the 10% of NHP diluted in 50% FCS/PBS, positivity was not 
detected beyond 1:1,000. The same results are observed on the AxSYM. These are illustrated 
below on Tables 3.9 and 3.10 and represented graphically on Figure 3.4.  
The loss of some sensitivity was not considered to be important, as we wanted to avoid 
detecting maternal anti-HBc (total) and limit our ability to detect positive anti-HBc (total) in 
those infants who were exposed to HBV i.e. truly anti-HBc positive.  
Table 3. 9: Anti-HBc (total) testing on Architect (S/CO values) 
  Anti-HBc (total)+ Pool 
Dilution NHP 50% 
FCS/PBS 
  10% of NHP diluted in 50% 
FCS/PBS 
1:10 13.31 12.51 11.45 
1:100 12.65 11.74 9.15 
1:1,000 10.16 9.12 2.20 
1:10,000 2.40 1.83 0.26 
1:100,000 0.50 0.16 0.10 
1:1,000,000 0.32 0.02 0.15 
Neat pool:  13.95 S/CO 
 
Table 3. 10: Anti-HBc (total) testing on AxSYM (S/N values) 
  Anti-HBc (total)+ Pool 
Dilution NHP 
50% 
FCS/PBS  
 10% of NHP diluted in 50% 
FCS/PBS 
1:10 0.085 0.076 0.074 
1:100 0.092 0.100 0.071 
1:1,000 0.094 0.096 0.181 
1:10,000 0.208 0.172 1.466 
1:100,000 1.070 1.364 1.918 
1:1,000,000 1.207 2.091 1.915 
Neat pool:  0.080 S/N 
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Figure 3. 4:  Plot of results of Anti-HBc (total) positive pool testing on the Architect and AxSYM. The 
three samples used to make the pool had S/CO>10 on ARCHITECT. The X axis represents the S/CO and S/N 
readings respectively and the Y axis represent the dilutions. On the ARCHITECT curve, all points above the 
cut-off line are positive samples whereas the points below are negative samples. The opposite is seen on the 
AxSYM curve because the assay is competitive on the AxSYM.  
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3.2.3.3 HBsAg testing 
Principle 
The HBsAg assay on the ARCHITECT system is a one-step chemiluminescent microparticle 
immunoassay (CMIA) for the qualitative detection of HBsAg in human serum or plasma. The 
sample is incubated at first with anti-HBs coated paramagnetic microparticles and anti-HBs 
acridinium-labeled conjugate, forming a reaction mixture. Incubation allows HBsAg present 
in the sample to bind to the anti-HBs. Then, the reaction mixture is washed to remove 
unbound particles. Following these steps, the pre-trigger (Hydrogen peroxide) and trigger 
(Sodium hydroxide) solutions used here as substrates, are added to the reaction mixture. 
These two solutions, as the name suggests, trigger a chemiluminescent signal measured as 
relative light unit (RLUs) and directly proportional to the amount of HBsAg present in the 
specimen. This reaction is initiated by the addition of the pre-trigger solution which causes 
the release of the label, being acridinium, from the microparticles into solution. A magnetic 
separation of the microparticles from the label then occurs. The microparticles are attracted to 
the inner walls of the reaction vessels and the label remains in solution. Finally, the trigger 
solution containing base is added to the reaction causing the chemiluminescence (Wild, 
2005). The chemiluminescent signal generated in the reaction is compared to a cut-off value 
determined from an active ARCHITECT HBsAg calibration. If the signal generated by the 
sample is lower than the cut-off value, then the sample is considered negative for HBsAg and 
if superior or equal to the cut-off value, the sample is considered positive for HBsAg.  
3.2.3.4  Anti-HBs testing 
Principle 
This is a CMIA for the quantitation of anti-HBs present in serum and plasma of human origin 
completed in two steps on the ARCHITECT system. Anti-HBs present in the sample binds to 
recombinant HBsAg (rHBsAg) coated on the paramagnetic microparticles that were 
incubated with the sample during the first step of the assay. The reaction mixture is washed 
then incubated with acridinium-labeled rHBsAg conjugate. Following another wash step, the 
pre-trigger and trigger solutions are added to the reaction mixture for the quantification of 
anti-HBsAg present in the specimen. The chemiluminescent signal, generated by the pre-
trigger and trigger solutions, is directly proportional to the quantity of anti-HBsAg present.  
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The concentration of anti-HBs in the sample is determined using a previously generated anti-
HBs calibration curve generated by the ARCHITECT instrument. According to the criteria of 
the ARCHITECT anti-HBs assay, a sample is considered positive for anti-HBs if the 
concentration of anti-HBs calculated is greater or equal to 10,0 mIU/mL. The upper limit of 
detection of the assay was determined to be 1000 IU/mL (Kim et al., 2007). The lower limit 
of detection of the assay using dilution was determined during the validation of the assay 
(See Section 3.2.3.2).    
3.2.3.5  Anti-HBc (total) testing 
Principle 
The anti-HBc (total) assay on the ARCHITECT is also a two-step sandwich CMIA for the 
qualitative detection of total antibodies against the hepatitis B virus core antigen (anti-HBc 
(total)) in serum or plasma from human. During the test, the specimen is incubated with 
recombinant hepatitis B virus core antigen (rHBcAg) coated on paramagnetic microparticles, 
allowing the binding of anti-HBc (total) present in the sample to the rHBcAg. A washing 
cycle follows this incubation then the reaction mixture is incubated with anti-human 
acridinium-labeled rHBcAg conjugate. Once the incubation period is finished, the reaction 
mixture is again washed and the pre-trigger and trigger solutions are added to it, creating a 
chemiluminescent signal detected by the optics of the machine. The strength of the signal is 
directly related to the quantity of anti-HBc (total) detected in the specimen. 
The chemiluminescent signal generated in the reaction is compared to a cut-off value 
determined from an active ARCHITECT anti-HBc (total) calibration curve. If the signal 
generated by the sample is greater than or equal to the cut-off value, then the sample is 
considered positive for anti-HBc (total). 
Method 
Due to the low volume of sample available for testing, samples were at first diluted to 1:10 
with 50% inactivated FCS/PBS. The samples were then inserted into the ARCHITECT 
machine for the testing of all three HBV markers (HBsAg, anti-HBs and anti-HBc (total)) at 
one time.  
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3.2.3.6  Quality control of serological assays 
To ensure the validity of the serology assays used, each assay had a calibration and quality 
control procedures. Each test performed on the ARHICTECT i2000SR was calibrated 
according to the manufacturer‘s instructions. Calibrators were tested in triplicates for HBsAg 
and anti-HBc (total) testing and in duplicates for anti-HBs testing, every time a new kit was 
used.  The system of the machine calculates the mean signal-to-cut-off (S/CO) values from 
the calibrator replicates and uses it to calculate the S/CO values of the samples. 
Two controls, negative and positive, are supplied with the kits. Each control was tested once 
every day during the testing period to evaluate the assay calibration. Each control values were 
ensured to be within the ranges specified in the package insert of the control before the 
testing of samples.  
During the dilution procedures, clean pipettes and microcentrifuge tubes were used. Samples 
were centrifuged before being opened to avoid contact with gloves and the formation of 
droplets in the lid of the tubes, which could result in cross contamination of samples. Tips 
were changed after each pipetting to avoid cross contamination between samples and 
contamination of the reagents used for dilution. Before dilution, the NHP was screened for all 
HBV markers being HBsAg, anti-HBs, anti-HBc (total) and tested negative for all.  
 
3.2.4 Molecular procedures 
3.2.4.1  Individual viral HBV DNA extraction 
The QIAamp® MinElute® Virus Spin (QIAGEN GmbH, Hilden, Germany) was used for the 
extraction of viral DNA from HBsAg positive samples.  The extraction procedure followed 
the manufacturer‘s instructions using 200μl of serum or plasma sample. 
A lysis buffer mix was prepared with 200μl of buffer AL (the lysis buffer) containing 5.6μg 
of carrier RNA (provided with the kit) and 3.5μl of murine cytomegalovirus (mCMV) extract 
used as internal control (400 copies/μl) prior to extraction. The internal control was received 
from the Blood Borne Virus Unit (BBVU), PHE (Colindale, UK). A volume of 200μl of each 
sample was pipetted into 1.5mL microcentrifuge tubes containing 25μl of QIAGEN protease. 
Then, 200μl of the buffer AL mix was dispensed into the solution. Contents of the 
microcentrifuge tubes were mixed through pulse-vortexing and incubated at 56ºC for fifteen 
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minutes on a heating block to ensure efficient lysis of the cells and inactivation of RNases. A 
brief spin was performed after incubation to remove drops from inside the lid and 250μl of 
100% ethanol (Sigma-Aldrich, St Louis, MO) was added. The solution was mixed by pulse-
vortexing and incubated at room temperature for five minutes. After brief centrifugation of 
the microcentrifuge tubes, each sample mix was carefully applied to the QIAamp Mini spin 
column and centrifuged at 8000 rpm (6000 x g) for a minute. This enabled the binding of the 
nucleic acid to the silica membrane of the column for further purification. Two washing steps 
were performed subsequently with 500μl buffer AW1 and 500μl buffer AW2. Each wash was 
followed by two centrifugations at 8000rpm (6000 x g) for a minute for complete purification 
of the nucleic acid. The washing done, 500μl of 100% ethanol was added into the QIAamp 
mini columns for DNA purification. The QIAamp mini columns were centrifuged at 8000 
rpm (6000 x g) for three minutes. An additional centrifugation step was performed at full 
speed 14 000 rpm (20 000 x g) to ensure that there is no more ethanol left in the column. The 
columns were incubated at 56ºC on a heating block for three minutes with caps opened, for 
complete dry out of the membrane.  Finally 60μl of buffer AVE, the elution buffer, was 
added to the mini columns. The latter were incubated at room temperature for five minutes 
then centrifuged at 14 000 rpm (20 000 x g) for a minute for DNA elution. 
3.2.4.2  Determination of limit of detection of the in-house real-time PCR assay 
The quantitative real-time PCR (qPCR) was established in this laboratory (Maponga TG, 
MSc Thesis, Stellenbosch University, 2012) using for reference the in-house real-time HBV 
assay used at the BBVU, PHE London 
(http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684).  
The limit of detection of the assay, DL IU/ml, was to be determined. A ten-fold dilution of 
sample, ―Chong‖ standard, with a known viral load of 108 IU/mL was made. Additionally, 
the 10
2
 IU/mL dilution was further diluted at 1:2, 1:5 and 1:10 to a concentration of 50 
IU/mL, 20 IU/mL and 10 IU/mL respectively (see Table 3.11). A 60μl elute of viral nucleic 
acid DNA was extracted from the diluted samples using the same QIAamp
®
 MinElute® 
Virus Spin kit (QIAGEN GmbH, Hilden, Germany). The DNA extracts were run in 
quadruplicate in one run and in quintuple in a second run during two different days using a 
real-time PCR protocol defined later. Those results were used to draw a standard curve. 
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Table 3. 11: Ten-fold dilution of the “Chong” standard 
In-house Control  Composition  
10 000 000  IU/mL  30μl 100 000 000  IU/mL control + 270μl NHP  
1 000 000  IU/mL  30μl 10 000 000  IU/mL control + 270μl NHP  
100 000  IU/mL  30μl 1 000 000  IU/mL control + 270μl NHP  
10 000  IU/mL  30μl 100 000  IU/mL control + 270μl NHP  
1 000 IU/mL  30μl 10 000  IU/mL control + 270μl NHP  
100 IU/mL  30μl 1 000  IU/mL control + 270μl NHP 
50 IU/mL 250µl 100 IU/mL control + 250µl NHP 
20 IU/mL 60µl 100 IU/mL + 140 µl NHP 
10 IU/mL  30μl 100  IU/mL control + 270μl NHP  
Negative 300μl NHP  
NHP: Normal Human Plasma 
IU/mL: International units per millilitres  
 
3.2.4.3  Quantification of HBV viral copies using quantitative Real-Time PCR (qPCR) 
HBV viral DNA loads of all HBsAg and anti-HBc (total) positive samples were determined 
using the probe-based real-time PCR assay developed by Garson et al. (Garson et al., 2005) 
with a final volume of 25µL per reaction on the Rotor Gene 6000 real-time PCR machine 
(Corbett Sciences, Australia).  
Table 3.12 shows the primers and probes used during the assay. These are specific for highly 
conserved regions of the HBs gene and for the detection of the internal control, mCMV. The 
TAMRA fluorochrome was used as a quencher dye and FAM and VIC were used as reporter 
dyes for HBV and mCMV detection, respectively. These three fluorochromes were used to 
identify only DNA molecules containing the probe sequence. The green channel of the 
thermal cycler was used to detect HBV after excitation of FAM and the yellow channel was 
used to identify the internal control, mCMV, after excitation of VIC.  Calculation of the viral 
loads was done using the standard curve constructed with the real-time PCR standards 
previously extracted as described in section 3.2.4.2. and quantified in IU/mL. 
Table 3. 12: List of primers and probes used for HBV and mCMV detection 
Primer / Probe Sequence 
HBV forward primer 5‘-GTG TCT GCG GCG TTT TAT CA-3‘ 
HBV reverse primer 5′- GAC AAA CGG GCA ACA TAC CTT-3′ 
HBV probe 5‘FAM-CCT CT(T/G) CAT CCT GCT GCT ATG CCT CAT C-3‘-
TAMRA 
mCMV forward primer 5′-AAC CCG GCA AGA TTT CTA ACG-3′ 
mCMV reverse primer 5′-ATT CTG TGG GTC TGC GAC TCA -3′ 
mCMV probe 5‘-VIC-CTA GTC ATC GAC GGT GCA CAT CGG C-3‘-TAMRA 
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The real-time PCR master mix was prepared according to the number of samples, controls 
and standards processed at a time. The standards were run in duplicates. The 2× Quantitect 
qPCR master mix kit (QIAGEN, GmbH, Hilden, Germany) was used to carry on the assay. 
Table 3.13 shows details on the reagents used to prepare the real-time PCR master mix. A 
10µL volume of each sample, control and standard was added to 15 µL of the master mix. 
Amplification and detection of the targets were run at the cycling conditions represented on 
Table 3.14. For purpose of quality control, a negative control (NC), a no template control 
(NTC) and a working control were added in each run. The working control used was a 
sample which previously tested positive for HBV viral load hence had a known viral load. 
This sample was used to ensure the reproducibility and assess the variability of the assay. The 
NTC was nuclease-free water and the NC was NHP, to assess if no contamination had 
occurred during the handling and manipulation of the PCR tubes and during viral nucleic acid 
extraction. An internal control, mCMV, added to the samples during DNA extraction was 
also used as a quality control. The yellow channel of the machine was used to monitor if the 
internal control was detected in the assay and was used to validate the results for each 
sample. 
Table 3. 13: Composition of the quantitative real-time PCR master mix 
Reagent Working 
Concentration 
Final 
concentration 
Volume/reaction 
(µL) 
2X Quantitect PCR kit 2X 1X 12.50 
HBV forward primer 100µM 400nM 0.10 
HBV reverse primer 100 µM 400 nM 0.10 
HBV probe 100 µM 200 nM 0.05 
mCMV forward primer 100 µM 400 nM 0.10 
mCMV reverse primer 100 µM 400 nM 0.10 
mCMV probe 100 µM 200 nM 0.05 
Water n/a n/a 2.00 
Total Volume n/a n/a 15.00 
 
Table 3. 14: Real-time PCR cycling conditions 
Cycling parameters Cycles Temperature Time 
Initial denaturation 1 95ºC  15 minutes 
Denaturation 
40 
95ºC  15 seconds 
Annealing and extension 60ºC  60 seconds 
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Acceptance criteria of a valid run 
To ensure the validity of a run, a number of criteria had to be considered, including the 
following: 
i. No HBV DNA was to be detected from the negative control (NHP) and the NTC. 
However, the NC must have a valid internal control cycle threshold (Ct). The cycle 
threshold is the cycle at which the fluorescence exceeds the background level 
(transition from negative value to positive value). 
ii. The standard curve of the run had to be valid according to the following values: 
 The slope of the standard curve (M) should be within -3.0 to -3.6. It determines 
the efficiency of the qPCR. Ideally, for an efficiency of 100% the slope is -3.32. 
 The R2 value should be between 0.9 and 1.1. R2 indicates how well data points fit 
a curve, showing how linear the data are.  
 The B value had to be higher than the Ct values of the samples and standards. B 
represents the highest cycle number at which the viral load obtained from the 
graph was considered to be reliable. 
iii. The Ct values of samples for HBV and mCMV, the internal control, should be no 
further than 3 standard deviations.  
3.2.4.4  Nucleotide sequencing of the Polymerase and Surface (pol/surface) HBV ORFs 
Positive samples with known HBV DNA viral loads were subjected to Sanger sequencing for 
the purpose of determining the HBV genotype and detecting the presence of mutations 
associated with drug resistance or vaccine-escape. 
Pre-nested PCR 
Remnants of DNA extracted were used to perform pre-nested qualitative polymerase chain 
reactions (PCRs) on the HBV DNA positive samples for further pol/surface sequencing. Each 
pre-nested PCR reaction required 2.5μl of 10× PCR buffer (Invitrogen, California), 0.5μl of 
10 mM deoxynucleotide triphosphate (dNTP) mix (Bioline, London), 0.5μl of the 20 pmol/μl 
HBV 3 reverse primer, 0.5μl of the 20 pmol/μl HBV Z forward primer (listed in Table 3.15), 
0.75μl of 50 mM magnesium chloride (MgCl2) (Invitrogen, California), 0.1μl Thermus 
aquaticus (Taq) Polymerase (Invitrogen, California), 5μl of DNA template and 15.15μl of 
nuclease-free water combined to make a final volume of 25μl. The reaction tubes were 
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inserted into the GeneAmp PCR system 9700 (Applied Biosystems) and the reaction was run 
at the cycling conditions shown in Table 3.16. 
Table 3. 15: Pre-nested PCR primers of the pol/surface region  
Primer Sequence Binding position from Eco R1  
HBV Z – Forward 5′- AGC CCT CAG GCT CAG GGC ATA -3′  3134 – 3154  
HBV 3 – Reverse 5′- CGT TGC CKD GCA ACS GGG TAA 
AGG -3′  
1170 – 1146  
 
Table 3. 16: pre-nested PCR cycling conditions of the pol/surface region 
Cycling parameters Cycles Temperature Time 
Initial denaturation 1 95ºC 5 minutes 
Denaturation 
34 
 
94ºC 30 seconds 
Annealing 55ºc 30 seconds 
Extension 72ºC 1 minute 
Final extension 1 72ºC 2 minutes 
 
Nested PCR 
A second PCR round was performed to improve the specificity of the products obtained from 
pre-nested PCR and to obtain sufficient DNA material, of an approximate size of 900 bp, 
required for cycle sequencing. Pre-nested PCR products were used to carry on the nested 
PCR. For each reaction, 5μl of 10× PCR buffer (Invitrogen, California), 1μl of 10 mM dNTP 
mix (Bioline, London), 1μl of HBV P forward primer (20 pmol/μl), 1μl of HBV M reverse 
primer (20 pmol/μl) (listed in Table 3.17), 1.5μl of 50 mM MgCl2 (Invitrogen, California), 
0.2μl Taq Polymerase (Invitrogen, California), 1μl of DNA template and 39.3μl of nuclease-
free water were mixed to a total volume of 50μl. The reaction was run in the GeneAmp PCR 
system 9700 (Applied Biosystems) at the cycling conditions shown in Table 3.18. 
Table 3. 17: Nested PCR primers of the pol/surface region  
Primer Sequence Binding position from Eco R1 
HBV P – Forward  5′- TCA TCC TCA GGC CAT GCA GT -3′  3247 – 3266  
HBV M – Reverse  5′- GAC ACA CTT TCC AAT CAA TNG G -3′  997 – 976  
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Table 3. 18: Nested PCR cycling conditions of the pol/surface region 
Cycling parameters Cycles Temperature Time 
Initial denaturation 1 95ºC  5 minutes 
Denaturation 
34 
 
94ºC 30 seconds 
Annealing 50ºc 30 seconds 
Extension 72ºC 1 minute 
Final extension 1 72ºC 7 minutes 
 
Visualization of nested PCR products 
Nested PCR products were visualized by gel electrophoresis. A 2% agarose gel was made by 
heat dissolving 2g of powder SeaKem
®
 LE agarose (LONZA, Rockland, ME, USA) into 
100ml of 1× tris-acetate-ethylene diamine tetra acetic acid (TAE) buffer for 2 minutes into a 
microwave. The 1× TAE buffer was prepared from a 50× TAE stock solution. The latter was 
made up by dissolving 242g Tris base (Boehringer Mannheim, USA) into 57.1ml glacial acid 
(Merck Chemicals, Germany), 100mL of 0.5 M ethylenediamine tetra acetic acid (EDTA) of 
pH= 8.0 and distilled water to make up a 1L volume. The heating gel mix was cooled then 
poured into the gel mold and left for a few minutes to allow the gel to solidify. Before the 
loading of samples, the gel was submerged in the 1× TAE buffer. A volume of 5μl of each 
sample was stained with  1μl Novel Juice (GeneDireX, Taiwan), the loading dye, and loaded 
into each well of the gel. A 1kb DNA ladder (GeneRuler™ 1 kb DNA Ladder, Fermentas) 
was loaded at both ends of the gel as a molecular marker for purpose of confirming if the 
correct DNA size had been amplified during PCR. Following sample loading, electrophoresis 
was performed at a voltage of 80V for at least 30 minutes. Visualization of the gel was done 
on the UVItec Prochemi (Cambridge, UK) image acquisition system. The gel was exposed to 
the transluminator light at a high wavelength. The images resulting from the acquisition 
system were edited using the UVIband-1D gel analysis software (Cambridge, UK) and stored 
for interpretation. 
Clean-up of nested PCR products  
Visualization of the PCR products for the confirmation of the correct size of DNA amplified 
being done, all positive samples were cleaned up using the QIAGEN® QIAquick PCR 
Purification Kit (QIAGEN GmbH, Hilden, Germany) following the manufacturer‘s 
instructions. This kit allows the purification and concentration of DNA and uses the principle: 
DNA capture, DNA binding, washing and elution. 
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Five volumes of buffer PB were pipetted into one volume of the nested PCR products. Hence 
225µl of buffer PB was added to 45µl of PCR product. The solution was mixed through 
pulse-vortexing. For DNA binding, the mixture was applied to a silica-membrane column 
provided in the kit. Centrifugation followed for one minute at 13000 rpm. The flow-through 
was discarded and the column placed in the same collection tube. A volume of 0.75ml of 
washing buffer, buffer PE, was then added and the column was centrifuged for one minute at 
13000 rpm. The filtrate was discarded and the column placed in the same collection tube. The 
column was centrifuged for an additional minute at 13000 rpm to remove residual ethanol 
from the washing buffer from the membrane. Next, the column was placed in a clean 1.5ml 
microcentrifuge tube and 50µl of elution buffer, buffer EB, was pipetted to the centre of the 
QIAquick membrane. The purified DNA was eluted by centrifuging the column at 13000 rpm 
for one minute. 
Quantification of the purified HBV DNA concentration was performed 
spectrophotometrically using the NanoDrop® ND-100 (Thermo Fisher Scientific, USA). The 
concentration and purity of the nucleic acid was automatically calculated with the ―Nucleic 
Acid‖ Application module of the NanoDrop Software Version 3.1.0. Samples with a 
concentration above 20ng/µl were diluted to the recommended range (5-20ng/µl) for the 
sequencing PCR reaction. 
 
Cycle sequencing PCR reaction 
This was performed using the BigDye
® 
Terminator v3.1 Cycle Sequencing Ready Reaction 
kit (Applied Biosystems, California, USA), a pre-mixed format to which the template and 
specific primers (listed in Table 3.19) were added to perform the reaction. The kit is used to 
perform fluorescence-based cycle sequencing reactions on single-stranded or double-stranded 
DNA templates, on PCR fragments, and on large templates. The BigDye
®
 Terminator v3.1 
Cycle Sequencing Ready Reaction kit uses the same principle as the Sanger sequencing with 
the use of fluorescent-labelled dNTPs and nucleotide base analogues called 
dideoxynucleotide triphosphates (ddNTPs). The latter, unlike dNTPs, lack the 3‘-OH group 
essential in forming the phosphodiester bond between two nucleotides and thus act as chain 
terminators during the sequencing process.  Hence during cycle sequencing, when a dNTP 
(A, C, G, or T) is added to the 3′ end, chain extension can continue. However, when a ddNTP 
(ddA, ddC, ddG, or ddT) is added to the 3´ end of the primer, chain extension terminates. 
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This results in the formation of DNA fragments of various lengths with ddNTPs at the 3′ -OH 
end. 
The reaction was set up on a 96-well reaction plate. A master mix was prepared with 1μl of 
Terminator Ready Reaction mix, 3μl of ABI sequencing buffer and 4μl of water for each 
reaction. 1μl of each primer and 1μl of the clean nested PCR product were added into the 
specific wells. The reaction was executed on the GeneAmp PCR system 9700 (Applied 
Biosystems) following the cycling parameters indicated in Table 3.20. The latter were used 
for both sequencing reactions. 
Table 3. 19: Oligonucleotide primers used for pol/surface sequencing 
Primer Sequence Binding position from Eco R1 
HBV P – Forward  5′- TCA TCC TCA GGC CAT GCA GT -3′  3247 – 3266  
HBV M – Reverse  5′- GAC ACA CTT TCC AAT CAA TNG G -3′  997 – 976 
HBV H – Forward  5′-TAT CAA GGA ATT CTG CCC GTT TGT 
CCT -3′  
628 – 655  
HBV N – Reverse  5′-ACT GAG CCA GGA GAA ACG GAC TGA 
GGC -3′  
682 – 656  
 
Table 3. 20: pol/surface cycle sequencing cycling conditions  
Cycling parameter Cycles Temperature Time 
Denaturation 
30  
96°C 20 seconds 
Annealing 55ºC 20 seconds 
Extension 60°C 4 minutes 
 
Purification of sequencing products 
Following cycle sequencing, the sequencing products were purified using the BigDye
®
 
Xterminator Purification Kit (Applied Biosystems, Foster City, California, USA) to remove 
unincorporated BigDye terminators used during the sequencing reaction and salts which 
might interfere for base calling during capillary electrophoresis. The kit contains two 
reagents: (1) the XTerminator
®
 solution eliminates unincorporated dye terminators and free 
salts from the post-cycle sequencing reaction and, (2) the SAM
TM
 solution enhances BigDye 
XTerminator performance and stabilizes sample after purification. 
Purification of each well of the 96-wells reaction plate required a master mix made up of 
49.5µL SAM solution and 11µL XTerminator solution per sample. A volume of 55μl of the 
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master mix was pipetted to the post-cycle sequencing products. The reaction plate was sealed 
with a MicroAmp Optical sheet (Applied Biosystems, California) and vortexed on a Multi-
microplate Genie microplate shaker (Scientific Industries, New York) for thirty minutes at 
2000 x g. Following vortexing, the plate was centrifuged for two minutes at 1000 x g.  
The 96-well plate was sealed with a septa mat and placed into the ABI Prism 3130xl genetic 
analyzer (Applied Biosystems, California) for capillary electrophoresis. The latter is an 
instrumental evolution of the polyacrylamide gel separation technique previously used to 
separate DNA sequencing products. 
Sequencing data analysis 
The raw data created by the DNA sequencing analysis software from Applied Biosystems, 
USA, were used for further analysis using the software Sequencher v5 (Gene Codes 
Corporation, Ann Arbor, Michigan, USA). The quality of sequences was improved through 
trimming and editing where necessary. Consensus sequences were formed for each sample 
from the four primer sequences and edited for improvement of the quality using Sequencher 
v5. These consensus sequences were  saved in FASTA format then submitted to the 
following online genotyping tools and databases:  The HBV section of the HIV drug 
resistance data base from Stanford (http://hivdb.stanford.edu/HBV/HBVseq/development.html), 
the Max Planck Institute (http://www.geno2pheno.org) and the HepSeq Research genotyping 
tool (http://www.hepseq.org/Public/Tool/genotype_tool.php) and the NCBI HBV Genotyping 
tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi). 
These tools were used for the identification of the genotype of the HBV strains and the 
detection of mutants related to immune or drug escape. 
3.2.4.5  Phylogenetic analysis 
Phylogenetics is a tool used to confirm the genotype of the HBV strains and to establish the 
relationship between sequences. The consensus sequences obtained from the polymerase and 
surface regions sequencing were aligned with reference sequences of HBV genotype A 
originating from SA and other countries using the software ClustalW (Larkin, 2007). 
Reference sequences of HBV from other genotypes were also added to the alignment. These 
reference sequences were obtained from queries on GenBank, from Maponga TG, MSc 
Thesis, Stellenbosch University (2012) and Chotun BN, MSc Thesis, Stellenbosch University 
(2012).  The alignments were then submitted to MEGA v6 (Tamura et al., 2013) for the 
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construction of phylogenetic trees. The latter show the comparison between the sequences 
forming the alignments. The evolutionary relationship between our sequences was inferred 
using the Neighbor-Joining method (Saitou and Nei, 1987) and the Kimura 2-parameter 
method (Kimura, 1980) was used to calculate the evolutionary distances between them. The 
Neighbor-Joining method is used when dealing with a large number of data sets and for 
bootstrapping analysis. The algorithm uses the least distance between pairs of sequences to 
infer nodes resulting in a tree which represents sequences associated with their most related 
ancestors. The Kimura 2-parameter generates evolutionary distance between sequences and is 
able to distinguish between transitions appearing where a purine is replaced by the other one 
(A<-->G) or a pyrimidine is substituted by another pyrimidine (C<-->T), and transversions 
where a pyrimidine is substituted by a purine or vice versa (A or G <--> C or T).  
3.2.4.6  Quality control of molecular assays 
(1) A NC (NHP) tested negative for all HBV markers was added during each extraction 
procedure to detect contamination.  DNA extraction was performed in a dedicated room, 
under a laminar flow cabinet. The latter is an enclosed bench designed to reduce the risk of 
contamination during the handling of biological samples. Prior to the processing of samples, 
they were briefly centrifuge before opening. This precaution was performed in order to avoid 
contact of any droplets formed in the lid of the tubes with the gloves, which could be a 
possible source of cross contamination between samples. An internal control, mCMV, was 
used as a marker successful extraction of nucleic acids.  
Setup of the PCR assays was performed in different work areas: reagent preparation, sample 
loading and amplification had dedicated rooms. A NC and a NTC were added into each HBV 
PCR procedure. The NTC was used to assess that all reagents used during the assay were not 
contaminated whereas the NC was used to make sure that all reagents were working as they 
should be hence ensuring that every positive result was a true positive result. Nuclease free 
water was used as the NTC and the NC was the extract from NHP performed during DNA 
extraction. The quantitative HBV PCRs had an additional working control added. The latter 
was a sample known to have a high viral load and was used to ensure the reproducibility of 
the assay and assess the variability of the assay hence to ensure the long term validity of the 
assay. Additionally, standards were run during each quantitative run. These standards were 
run in duplicate to increase confidence in the interpretation of the results. Successful 
amplification of the internal control was indicative of a successful run whereas failure in 
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amplifying the internal control was indicative of an invalid run.  Gel electrophoresis, 
sequencing and capillary electrophoresis procedures were also executed in dedicated rooms. 
(2) Each room had dedicated sets of pipettes and filtered tips to use and those were not 
moved from one room to the other one. Clean gloves were always worn when executing all 
procedures and the work benches were disinfected with 10% bleach to denature nucleic acids 
followed by 70% ethanol to destroy any remaining microorganisms left on the work bench 
before and after each procedure. 
 
3.3 Results 
3.3.1 Sample and data collection 
Of the 916 infants from whom blood samples were collected, a total of 851 samples from 
three different locations of SA: Johannesburg, Durban and Cape Town were received.  From 
Johannesburg 555 samples, 46 samples from Durban and 250 samples from Cape Town. The 
others 65 samples were found absent in the lots received from those three locations. From the 
851 samples received, 836 samples were from ―week 48‖ of the study whereas 3 samples 
were from ―week 12‖ and 12 samples were from unknown time period.  
3.3.2 Serology results 
3.3.2.1  Prevalence of HBsAg among study population 
Prevalence of HBsAg among screening samples 
Out of the 851 samples available for testing, one sample was found insufficient hence e 850 
samples were screened for HBsAg using the ARCHITECT i2000R system. A total of three 
out of the 850 samples, originating from Johannesburg, Durban and Cape Town, were found 
highly reactive for HBsAg, giving an HBsAg prevalence of 0.4%. Fifteen samples were 
found HBsAg equivocal i.e. HBsAg S/CO values were in the interval of 1.0 and 4.0.  
However due to low sample volumes, HBsAg neutralisation could not be performed to 
confirm the true HBsAg positivity of these eighteen patients, but HBV DNA testing was 
performed to confirm the presence or absence of viral replication. Table 3.21 gives a 
summary of the serology results of all samples truly positive for HBsAg. 
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Table 3.21: Serology results of true HBsAg positive samples 
Patient ID Location HBsAg (S/CO) Anti-HBs 
(mIU/mL) 
Anti-HBc (total) 
(S/CO) 
350V06029315 Johannesburg 2830.25 2.9 10.83 
262V08006189 Durban 6014.78 3.0   8.74 
279V07019441 Cape Town 5690.34 0.9 10.75 
 
Prevalence of HBsAg among follow-up samples 
The breakdown of data available on the followed up infants are listed below on Table 3.22. 
However, despite extensive efforts, the infants and mothers from Johannesburg and Durban 
could not be contacted for follow up. 
A serum sample collected at point of entry i.e. ―Week 0‖ but not at ―Week 12‖ of sample 
279V07019441, originating from Cape Town, was retrieved. The child and his mother were 
able to be traced and serum samples were collected from both mother and child. The infant 
and his mother were both HIV positive. The child was put on antiretroviral treatment (ART), 
stavudine, 3TC and lopinavir/ritonavir (Kaletra (KLT)), two years prior to this testing. The 
mother, HIV-infected and referred here as ―Cape Town mother‖, was also put on ART two 
years previously. Her regimen consisted of 3TC, TNF and KLT. Both samples tested HBsAg 
positive. The child sample retrieved from ―Week 0‖ was diluted as described previously 
(Section 3.2.3.1.) and screened for HBsAg. The specimen, showed strong HBsAg reactivity.  
Again, due to low sample volume, HBsAg neutralization was not performed on these samples 
to confirm the true HBsAg positivity. 
Table 3. 22: Demographic data of the followed up infants and their mothers 
Patient ID Location Sex Age (years) HIV status 
279V07019441 Cape Town Male 8 Infected 
Cape Town mother Cape Town - 34 Infected 
262V08006189 Durban Unknown Unknown Unknown 
Durban mother Durban - Unknown Infected 
350V6029315 Johannesburg Unknown Unknown Unknown 
Johannesburg 
mother 
Johannesburg - Unknown Infected 
 
Stellenbosch University  http://scholar.sun.ac.za
 
85 
 
3.3.2.2  Prevalence of anti-HBs 
A total number of 474 samples (55.8%) were found positive for anti-HBs with protective 
anti-HBs titres greater than 10 IU/mL. Among those specimens, four had unknown point of 
entry and one was from ―Week 12‖. On the other hand, 293 samples displayed anti-HBs titres 
lower than 10 IU/mL. Three of these samples had unknown point of entry and one was 
collected from ―Week 12‖. Moreover, 83 of the 850 samples (9.8%) showed anti-HBs titres 
lower than 1mIU/mL. Five of these 83 samples had unknown point of entry and one was 
from ―Week 12‖ leaving 77 samples (9.1%) of ―Week 48‖ with anti-HBs titres < 1mIU/mL.  
3.3.2.3  Prevalence of anti-HBc (total) 
Among the 850 specimens screened, two samples which tested negative for HBsAg and anti-
HBs positive, were anti-HBc (total) positive. The three HBsAg positive samples were also 
reactive for anti-HBc (total) whereas all fifteen HBsAg equivocal specimens were anti-HBc 
(total) non-reactive. This shows a 0.6% (5/850) prevalence for anti-HBc (total) in our cohort.   
3.3.2.4 Prevalence of HBeAg and anti-HBe among HBsAg positive follow-up samples 
Due to the low volume of samples, the ―Week 48‖ specimens positive for HBsAg were not 
tested for either HBeAg or anti-HBe. However samples collected at ―Week 0‖ or ―Week 12‖ 
of study and the follow-up samples from both mothers and children were screened for these 
two markers.  
Sample collected at ―Week 0‖ from the child originating from Cape Town was reactive for 
HBeAg and non-reactive for anti-HBe. However, the follow-up sample was found HBeAg 
negative and anti-HBe positive, it is likely that the child had seroconverted. The mother was 
also HBeAg negative and anti-HBe positive. Table 3.23 illustrates the serology status of the 
follow-up HBsAg positive infant and mother. 
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Table 3. 21: Serology results of follow-up HBsAg positive infant and mother 
Patient ID Location HBsAg (S/CO) Anti-HBs 
(mIU/mL) 
Anti-HBc 
(total) (S/CO) 
HBeAg 
(S/CO) 
Anti-HBe 
(S/CO) 
279V07019441 
(12 weeks) 
Cape Town 6548.46 (POS) 0.23 (NEG) 10.11 (POS) 190.52 (POS) 
 
29.09 
(NEG) 
279V07019441 
(60 weeks) 
Cape Town 
5690.34 (POS) 
0.9 (NEG) 
10.75 (POS) 
NT NT 
279V07019441* 
(8 years old) 
Cape Town 4731.37 (POS) 0.02 (NEG) 11.13 (POS) 0.403 (NEG) 0.02 (POS) 
 Cape Town 
Mother 
Cape Town 4779.94 (POS) 0.45 (NEG) 11.13 (POS) 0.550 (NEG) 0.25 (POS) 
*  HIV positive and on ARTs being D4T, 3TC, KLT  
NT:  Not tested  
3.3.3 Molecular results 
3.3.3.1 Viral HBV DNA extraction 
A total number of 815 samples that were found negative for both HBsAg and anti-HBc (total) 
had no further molecular testing performed. HBV DNA extraction was performed on 36 
samples of which the three HBsAg positive samples, the fifteen HBsAg equivocal samples, 
the two anti-HBc (total) positive samples and an additional number of sixteen samples with 
HBsAg S/CO values between 0.70 and 1.0. HBV DNA extraction was performed on those 
sixteen samples to ensure that these samples were truly HBV negative.  
HBV DNA was also extracted from the ―Week 0‖ sample of the Cape Town child and his 
follow-up blood sample. The serum sample from the mother was also processed for HBV 
DNA extraction. 
3.3.3.2  Quantification of HBV viral copies 
3.3.3.2.1 Quantification at screening stage 
The lower limit of quantitation for the assay on the Rotor Gene 6000 was determined to be 20 
IU/ml through repeat testing of standard serial dilutions (Maponga TG, MSc Thesis, 
Stellenbosch University, 2012).  
HBV viral load quantitation was achieved on 36/851 HBV DNA extracted samples using our 
validated in-house real-time PCR assay. The viral load results seen on Table 3.24 showed that 
3/36 samples had a high viral load.  
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The 15 HBsAg equivocal samples and the 16 samples with low HBsAg S/CO values had no 
detectable HBV DNA.  None of the 2 anti-HBc (total) samples had a detectable HBV viral 
DNA.  
This calculates to an active HBV infection prevalence of 0.4% (3/851) of the whole cohort.  
 
Table 3. 22: HBV viral copies of true HBsAg positive “Week 48” samples 
Patient ID Location HBV DNA IU/mL HBV DNA 
log 10 
HBsAg Anti-HBs Anti-HBc 
(total) 
350V06029315 Johannesburg 286 976 397 IU/mL 8.46 + - + 
262V08006189 Durban 147 117 IU/mL 5.17 + - + 
279V07019441 Cape Town 846 254 976 IU/mL 8.93 + - + 
 
3.3.3.2.2 Quantification at follow-up 
As shown on Table 3.25, the specimen collected at ―Week 0‖ from the Cape Town infant had 
a high viral load of 750 746 079 IU/mL but had no detectable viral load at follow up. Serum 
collected from the mother showed a low detectable viral load of 19 IU/mL.  
Table 3. 23: HBV viral copies at follow up 
Patient ID Location HBV DNA IU/mL HBsAg Anti-HBc 
(total) 
HBeAg Anti-
HBe 
279V07019441 
(Twelve weeks) 
Cape Town 750 746 079 IU/mL + + + - 
279V07019441 
(8 years old) 
Cape Town Undetectable + + - + 
Cape Town 
mother  
Cape Town 19 IU/mL + + - + 
 
3.3.3.3  Nucleotide sequencing of the Polymerase and Surface ORFs results 
The three infants positive for HBV DNA were sequenced for the pol/surface gene to 
determine the genotype of the HBV strains through pre-nested and nested PCR runs. The 
―Week 0‖sample of the Cape Town infant, with high viral load was also used for sequencing. 
Due to the low viral load of the Cape Town mother, sample could not be 
sequenced.Visualization of the PCR products is shown on Figure 3.5. The pre-nested DNA 
products obtained from the Johannesburg and Cape Town ―Week 48‖samples were used 
whereas the nested product from the Durban ―Week 48‖ sample was used for sequencing.     
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Figure 3. 5: Pol/surface clean PCR products obtained from “Week 0” of the Cape Town infant. M: 1kb 
molecular weight marker; NC: Negative Control; PN: pre-nested; N: Nested.  
 
These products were cleaned up and the DNA products were analyzed via spectrophotometry 
to determine the purity (A260nm and A260/280nm values) and concentration (ng/µL) of the 
products, see Table 3.26. The A260/280nm ratio is a measure of the purity of DNA. This ratio 
should be approximately 1.8 to consider the DNA product ―pure‖.  
Table 3. 24: Concentration and purity of pol/surface DNA products  
Sample ID ng/µL A260nm  A260/280nm  
NC 5.38 0.108 1.84 
350V06029315 3.69 0.074 1.33 
262V08006189 24.07 0.481 2.11 
279V07019441  10.93 0.219 2.20 
279V07019441* 42.83 0.857 1.92 
* ‖Week 0‖ sample 
ng/µL:  nanogram per microliters 
A:  Absorbance 
NC: Negative Control 
 
The 279V07019441 ―Week 0‖ sample was diluted to the recommended DNA concentration 
range (5 – 20ng/µl) for the sequencing reaction. The sample was diluted using DNA 
nuclease-free water.  A volume of 1µL of each sample, including the NTC, was used for the 
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sequencing reaction. None of the ―Week 48‖samples were diluted giving the low DNA 
concentration. The sequences were amplified with four different primers, as previously 
mentioned.  
After the sequencing reaction, the products were cleaned up and analysed on the ABI Prism 
3130xl genetic analyzer. The sequences obtained were analyzed, trimmed and aligned. A 
contiguous sequence of approximately 900 bp long was obtained from each infant.  
The sequences were then submitted on the HepSeq Research website and the NCBI HBV 
genotyping tool website and these HBV strains were found to belong to Genotype A, 
subgenotype A1. The sequences were also submitted to the Max Plank institute 
(Geno2pheno) website and the HBV section of the HIV drug resistance data base from 
Stanford to identify the presence or absence of clinically relevant mutations. No drug-
resistance or vaccine-escape mutation was identified in the pol/surface gene of the infants 
originating from Johannesburg and Cape Town. The Durban infant showed the M204I 
mutation on the RT domain of the polymerase gene. This mutation is clinically associated 
with drug resistance to 3TC and telbivudine and convers partial resistance to entecavir. No 
other clinically significant mutations were identified on any of these three infants.  
A phylogenetic tree, seen on Figure 3.6, was constructed using these infant‘s‘ HBV 
sequences. The three sequences clustered with genotype A sequences. A second tree, in 
which was added the ―Week 0‖ Cape Town infant‘s sequence, was constructed to compare 
the sequences from ―Week 48‖ to the sequence from ―Week 0‖of that infant (Figure 3.7). The 
two sequences appeared close to each other. 
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Figure 3. 6: Phylogenetic tree of HBV-infected infants with HBV strains belonging to subgenotype A1 
based on pol/surface region of the genome.  
BH3, MH3, D004263, D005813 and D004483 are sequences from patients from the Western Cape (Chotun BN 
and Maponga TG, MSc Thesis, Stellenbosch University, 2012). Sequences with accession numbers starting 
with AY, HM, AF, FJ, GQ, AM and X5 were downloaded from GenBank. The evolutionary history was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch 
length = 0.34175109 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the 
Kimura 2-parameter method (Kimura, 1980) and are in the units of the number of base substitutions per site. 
The analysis involved 27 nucleotide sequences. There were a total of 898 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA6 (Tamura et al., 2013). 
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Figure 3. 7: Phylogenetic tree of HBV-infected infants and the “Week 0” sample with HBV strains 
belonging to subgenotype A1 based on pol/surface region of the genome. 
279V07019441* represents the ―Week 0‖sample of the Cape Town infant. BH3, MH3, D004263, D005813 and 
D004483 are sequences from patients from the Western Cape (Chotun BN and Maponga TG, MSc Thesis, 
Stellenbosch University, 2012). Sequences with accession numbers starting with AY, HM, AF, FJ, GQ, AM 
and X5 were downloaded from GenBank.  
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal 
tree with the sum of branch length = 0.33538548 is shown. The tree is drawn to scale, with branch lengths in the 
same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances 
were computed using the Kimura 2-parameter method (Kimura, 1980) and are in the units of the number of 
base substitutions per site. The analysis involved 27 nucleotide sequences. There were a total of 896 positions in 
the final dataset. Evolutionary analyses were conducted in MEGA6 (Tamura et al., 2013). 
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3.4  Summary of findings 
To summarize, an HBV infection prevalence of 0.6% (5/850) was described in HIV-exposed 
infants. Three of these five infants were positive for HBsAg whilst two were positive for anti-
HBc (total). The three HBsAg positive infants were HBV DNA positive whereas the two 
anti-HBc (total) positive samples where negative for HBV DNA. No clinically relevant 
mutation in the analysis of the pol/surface of these three HBsAg positive infants was found in 
two infants. In the third, the 3TC drug-resistant mutation (M204I) in the polymerase gene 
was found. The significance of these findings will be discussed in chapter 5. 
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CHAPTER 4: THE PREVALENCE OF HCC-RELATED HBV MUTATIONS IN 
HIV/HBV CO-INFECTED AND HBV MONO-INFECTED WOMEN AND IN HIV-
EXPOSED CHILDREN 
 
This chapter reports on the prevalence of HBV mutations, which have been associated with 
HCC, in antenatal samples from the Western Cape Province, SA. 
 
4.1  Introduction 
Infants infected through vertical transmission are at a great risk (>90%) of becoming chronic 
carriers of HBV. Chronic HBV carriers are at a high risk of developing HCC. In chapter 3, 
three possible cases of perinatal transmission with one confirmed case were described. In a 
previous antenatal study, a high prevalence of BCP and pre-core mutations was described in 
HIV-infected pregnant women as compared to HIV-uninfected pregnant women (Andersson 
et al., 2013). These mutations have also been reported in CHB and HCC patients in SA 
(Baptista et al., 1999; Mayaphi et al., 2013). Many Asian studies have associated the 
presence of these specific HBV mutations with a high risk of HCC in CHB patients (Kao et 
al., 2003; Tong et al., 2006, 2007; Qu et al., 2011). These HBV mutations are currently used 
as a biomarker in algorithms which are accurately able to predict the risk of HCC 
development in patients with chronic hepatitis (Yuen et al., 2009). The findings from the 
transmission study (chapter 3) prompted questions about the prevalence of HCC-related 
mutations in the context of HIV. This study aimed to investigate the prevalence of HCC-
related mutations in HIV-infected and HIV-uninfected antenatal women and HIV-exposed 
infants. 
 
4.2  Materials and Methods 
4.2.1 Ethical aspect 
For this study, we made use of samples from three studies conducted in the Division of 
Medical Virology, Stellenbosch University. All studies had approval from the Health 
Research Ethics Committee (HREC) of the Faculty of Medicine and Health Sciences, 
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Stellenbosch University. The ethics reference numbers are: N11/05/151, N10/04/115 and 
N09/11/319 for the two paediatric and antenatal studies, respectively.  
4.2.2 Sample and data collection 
Sixty samples were retrieved from three HBV-related studies conducted in the Division of 
Medical Virology, Stellenbosch University: 
(1) Five samples (three maternal and two paediatric) were collected from the study: The 
prevalence of hepatitis B virus infection in an HIV-exposed paediatric cohort from the 
Western Cape, SA, the so-called NHLS Paediatric Study  (Chotun, BN, MSc Thesis, 
Stellenbosch University, 2012)  
(2) Fifty antenatal samples were collected from the study: An investigation of hepatitis B 
virus in antenatal women tested for human immunodeficiency virus, in the Western 
Cape Province of SA (Andersson et al., 2013)  
(3) Four paediatric samples and one maternal sample from the transmission study 
(chapter 3) were also included. 
Data collection involved retrieving HBV genome sequencing results performed on samples 
from the NHLS Paediatric Study and the Antenatal Study. 
 
4.2.3 Molecular procedures 
4.2.3.1  Nucleotide sequencing of the core ORF 
These data were already available for the NHLS Paediatric and the Antenatal studies. Hence, 
the assay was only performed on the five samples from the transmission study. 
Pre-nested PCR 
For each pre-nested PCR reaction, 2.5μl of 10× PCR buffer (Invitrogen, California), 0.5μl of 
10 mM deoxynucleotide triphosphate (dNTP) mix (Bioline, London), 0.5μl of the 20 pmol/μl 
H4072, 0.5μl of the 20 pmol/μl Outer core (listed in Table 4.1) , 0.75μl of 50 mM magnesium 
chloride (MgCl2) (Invitrogen, California), 0.1μl Taq Polymerase (Invitrogen, California), 5μl 
of DNA template and 15.15μl of nuclease-free water were mixed to make a final volume of 
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25μl. The reaction tubes were inserted into the GeneAmp PCR system 9700 (Applied 
Biosystems) and the reaction was run at the cycling conditions shown in Table 4.2. 
Table 4. 1: Pre-nested PCR primers of the core region 
Primer Sequence Binding position from Eco 
R1 
H4072 – Forward  5'- TCTTGCCCAAGGTCTTACAT 3‘ 1602 – 1621  
Outer core – Reverse  5'- TCCCACCTTATGAGTCCAAG 3‘  2509 – 2528  
 
Table 4. 2: Pre-nested PCR cycling conditions of the core region 
Cycling parameters Cycles Temperature Time 
Initial denaturation 1 94ºC 2 minutes 
Denaturation  
35 
 
94ºC 30 seconds 
Annealing 55ºc 30 seconds 
Extension 72ºC 1 minute 
Final extension 1 72ºC 2 minutes 
 
Nested PCR 
A second PCR round was performed to obtain sufficient DNA material required. The pre-
nested PCR products were used to carry on this step. An approximate DNA size of 700 bp 
was expected. Each reaction required a mix of 5μl of 10× PCR buffer (Invitrogen, 
California), 1μl of 10 mM dNTP mix (Bioline, London), 1μl of H4072 (20 pmol/μl), 1μl of 
Inner core (20 pmol/μl) (listed in Table 4.3), 1.5μl of 50 mM MgCl2 (Invitrogen, California), 
0.2μl Taq Polymerase (Invitrogen, California), 1μl of DNA template and 39.3μl of nuclease-
free water to obtain a total volume of 50μl. The reaction was once again run in the GeneAmp 
PCR system 9700 (Applied Biosystems) at the cycling conditions shown in Table 4.4.  
Table 4. 3: Nested PCR primers of the core region 
Primer Sequence Binding position from Eco 
R1 
H4072 – Forward   5'- TCTTGCCCAAGGTCTTACAT 3‘ 1602 – 1621  
Inner core – Reverse  5'- CAGCGAGGCGAGGGAGTTCTTCTT 
3‘  
2422 – 2445  
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Table 4. 4: Nested PCR cycling conditions of the core region 
Cycling parameters Cycles Temperature Time 
Initial denaturation 1 94ºC  2 minutes 
Denaturation 
35 
 
94ºC 30 seconds 
Annealing 55ºc 30 seconds 
Extension 72ºC 1 minute 
Final extension 1 72ºC 2 minutes 
4.2.3.2 Nucleotide sequencing of the pre-Surface (pre-S) ORF 
All samples with known HBV DNA viral loads were subjected to pre-S cycle sequencing to 
determine the nucleotide sequence of the Pre-S region for the mutation analysis. Two PCR 
reactions were performed using the kit MyFi™ Mix (Bioline, GmbH, Germany). This mix 
makes use of a high-fidelity DNA enzyme polymerase to which are added specific primers 
and the DNA template. 
Pre-nested PCR 
This first round of PCR was used to obtain a fragment size of around ~2.5kb using two 
specific primers. This pre-nested PCR master mix was made up of 25µL of 2×MyFi
TM
 mix 
(Bioline, GmbH, Germany), 1µL of 20pmol/µl UBC_7F, 1µL of 20pmol/µl UBC_6R (listed 
in Table 4.5) and 18µL of water to make up a volume of 45µL per reaction. Five microliters 
of DNA extract was added to the master mix to make up a final volume of 50µL. The 
reaction tubes were inserted into the GeneAmp PCR system 9700 (Applied Biosystems) and 
the reaction was run at the cycling conditions shown in Table 4.6.  
Table 4. 5: Pre-nested PCR primers of the pre-S region  
Primer Sequence Binding position from Eco R1 
UBC_7 – Forward 5‘- CTT TTT CAC TTC TGC CTA ATC 
ATC -3‘ 
1821 - 1843 
UBC_6 – Reverse  5‘- AAA AAG TTG CAT GGT GCT 
GGT G -3‘ 
1825 - 1804 
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Table 4. 6: Pre-nested PCR cycling conditions of the pre-S region 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 2 minutes 
Denaturation 
30 cycles 
95°C 15 seconds 
Annealing 55°C 30 seconds 
Elongation 72°C 2 minutes 
Final Elongation 1 hold 72°C 10 minutes 
 
Nested PCR 
A second round of PCR was performed to obtain two fragments of around ~1.7kb using two 
set of primers. Two master mixes were prepared for this reaction. The first master mix was 
made up with 25µL of 2×MyFi
TM
 mix (Bioline, GmbH, Germany), 1µL of 20pmol/µl P‘1, 
1µL of 20pmol/µL MD16 (listed in Table 4.7) and 18µL of water to make up a volume of 
45µL per reaction. The second master mix was a mixture of 25µL of 2×MyFi
TM
 mix (Bioline, 
GmbH, Germany), 1µL of 20pmol/µl MD19, 1µL of 20pmol/µl B1as (listed in Table 4.8) 
and 18µL of water to make up again a volume of 45µL per reaction. For each reaction, 5µL 
of DNA template was added to 45 µL of master mix to perform the reaction. Both reactions 
were done at the same cycling conditions, listed in Table 4.9.  
Table 4. 7: Nested PCR primers of the pre-S region – first master mix 
Primer Sequence Binding position from Eco R1 
P‘1 – Forward 5‘- TGC CTA ATC ATC TCA TGT 
TCA TGT CC -3‘ 
1832 – 1857 
MD16 - Reverse 5‘- GCA GGG GTC CTA GGA ATC 
CTG ATG -3‘ 
193 – 170  
 
Table 4. 8: Nested PCR primers of the pre-S region – second master mix  
Primer Sequence Binding position from Eco R1 
MD19 – Forward 5‘- GTG GGT CAC CAT ATT CTT 
GGG -3‘ 
2818 – 2838 
B1as – Reverse 5‘- GGC AGC ACA SCC TAG CAG 
CCA TGG -3‘ 
1395 – 1372  
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Table 4. 9: Nested PCR cycling conditions for the pre-S region 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 2 minutes 
Denaturation 
35 cycles 
95°C 40 seconds 
Annealing 55°C 40 seconds 
Elongation 72°C 60 seconds 
 
Nested PCR products were visualized by gel electrophoresis. A 1% agarose gel was made by 
heat dissolving 1g of powder SeaKem
®
 LE agarose (LONZA, Rockland, ME, USA) into 
100ml of 1× TAE buffer for 2 minutes into a microwave. Visualization of these products was 
done as described previously in chapter 3, section 3.2.4.4. Positive samples were cleaned up 
following the procedure described previously in chapter 3, section 3.2.4.4. 
Cycle sequencing 
This reaction was achieved using the BigDye
® 
Terminator v3.1 Cycle Sequencing Ready 
Reaction kit (Applied Biosystems, California, USA), a pre-mixed format to which the 
template and  specific primers (listed in Table 4.10 and Table 4.11) were added to perform 
the reaction.` 
For each sample, 2 pre-S nested PCR products of around ~1.7kb were amplified hence for 
each sample 4 sequences were to be obtained from the cycle sequencing assay.  
The reaction was set up as described previously and executed on the GeneAmp PCR system 
9700 (Applied Biosystems) following the cycling parameters indicated in Table 4.12.  
Table 4. 10: Oligonucleotide primers used for core sequencing 
Primer Sequence Binding position from Eco R1 
H4072 - Forward 5'- TCT TGC CCA AGG TCT TAC AT- 3‘ 1602 – 1621 
Inner Core– Reverse  
5'-CAG CGA GGC GAG GGA GTT CTT 
CTT- 3‘ 
2422 – 2445 
CSEQR – Reverse  5‘- GGA GGA GTG CGA ATC CAC ACT- 3‘ 2314 – 2334  
RSP – Forward 5‘- GTT CAA GCC TCC AAG- 3‘ 1830 – 1844  
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Table 4. 11: Oligonucleotide primers used for pre-S sequencing 
Primer Sequence Binding position from Eco R1 
MD19 – Forward 5′- GTG GGT CAC CAT ATT CTT GGG -3′ 2818 – 2838 
MD16 – Forward 5′- GCA GGG GTC CTA GGA ATC CTG 
ATG -3′ 
193 – 170 
 
Table 4. 12: Pre-S and core cycle sequencing cycling conditions 
Cycling parameters Temperature Time Cycles 
Denaturation 96ºC 20 seconds 30 
Annealing 55ºC 20seconds 30 
Extension 60ºC 4minutes 30 
 
At the end of cycle sequencing, the sequencing products were purified using the BigDye
®
 
Xterminator Purification Kit (Applied Biosystems, Foster City, California, USA) following 
the procedure described previously (Chapter 3, section 3.2.4.4.).  
The raw data created by the DNA sequencing analysis software from Applied Biosystems, 
USA, were used for further analysis using the software Sequencher v5 (Gene Codes 
Corporation, Ann Arbor, Michigan, USA). The quality of sequences was improved through 
trimming and editing where necessary. Consensus sequences were formed for each sample 
from the four sequences obtained and edited to improve the quality of the consensus, when 
needed. These consensus sequences were saved in FASTA format. Multiple alignments were 
formed with all sample sequences, the pre-core gene sequence reference, X gene sequence 
reference and the pre-S gene sequence reference using the molecular software Geneious 
v7.1.5 (Biomatters, New Zealand). The specific regions being pre-core, BCP and pre-S, 
needed for our analysis were extracted using HBV pre-core gene, X gene and Pre-S gene 
sequences references. These extracts were analysed manually for mutations using BioEdit 
v7.2.5. Following manual analysis of these sequences, phylogenetic trees were constructed 
using the MEGA v6 to observe their clustering. 
Quality control of molecular assays 
This was discussed previously in Chapter 3, section 3.2.3.6. 
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4.3  Results 
4.3.1 Sample and data collection 
Sixty samples in total were identified for this study: fifty samples from the Antenatal Study 
(Maponga, TG, MSc Thesis, Stellenbosch University, 2012); five samples from the NHLS 
Paediatric Study (Chotun, BN, MSc Thesis, Stellenbosch University, 2012) and five 
samples from the transmission study. The five samples from the transmission study were 
from 3 infants each from Johannesburg, Durban and Cape Town (―Week 0‖and ―Week 48‖), 
and the mother of the Cape Town infant. These samples were all HBV DNA and HBsAg 
positive. 
Thirty five samples from this cohort were HIV positive: thirty mothers from the antenatal 
study, two (Cape Town infant and mother) from the transmission study and three mothers 
from the NHLS Paediatric Study. 
Concerning data collection, whole genome sequencing data were retrieved for the 5 
paediatric specimens whereas core and pol/surface sequencing data were retrieved from the 
50 antenatal specimens. Pol/surface sequencing data were also available (see section 3.3.3.3) 
for the transmission study samples with the exception of the Cape Town mother for who 
pol/surface sequencing was unsuccessful. 
 
4.3.2 Molecular results 
4.3.2.1 Nucleotide sequencing of the core ORF results 
All three ―Week 48‖ HBsAg positive samples were used for the pre-core/core sequencing. 
The samples collected at ―Week 0‖ of Cape Town infant and his mother were also used for 
the core sequencing. The PCR products obtained are represented on Figure 4.1 and Figure 
4.2.  
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Figure 4. 1: Core clean PCR products of “Week 48”samples collected from the Johannesburg and 
Durban infants. M: 1kb molecular weight marker; NTC: No Template Control; NC: Negative Control; 1. 
350V06029315 (Johannesburg); 2. 262V08006189 (Durban) 
 
 
Figure 4. 2: Core clean PCR products of “Week 48”and “Week 0”* samples collected from the Cape 
Town infant. M: 1kb molecular weight marker; NTC: No Template Control; NC: Negative Control. * 
represents ―Week 0‖ labeled 12 on the gel. 
The DNA products were cleaned up and analyzed on the spectrophotometer to assess the 
purity and calculate the DNA concentration of the products (See Table 4.13). The DNA 
concentration of sample 279V07019441 (Week 0) was diluted using DNA nuclease-free 
water to a concentration of 20ng/µL. A volume of 1µL of each sample, including the NC, 
was used for the sequencing PCR reaction. Each sequence was amplified with a set of four 
primers. 
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Table 4. 13: Concentration and purity of core DNA products 
Sample ID ng/µL A260nm A260/280nm 
NC 19.32 0.386 1.71 
350V06029315 29.49 0.59 2.22 
262V08006189 23.87 0.477 2.39 
279V07019441 (Week 48) 26.64 0.533 1.93 
279V07019441 (Week 0) 34.1 0.682 1.9 
NC: Negative Control 
After the sequencing PCR reaction, the products were cleaned up and analyzed with the ABI 
Prism 3130xl genetic analyzer. The sequences obtained were analyzed, trimmed and aligned. 
A contiguous sequence of approximately 700 bp long was obtained from each infant. The NC 
did not amplify, hence no contamination had occurred.  
The contiguous sequences obtained were analyzed manually and the K130M/V131I double X 
mutation was found on both sequences (―Week 0‖and ―Week 48‖ sequences) of the Cape 
Town sample (279V07019441). This mutation is associated with the A1762T/G1764A 
double mutation on the BCP region of the core gene. The S101P, L116V, L123S, A146S and 
the P147S mutations were also identified on both sequences, based on analysis of the X gene. 
No pre-core mutation was found in the infant. Analysis of the BCP sequence from the mother 
of this infant revealed that she also had the double A1762T/G1764A BCP mutation and no 
pre-core mutation. No major mutations on the sequences obtained from the Johannesburg 
(350V06029315) and Durban (262V08006189) samples other than the S101P, L116V, 
L123S, A146S and the P147S mutations on the core gene.  
A phylogenetic tree, showed on Figure 4.3, was constructed using these infant‘s sequences. 
The three sequences appeared to be genetically different but all clustered with genotype A 
sequences. The two sequences 279V07019441 and 279V07019441 mother, representing the 
Cape Town infant and his mother respectively, appeared to be similar.  
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
103 
 
 
Figure 4. 3: Phylogenetic tree of HBV-infected infants and Cape Town mother with HBV strains 
belonging to subgenotype A1 based on the core region of the genome.  
Sequences with accession numbers starting with JX and KF were downloaded from GenBank. 
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal 
tree with the sum of branch length = 0.25525873 is shown. The tree is drawn to scale, with branch lengths in the 
same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances 
were computed using the Kimura 2-parameter method (Kimura, 1980) and are in the units of the number of 
base substitutions per site. The analysis involved 25 nucleotide sequences. There were a total of 883 positions in 
the final dataset. Evolutionary analyses were conducted in MEGA6 (Tamura et al., 2013). 
 
4.3.2.2 Nucleotide sequencing of the pre-S ORFs results 
On a total of 60 specimens, 42 pre-S sequences were obtained from the pre-S PCR, of which 
33 were from the Antenatal Study. Despite numerous efforts, the remaining 18 samples could 
not be amplified. This was likely to be due to low DNA viral load (HBV DNA viral load <  
300 IU/mL). Pre-S sequencing was successful on all 5 samples from the NHLS Paediatric 
Study. From the transmission study, pre-S sequences were acquired for all samples but the 
Cape Town mother. Figure 4.4 shows a representation of pre-S positive samples after nested 
PCR. For each sample, two fragments each of around 1.7kb were amplified during the PCR 
reaction as seen on Figure 4.4.  
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Figure 4. 4: Agarose gel showing successful pre-S amplification. M: 1kb molecular weight marker; 
NTC: No Template Control; NC: Negative Control; 1.7kb A: segment amplified with P‘1 and MD16 
primers; 1.7kb B: segment amplified with MD19 and B1as primers. 
DNA products were cleaned up then analyzed on the spectrophotometer to assess the purity 
and calculate the DNA concentration of PCR products. Samples with high DNA 
concentration were diluted to a final concentration of 20ng/µL using DNA nuclease-free 
water. A volume of 1µL of each sample, including the NC, was used for the sequencing PCR 
reaction. For each sample, two fragments were amplified thus for each sample, four 
sequences were acquired. Following sequencing PCR reaction, the products were cleaned up 
and analyzed with the ABI Prism 3130xl genetic analyzer. The sequences obtained were 
analyzed, trimmed and aligned. A contiguous sequence of approximately 1700 bp long was 
obtained from each sample. 
All pre-S sequences were aligned with reference sequences received from Guillaume Fallot 
(personal communication) on Geneious v7.1.5 (Biomatters, New Zealand). Using the 
alignment, the pre-S1 (119 aa i.e. 357 bp) and pre-S2 (55 aa i.e.165 bp) regions of 522 bp in 
total were extracted. The extract was analysed manually on BioEdit for the deletions 
positions. 
Analysis of these 42 pre-S sequences revealed 8 sequences with deletions of which 5 were 
from HIV-infected samples. These 8 sequences, summarized in Table 4.14, originated from 
women recruited in the Antenatal Study. Four types of pre-S deletions were observed: pre-S1 
start codon deletion accompanied with other pre-S1 deletions, pre-S1 deletions alone, pre-S2 
deletions alone and pre-S2 start codon deletion accompanied with pre-S1 deletions and other 
pre-S2 deletions, respectively.  
Stellenbosch University  http://scholar.sun.ac.za
 
105 
 
In addition to pre-S deletions, an HIV-uninfected woman (D004659) of 23 years old harbored 
two pre-S start codon mutations at pre-S1 (ATG/TCA) and pre-S2 (ATG/TCC) leading to a 
change of the amino acid methionine to serine (M/S) at both positions.  
Table 4. 14: Summary of samples with pre-S region deletions 
Sample ID Age (years)  Genotype HIV status Pre-S region, aa Deletion type 
300685 36 D Infected 1-11 Type 1 
300843 25 A1 Infected 67-97 Type 2 
300030 33 A1 Infected 133-141 Type 3 
D004411 28 A1 Infected 135-141 Type 3 
303962 27 A1 Infected 119-120, 137-
142  
Type 4 
300214 26 D Uninfected 1-11 Type 1 
D005219 20 A1 Uninfected 2-7 Type 1 
300768 29 A1 Uninfected 40, 48-50, 54-97 Type 2 
aa: amino acid 
 
All sequencing data on the pre-S, BCP and pre-core regions acquired from all three studies 
were analyzed together. The following sections will be presenting results from this analysis. 
4.3.2.3  Analysis of pre-core and BCP/X gene mutations 
Although only 42 pre-S sequences were acquired from pre-S sequencing, pre-core and 
BCP/X sequences were acquired from all 60 samples included in the study (See Table 4.15).  
In the Antenatal Study, six women had the double BCP A1762T/G1764A mutations and no 
pre-core mutations; six showed the BCP T1753C mutation combined to the double BCP 
mutants with two also harbouring the A1896T pre-core mutant. These two women were each 
genotype D and genotype A1. Three patients had the C1766T/T1768A BCP mutations and no 
pre-core mutation. A 34 year old woman had the combined T1753C, A1762T/G1764A, and 
C1766T/T1768A BCP mutations accompanied with the A1896T mutation and the stop codon 
G1899A mutation in the pre-core region. Another 32 years old women had the G1764A and 
C1766T/T1768A BCP mutations and no pre-core mutant.  
Eight HIV-infected women harboured different mutations profiles. These women had no BCP 
mutations but showed two types of pre-core mutations: six mutations at the initiation codon 
(1816: M1R or M1L) of the pre-core region and a stop codon at position 1872 (K21*).  
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The three mothers from the Paediatric Study showed no BCP or pre-core mutations. The core 
sequences of the Cape Town infant at ―Week 0‖ and ―Week 48‖ from the transmission study 
revealed the double A1762T/G1764A BCP mutation and no other mutation on the pre-core 
region. The Cape Town mother had the same double BCP mutation as her child and no pre-
core mutation.  
The remaining twenty four samples of the cohort were HIV-uninfected. These consisted of 
twenty women from the Antenatal Study, two babies from the Paediatric Study and two 
babies from the transmission study. All four babies displayed no BCP or pre-core mutations 
in their core sequences. However among the twenty women, three had the double 
A1762T/G1764A BCP mutation, one C1766T/T1768A BCP mutation, two combined 
G1764A and C1766T/T1768A mutations and one combined T1753C and A1764T/G1764A 
BCP mutations. Out of the three women harbouring the double A1764T/G1764A BCP 
mutations, two also had pre-core mutations: the stop codon G1899A and a mutation at the 
start codon (position 1816). The women harbouring the G1899A stop codon was infected 
with HBV genotype D strain. 
These pre-core and BCP/X gene mutations were analysed with the pre-S deletions observed 
in the cohort. Samples harbouring these mutations in combination are summarized in the 
table below, Table 4.16. 
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Table 4. 15: Samples with BCP/X and pre-core mutations  
Sample ID HIV status Age  Genotype BCP  Pre-C  
300030 INFECTED 33 years A1 A1762T/G1764A NONE 
300632 INFECTED 28 years A1 C1766T/T1768A NONE 
300685 INFECTED 36 years D T1753C, A1762T/G1764A G29D 
300843 INFECTED 25 years A1 T1753C, A1762T/G1764A NONE 
301066 INFECTED 22 years A1 T1753C, A1762T/G1764A NONE 
301073 INFECTED 31 years A1 A1762T/G1764A NONE 
301578 INFECTED 28 years A1 T1753C, A1762T/G1764A G29D 
303374 INFECTED 26 years A1 NONE M1L 
303484 INFECTED 32 years A1 NONE M1L 
303557 INFECTED 22 years A1 C1766T/T1768A NONE 
303962 INFECTED 27 years A1 A1762T/G1764A NONE 
D000504 INFECTED 32 years A1 G1764A, C1766T/T1768A NONE 
D000756 INFECTED 36 years A1 NONE M1L 
D000764 INFECTED 27 years A1 NONE M1L 
D002436 INFECTED 36 years A1 NONE K21* 
D002473 INFECTED 37 years A1 A1762T/G1764A NONE 
D002526 INFECTED 22 years A1 T1753C, A1762T/G1764A NONE 
D002911 INFECTED 21 years A1 NONE M1R 
D003934 INFECTED 34 years A1 
T1753C, A1762T/G1764A, 
C1766T/T1768A 
G29D, 
W28* 
D004066 INFECTED 30 years A1 T1753C, A1762T/G1764A NONE 
D004411 INFECTED 28 years A1 NONE M1L 
D004528 INFECTED 19 years A1 A1762T/G1764A NONE 
D005512 INFECTED 22 years A1 C1766T/T1768A NONE 
279V07019441 INFECTED 
12, 60 
weeks 
A1 A1762T/G1764A NONE 
Cape Town mother INFECTED 34 years  A1 A1762T/G1764A NONE 
300032 UNINFECTED 27 years A1 NONE M1L 
300706 UNINFECTED 27 years A1 A1762T/G1764A NONE 
301433 UNINFECTED 28 years A1 NA V17L 
302490 UNINFECTED 26 years A1 NONE M1L 
302798 UNINFECTED 25 years A1 NONE M1L 
302977 UNINFECTED 36 years D A1762T/G1764A W28* 
303153 UNINFECTED 28 years A1 C1766T/T1768A NONE 
303521 UNINFECTED 38 years A1 A1762T/G1764A M1L 
D004015 UNINFECTED 31 years A1 NONE M1L 
D004483 UNINFECTED 27 years A1 T1753C, A1764T/G1764A NONE 
D004659 UNINFECTED 23 years A1 G1764A, C1766T/T1768A NONE 
NA: Not Available 
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Table 4. 16: Summary of sample with combined BCP, pre-core mutations and pre-S 
deletions 
Sample ID HIV status 
Age 
(years) 
Genotype BCP mutations 
Pre-C 
mutations 
Pre-S 
deletions 
300030 INFECTED 33 A1 A1762T/G1764A NONE Type 3 
300685 INFECTED 36 D 
T1753C, 
A1762T/G1764A 
G29D Type 1 
300843 INFECTED 25 A1 
T1753C, 
A1762T/G1764A 
NONE Type 2 
301578 INFECTED 28 A1 
T1753C, 
A1762T/G1764A 
G29D None 
303962 INFECTED 27 A1 A1762T/G1764A NONE Type 4 
D003934 INFECTED 34 A1 
T1753C, 
A1762T/G1764A, 
C1766T/T1768A 
G29D, W28* NA 
302977 UNINFECTED 36 D A1762T/G1764A W28* NA 
NA: Not available 
BCP: Basal Core Promoter 
Pre-C: Pre-core 
 
4.4  Summary of findings 
In summary, none of the paediatric samples were harbouring pre-S mutations or a 
combination of all pre-S, BCP and pre-core HBV mutations. However, eight maternal 
samples of which five were HIV-infected and three were HIV-uninfected harboured pre-S 
deletions. Moreover, a higher rate of combination of these mutations was found in HIV-
infected (6/7) as compared to HIV-uninfected mothers (1/7). In the following chapter, the 
interpretation of these results and the implications of these findings will be discussed. 
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CHAPTER 5: DISCUSSION 
 
This study has found an HBV infection prevalence of 0.6% (5/850) in a cohort of 850 HIV-
exposed infants. The HBsAg prevalence was 0.4% (3/850) whilst two of the five infants had 
evidence of past exposure to HBV. Of the three HBsAg positive infants, one harboured the 
mutation M204I associated with lamivudine-drug resistance. Unfortunately, this child was 
lost to follow up. A second infant who was followed up was HIV-infected, HBsAg positive 
and HBeAg negative. This child had been on ART treatment for a period of approximately 2 
years. The mother of this child was also HBsAg positive and HBeAg negative. The mother-
infant pair had similar core gene sequences, harbouring the double A1762T/G1764A BCP 
mutation. The latter has been well described in CHB and HCC patients and has been 
associated with the evolution of primary liver malignancy. These observations provided 
evidence of transmission of mutant viruses from mother to child and led to the investigation 
of HCC-related mutations in antenatal women with a risk of perinatal transmission. The 
screening of antenatal samples in this study revealed 15% (8/53) of women harbouring pre-S, 
BCP and pre-core mutations which have previously been described as high risk factors of 
development of liver tumours in Asia. Five of these women were HIV-infected, suggesting a 
possible impact of HIV on HBV.  This is the first study reporting the transmission of mutant 
virus from mother to child and describing the presence of HCC-related mutations in antenatal 
women. 
 
HBsAg prevalence 
A total HBsAg prevalence of 0.4% (3/850) was detected in this cohort of HIV-exposed 
infants. These results are similar to results obtained in a previous paediatric study conducted 
in the Division of Medical Virology, Stellenbosch University. One thousand HIV-exposed 
babies below 18 months of age were screened for HBV infection, of whom 0.3% (3/1000) 
were positive for HBsAg. Using antenatal HBsAg prevalence in pregnant women 
(Andersson et al., 2013) and the HBsAg prevalence in infants in that study, the rate of 
MTCT was about 12% (Chotun, BN, MSc Thesis, Stellenbosch University, 2012). 
However, the observed prevalence in infants was higher than that reported in a recent study 
conducted by Hoffmann et al. 2014. The latter was a prospective study which followed up 
189 HIV/HBV co-infected pregnant women and their babies in Soweto, Gauteng, SA. One 
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hundred and eighty four women were enrolled in the PMTCT programme to prevent perinatal 
child transmission of HIV prior to presenting in labour. Of these women, 23% (44/184) 
received zidovudine monotherapy, 10% (20/184) received stavudine or zidovudine and 63% 
(120/184) were on TNF. Fourteen (7.4%) of these mothers were found positive for HBsAg 
and these 14 mother-child pairs were followed up. An HBsAg seropositivity of 7.14% (1/14) 
was described among the babies born of those 14 HIV/HBV co-infected mothers. The mother 
of this HBsAg positive infant, although on an ART regimen which included stavudine, 3TC 
and efivarenz, was HBeAg positive and had an HBV DNA viral load of log10 8.3 IU/mL prior 
to delivery. This infant did not receive any immunization against HBV at birth and was only 
vaccinated at six weeks of age (Hoffmann et al., 2014). The low prevalence of HBsAg 
described in these HIV-exposed infants could be due to the fact that 63% were on TNF and a 
further 10% were likely to be on 3TC, both of which have anti-HBV activity. 
Earlier studies have described a higher HBsAg prevalence in children older than five years 
when compared to younger infants. The high HBV prevalence in children and adolescents 
was associated with horizontal transmission (Vos et al., 1980; Prozesky et al., 1983; Abdool 
Karim et al., 1988). This was used as a background for the administration of the first dose of 
the HB vaccine at the age of six weeks within the EPI in SA. However, Vardas and 
colleagues described an HBsAg prevalence which had not been previously observed in 
infants in SA, suggesting that perinatal transmission might be more important than previously 
thought. They conducted a large seroepidemiological study in unvaccinated rural and urban 
children from 0 to 6 years of age with the aim of determining the age of acquisition of HBV 
infection in SA. The highest HBsAg seroprevalences, of 8.1% and 8.9%, were reported in 
infants in the age groups of 0 – 6 months and 7 – 12 months, respectively (Vardas et al., 
1999). The high prevalence of HBsAg in infants aged below one year of age suggested that 
perinatal transmission should not be an underestimated mode of HBV transmission.  
Furthermore, the HBsAg prevalence observed in the current study is different to what was 
observed in the earliest years of the HB vaccine era. Westwood tested 326 children below 14 
years of age, all of whom tested negative for HBsAg (Westwood, 2001). The same HBsAg 
prevalence was reported by Tsebe et al. who tested 578 babies aged between 8 to 72 months 
(Tsebe et al., 2001). Results from these two studies have shown the positive impact of the 
HB vaccine on the incidence of HBV in children in SA. The studies by Westwood and Tsebe 
et al. investigated the general paediatric population without specifying HIV status, while this 
Stellenbosch University  http://scholar.sun.ac.za
 
111 
 
study adds to the current literature as it has investigated the impact of HIV exposure on HBV 
prevalence.  
 
Mother to child transmission 
Pre-HB vaccine studies reported a higher prevalence of HBsAg among children older than 5 
years old of age as compared to infants below one year old (Prozesky et al., 1983; Botha et 
al., 1984). MTCT was then considered as a neglected risk of transmission in the South 
African population. Vardas et al. reported a high HBs antigenemia in unvaccinated infants 
and suggested that MTCT might be underestimated as a contributing factor to the endemicity 
of HBV (Vardas et al., 1999).  
Thirty years ago, in Namibia, Botha et al. (Botha et al., 1984) described  a greater risk of HB 
perinatal transmission in mothers positive for both HBsAg and HBeAg as compared to 
HBsAg positive but HBeAg negative mothers. They found that 63% (12/19) of mothers 
positive for both HBsAg and HBeAg had HBsAg positive children compared to 17% (16/92) 
of mothers who were positive for HBsAg and anti-HBe. The authors took into consideration 
that mothers with older children might have been HBeAg positive at the time of pregnancy 
and could have seroconverted, and only determined the prevalence of HBeAg among mothers 
who were not expected to have seroconverted. Thus, among mothers with children aged less 
than 2 years old, 16% (16/97) were HBeAg positive. Cord blood testing revealed an 80% 
(12/15) HBsAg prevalence in unvaccinated babies born to 15 HBsAg positive women. 
(Botha et al., 1984). This report triggered a series of investigations which led to the 
implementation of the HB vaccine in SA based on the importance of horizontal transmission 
only. Since then, many studies have reported the efficacy of the HB vaccine but none have 
specifically looked at perinatal transmission of HBV until recently by Hofmann et al., 2014. 
The authors tested 189 HIV-infected women for HBV markers and 14 were found HBsAg 
positive, of whom 6 were also HBeAg positive. They tested the infants born from those 14 
women and reported four vertical transmissions. Among these four infants, one was both 
HBsAg and HBV DNA positive and the three others were HBV DNA positive but HBsAg 
negative. The authors also mentioned that due to the unavailability of routine HBV 
immunization at birth, no intervention was performed on these infants (Hoffman et al., 
2014); however 97.4% mothers were on anti-HBV therapy as part of PMTCT.  
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In this study, one case of MTCT was confirmed through analysis of the core sequences from 
both mother and child originating from Cape Town. Analysis of the pol/surface region would 
have been the best comparison between the mother-pair sequences. However, due to 
unsuccessful pol/surface sequencing for the mother, the core sequences were used. Both 
sequences had similar core protein sequences and were shown to be very close to each other 
on the phylogenetic tree (Figure 4.3). This case is very likely to represent MTCT. 
Unfortunately, information neither on the mothers HBsAg status, nor on the PMTCT regimes 
are unknown.  
This study highlighted that vertical transmission may be an important route of transmission 
particularly in HIV/HBV co-infected women. Immuno-suppression is one mechanism by 
which HIV hastens HBV pathogenesis by delaying HBsAg and HBeAg seroconversion and 
increasing HBV replication (Thio, 2009). A recent antenatal study observed a loss of immune 
control and high prevalence of both HBeAg (18.9%) and HBsAg (3.4%) in 1543 HIV-
infected pregnant women compared to HIV-uninfected women, in the Western Cape 
(Andersson et al., 2013). As mentioned earlier (Section 2.1), HBeAg is a marker of active 
viral replication and is often used as a marker of infectivity. This antigen has been also 
proven to cross the placenta to infect the foetus (Wang & Zhu, 2000). HBeAg positivity and 
high HBV DNA viral loads have been associated with higher chance of perinatal 
transmission by Dwevedi et al. They studied 4000 women with the aim of determining the 
risk factors for vertical transmission of HBV. Of these women, 0.9% (37/4000) tested 
seropositive for HBsAg and 56.8% (21/37) of the HBsAg positives were HBeAg positive. 
Babies born from these HBsAg positive mothers were also tested for HBV infection. MTCT 
occurred in 65% (13/20) and 9.1% 91/11) of babies born from HBeAg and HBV DNA 
positive mothers and HBeAg and HBV DNA negative mothers, respectively (Dwevedi et al., 
2011). Furthermore, a study from Kwazulu-Natal investigated the burden of HBV in HIV-
infected and HIV-uninfected women. The study included 570 pregnant women, of whom 215 
were HIV-infected. Sixteen (7.4%) of these HIV-infected women were HBsAg positive and 
among them six (37.5%) were HBeAg positive. In the HIV-uninfected group, fourteen (4.8%) 
were carrying HBsAg but none were HBeAg positive (Thumbiran et al., 2014). The higher 
presence of HBeAg in the HIV/HBV co-infected group would suggest high viral loads and 
hence constitute a significant reservoir as compared to HBV mono-infected women, putting 
the HIV/HBV co-infected women at greater risk of transmitting HBV to their infants.  
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The introduction of the HB vaccine has brought a major change in the epidemiology of 
hepatitis B in many regions of the world including SA. However, the benefits of the vaccine 
could be improved if the first dose was delivered within 24-hours of birth as recommended 
by the WHO instead of six weeks of age as is currently the case. Thumbiran and colleagues 
advocated for the implementation of antenatal screening for the identification of all HBV-
exposed infants hence allowing active immunization at birth for those babies (Thumbiran et 
al., 2014). Administration of the HB vaccine immediately after birth has been proven 
necessary to avoid vertical transmission in infants at risk in Asia (Wong et al., 1984; Lee et 
al., 2006b). 
 
Anti-HBs prevalence 
Anti-HBs testing of all infants revealed that 474 out of 850 (55.8%) of the babies had 
protective anti-HBs levels (>10mIU/mL). Tsebe et al. tested the efficacy of the HB vaccine 
after its implementation and focused on vaccinated children aged between 8 months and 6 
years old. Approximately 86.8% of these children presented with protective anti-HBs titres. 
In comparison to the current study, the anti-HBs positivity described in that study is higher 
but may be due to that the study was conducted in HIV-unexposed infants as compared to the 
current study (Tsebe et al., 2001). This observation was confirmed thirteen years later by a 
pre- versus post-HBV immunization analysis of 1206 children aged one to twenty five years. 
These patients were stratified by age into pre- and post-vaccine introduction and the two 
groups were compared for evidence of immunity and chronic carriage. The analysis revealed 
(1) an overall increased immunity to HBV infection from 13% to 57% which decreased with 
increasing age due to the waning levels of anti-HBs and, (2) a decreased HBV chronic 
carriage from 4.2% to 1.4% (Amponsah-Dacosta et al., 2014).  
However, 376 infants, 44.2% (376/850) had a low anti-HBs seroprotective status (anti-HBs< 
10 IU/mL). Simani et al. investigated the prevalence and exposure to hepatitis B in 
vaccinated babies aged between 5 and 24 months. Three hundred and three children, of whom 
243 were from the EPI clinic and 60 from a paediatric outpatient clinic (OPD), were 
included. Twenty four per cent of these babies were HIV-infected and had a lower rate of 
seroprotection as compared to the HIV-uninfected group (78.1% vs. 85.7%; p=0.125). The 
low rate of seroprotection in the HIV-infected group could have been a result to immune 
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suppression rather than a failure to the HB vaccine (Simani et al., 2009). HIV status of the 
babies tested in this study was unknown, so it is not clear whether the low levels of 
seroprotection of the 376 babies was due to the immune suppression or poor immune 
response as a result of HIV infection or was just an indicator of the waning levels of anti-HBs 
with time after vaccination. 
 Furthermore, among infants with non-protective anti-HBs levels, 22.1% (83/376) of the 
babies in this study had a very poor response to the HB vaccine characterized by anti-HBs 
titres less than 1mIU/ml. A nonresponse to HB vaccine has been previously observed in HIV-
exposed infants. Abramczuk and colleagues investigated the difference in the humoral 
response to HB vaccination between 45 HIV-exposed, uninfected (HEU) and 112 HIV-
unexposed infants. They observed that 6.7% (3/45) of the HEU infants did not respond to the 
HB vaccine (anti-HBs titre, <10 mIU/ml) as compared to only 3.6% (4/112) nonresponders in 
the HIV-unexposed group (Abramczuk et al., 2011). Such observations have been explained 
by the effect of HIV on thymic maturation in HEU infants which lead to an immature 
immune system. These infants show decreased CD4 T cell numbers but increased CD8 T 
cells due to the interaction between HIV soluble particles through placental transfer from the 
mother and the infant‘s immune response in-utero (Clerici et al., 2000). That interaction 
triggers (1) a minimal T cells immune response in the infant preventing  intrauterine infection 
and, (2) other defects such as abnormalities in antigen presenting cells (Velilla et al., 2008) 
and low naïve CD4 T cell counts (Nielsen et al., 2001). 
The observations regarding the immaturity of the neonatal immune system of HEU infants 
described above could thus explain the rate of nonresponse to HB vaccine in the 83 infants, 
that is, 9.8% of the cohort in this study.  
 
HBV genotyping and phylogenetic analysis significance 
Genotyping and phylogenetic analysis were performed on samples positive for HBV DNA to 
assess the molecular diversity of the HBV strains present in this cohort. Three samples 
positive for HBV DNA were sequenced to determine the genotype of the HBV strains present 
in this cohort. Sequencing of the pol/surface region of the HBV genome revealed that all the 
HBV strains belonged to genotype A, subgenotype A1. This subgenotype is considered to be 
the most common HBV strain in circulation in the country (Bowyer et al., 1997; Kimbi et 
Stellenbosch University  http://scholar.sun.ac.za
 
115 
 
al., 2004; Kramvis & Kew, 2007). However, very few sequences have been described in 
patients from the Western Cape Province, in particular HIV-exposed infants.  
Analysis of these pol/surface sequences also revealed a drug-resistance mutation in one of the 
three HBsAg positive infants. This infant harbored a mutation in the RT domain of the 
polymerase gene at position 204 (rtM204I). This mutation is found on the catalytic or C 
domain also called the YMDD locus of the polymerase gene and has been associated to 
resistance to the drug 3TC (Stuyver et al., 2000). Mutations in the YMDD locus related to 
3TC resistance have been previously reported in HBV mono-infected treatment-naïve and 
those treated with 3TC in SA (Selabe et al., 2007). To date, no data is available regarding 
transmission of HBV drug-resistant mutant viruses from mother to child. This is the first 
study, reporting possible vertical transmission of a drug-resistant mutation.  
Analysis of the phylogenetic tree constructed with the pol/surface sequences showed that 
they clustered with other South African subgenotype A1 sequences. At follow up the child 
was found to be HBsAg positive. He is therefore a chronic carrier. Chronic HBV carriers are 
at risk of developing HCC. Lin and Kao reported that HBV genotype A-infected patients 
have a higher tendency of developing HBV chronicity and hence have a higher rate of HCC 
development (Lin & Kao, 2011). Studies in SA, where genotype A predominates, have 
described a high rate of HCC in patients with HBV genotype A infections as compared to 
patients with non-A HBV infections (Kew et al., 1979; Kimbi et al., 2004; Kew et al., 
2005). In Southern Africa, the highest HCC rates have also been shown in patients under the 
age of 30 as compared to those over 60 years of age (73.5% vs. 28.6%) (Kew et al., 1979) 
and males are at a greater risk of developing the cancer as compared to females (Kew et al., 
1983).  
 
This study has described one case of perinatal transmission where the mother had transmitted 
a mutant virus. The transmitted virus had the double T1762/A1764 BCP mutation which has 
been described in chronic and HCC patients. The latter mutation has been associated with a 
high risk of developing HCC. A high prevalence of BCP and pre-core mutations, also 
associated with HCC, has been reported in HIV-infected compared to HIV-uninfected 
pregnant women in Cape Town, Western Cape (Maponga, TG, MSc Thesis, Stellenbosch 
University, 2012). In addition to BCP and pre-core HBV mutations, pre-S 
Stellenbosch University  http://scholar.sun.ac.za
 
116 
 
deletions/mutations have also been associated to HCC development in Asia where genotypes 
B and C predominate. These mutations were thus investigated in a cohort of HIV-infected 
and HIV-uninfected women and in HIV-exposed infants.  
 
Pre-S mutations/deletions prevalence and significance 
There has been an on-going accumulation of pre-S variants in the sera and malignant tissues 
in HCC patients observed in Asia, a highly HBV endemic region. The changes brought about 
by these deletions have been shown to trigger a cascade of events leading to genomic 
instability and abnormal proliferation of liver cells (Wang et al., 2006). Although these 
mutants are well recognized in Asia, where HBV genotypes B and C predominate, as marker 
of HCC development, the prevalence and association of these mutants with HCC remain 
unknown with regards to other HBV genotypes. Makondo and colleagues have previously 
described the presence of pre-S mutants in a cohort of HIV/HBV co-infected individuals. 
However, they did not discuss the meaning of the mutations (Makondo et al., 2012). Based 
on the importance of these mutations in Asia and background data on the presence of these 
variants in HIV/HBV South African individuals, this study investigated their epidemiology in 
an antenatal setting. 
The prevalence of pre-S mutants was assessed on 60 samples recruited from three studies: an 
antenatal study conducted during the period 2010-2012 (Maponga, TG, MSc Thesis, 
Stellenbosch University, 2012), a paediatric study conducted during 2011-2012 (Chotun, 
BN, MSc Thesis, Stellenbosch University, 2012) and the current study. 
None of the samples from the current study or any of the paediatric samples harboured pre-S 
mutants but 8(8/59 (13.6%)) samples, from the Antenatal Study, were harbouring pre-S 
mutations/deletions at the 5´end of the pre-S1 region and 3´end of the pre-S2 region. Asian 
studies have investigated mutations in individuals with CHB and severe liver diseases such as 
cirrhosis and HCC. An accumulation of pre-S mutations during the course of CHB was 
observed (Fan et al., 2001) and the association between pre-S deletions/mutations with the 
development of HCC has been established (Chen et al., 2006; Yeung et al., 2011). Among 
the pre-S mutations found in CHB or HCC patients, a high proportion of pre-S2 mutations 
compared to pre-S1 mutations were found. The latter were confirmed to be found in type II 
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ground glass hepatocytes (GGHs) whereas pre-S1 mutants are found in type I GGHs, a 
histological hallmark of CHB (Wang et al., 2003).  
Unlike the high prevalence of pre-S2 mutations observed in the Asian population, a high 
proportion of the pre-S mutations observed in this cohort were found in the pre-S1 region. 
Three samples of which two were HIV-uninfected showed pre-S1 start codon deletion and 
one HIV-uninfected sample had a pre-S1 start codon point mutation (ATG/TCA). This codon 
is responsible for encoding the LHBs protein hence its deletion or a point mutation at that 
position could abrogate synthesis of the L protein. The SHBs and LHBs surface proteins 
together are necessary for virion production (Bruss & Ganem, 1991) hence the lack of LHBs 
proteins in these samples would decrease the formation of virions. However, wild type 
viruses were found to co-exist with pre-S1 deletions strains to compensate for the 
defectiveness of those mutants to produce LHBs proteins hence sustaining the life cycle of 
the virus (Melegari, Bruno & Wands, 1994). Other than being important for the synthesis of 
LHBs proteins, the pre-S1 region contains B and T cell epitopes and other functional sites 
such as the hepatocyte binding site (aa 21-47); the transactivator domain (aa 21-90), the 
transcriptional binding sites and the nucleocapsid binding site (Chen et al., 2006). Pre-S1 
deletions at aa 54-77 and 67-97 were found in samples 300768 and 300843 respectively, 
partially overlapped with the region involved in virion secretion (aa 3-77) during the 
infection step of the life cycle of the virus. Hence, hepatocytes bearing these deletions could 
have a mild defect in HBsAg secretion as proven by Le Seyec et al. (Le Seyec et al., 1999). 
One HIV/HBV co-infected sample had a deletion of aa 119 which is found in the 
nucleocapsid binding site. This domain is responsible for the virus morphogenesis thus 
deletion in this region could have an impact on virion formation (Bruss, 1997). 
Although the number of pre-S1 mutants is higher, three samples (300030, 303962 and 
D00441) showed pre-S2 deletions. These samples presented deletions from aa 133 to aa 142 
approximately. In addition to this deletion, sample 303962 also had a pre-S2 start codon 
deletion. The latter could lead to a decrease in the formation of MHBs proteins whose 
deficiency would result in an accumulation of LHBs and formation of type II GGHs (Wang 
et al., 2003). The latter could also happen in case of point mutations at the pre-S2 start codon 
like the one found in an HIV-uninfected sample from this study (ATG/TCC). Furthermore, 
the deleted pre-S2 region in these sample‘s‘ sequences covers a big part of the B epitope 
situated in the pre-S2 region (aa 120-145). These deletions were thought to be a mechanism 
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of escape of the virus from the immune B cells causing an accumulation of LHBs in the ER 
of type II GGHs (Wang et al., 2003). Persistence of these oxidative products may deactivate 
certain signals involved in the suppressions of tumours or oncogenes, resulting to cellular 
transformation and HCC. Hsieh et al. presented a model explaining hepatocarcinogenesis 
whereby accumulation of unfolded LHBs causes oxidative stress and oxidative DNA lesions 
which in turn activates the DNA repair mechanism. These DNA lesions prompt mutagenesis 
which possibly leads to genomic instability (Hsieh et al., 2004). Five of eight of the pre-S 
mutations/deletions positive samples of the studied cohort were from HIV/HBV co-infected 
women. The high rate of pre-S mutations among HIV/HBV co-infected individuals observed 
in this cohort is in accordance with Makondo et al. who characterized HBV strains in 71 
HIV/HBV co-infected individuals from Southern Africa. Five of the seventy one (7.04%) 
patients had pre-S mutants (Makondo et al., 2012). Furthermore, we observed that pre-S2 
deletions were all found in HIV-infected samples with the exception of the sample 
harbouring the pre-S2 start codon point mutation. Andersson et al. reporting on these women, 
showed a loss of immune control over HBV in HIV-infected women. The formation of pre-
S2 mutants could be a mechanism to escape immune surveillance in these HIV/HBV co-
infected women. Moreover, it was observed that the HIV-infected women with pre-S2 
deletions had low HBV DNA titres < 1500 IU/mL). This is in accordance with Fan et al. who 
observed that pre-S2 mutants prevailed over pre-S1 mutants during the low or non- 
replicative phases of the chronic infection (HBV viral load <10
6
 genomes/mL) (Fan et al., 
2001).  
Pre-S deletions have always been thought to be more predominant in genotype B and C due 
to the high number of reports of these mutations in Asian and Korean studies where HBV 
genotype B and C strains predominate. In this study, pre-S deletions/mutations were found in 
2 samples from genotype D and 6 genotype A1 samples. 
 
Combination of BCP, pre-core and pre-S mutations/deletions prevalence and 
significance 
A pattern of combination of BCP, pre-core and pre-S mutations was observed among seven 
(12%) samples in our cohort. Each of these mutations has been previously found in CHB 
patients as well as HCC patients and is well recognized as risk factor for primary liver cancer. 
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Kramvis et al. investigated the pre-core gene in 71 black African sera and 16 additional black 
African tumorous and non-tumorous liver tissues from HCC patients for the identification of 
mutations that might play a role in hepatocarcinogenesis. Five sera harboured the stop codon 
at nucleotide 1896 (W28*), preventing the synthesis of HBeAg and 10 had a mutation at 
nucleotide 1899 (G to A), of which 3 also had the 1896 stop codon. The authors concluded 
that further investigations of the X and pol genes were necessary to have a full understanding 
of the lack of HBV DNA replication in HCC patients (Kramvis, Kew & Bukofzer, 1998).  
In another South African study, a year later, the BCP and enhancer II region in HCC patients 
and HBV asymptomatic carriers (ASCs) were investigated for the presence of mutations 
which might cause the interruption of HBeAg production and contribute to 
hepatocarcinogenesis. The authors recruited 52 ASCs and 59 HCC patients. The authors 
described the double A1762T/G1764A BCP mutation in 33 (66%) patients with HCC 
compared to only 5 (11%) of HBV asymptomatic carriers. The sera harbouring this mutation 
appeared to have a significant decrease in HBeAg titres (Baptista, Kramvis & Kew, 1999). 
Although these types of mutations have been described in South African HCC patients, the 
effect of the combination of mutations has not been investigated. In Asia, the presence of 
mutations in the BCP and pre-core regions serve as a predictor of HCC development (Tong 
et al., 2006, 2007). The risk for hepatocarcinogenesis is shown to highly increase with the 
combination of pre-S deletions, T1762/A1764, and A1899 rather than the presence of a single 
mutation, although each is an independent risk factor (Chen et al., 2008). 
Extrapolating from observations from Asian studies, it could be hypothesized that the seven 
samples with these combined mutations at the BCP, pre-core and pre-S regions of the HBV 
strains are at an increased risk of developing HCC as compared to the ones harbouring single 
mutations. However, a longitudinal study would be required to test this hypothesis. 
The chronic HBV HIV-exposed infant from Cape Town presented in chapter 3, was found to 
have the double T1762/A1764 BCP mutation at 12 weeks of age. Based on the hypothesis 
that different HBV mutations appear with time at different replicative phases of CHB, the 
presence of the double BCP mutation at such an early age in this infant could be used as a 
marker of prediction of hepatocarcinogenesis at a later stage of the disease.  
The mutations associated with a high risk of liver cancer found in this cohort (antenatal and 
paediatric) could be used as markers of risk of  HCC development, as has previously been 
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done in Asia, thus allowing a better screening  of CHB patients for those at high risk of HCC. 
Further work is needed to explore this hypothesis. 
 
Strengths and limitations of study  
The strengths of this study were the large sample size available for screening and study 
design. Moreover, because perinatal transmission has been underestimated in SA, this study 
is the first to report on MTCT of mutant viruses and to report on the prevalence of HCC-
related mutation in an antenatal setting. 
However, the study had a few limitations which could affect the interpretation of these 
results. The absence of maternal ART information would have been useful to determine if the 
reduced maternal HBV viral load had an impact on the HBsAg prevalence described in these 
HIV-exposed infants. Furthermore, maternal HBV status was unknown and could have 
helped to determine the risk of perinatal transmission. Lastly, the samples were collected 
more than two years ago from three different locations and patients were lost to follow up, 
making a prediction of chronic infection impossible. We were only able to trace and follow 
up one HBV-infected infant.  
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CHAPTER 6: CONCLUSION 
 
This study has found an HBV infection prevalence of 0.6% (5/850) in a cohort of HIV-
exposed infants. Only one infant was able to be contacted for follow up and showed 
persistence of HBsAg. He was likely to have been infected vertically. Phylogenetic analysis 
revealed similarities between the mother and infant pair sequences on the core region of the 
HBV genome with a mutation in the BCP domain. No mutation related to drug resistance or 
immune escape was found in the infant at 14 months of age. As he was HIV positive, he had 
been on an ART regimen including 3TC for approximately two years with no detectable viral 
load at follow up. However, the similarity between the mother and baby pair sequences with 
the same BCP mutation was evidence of the transmission of a mutant virus from the mother 
to her child.  
A number of factors such as HBeAg positivity, high HBV DNA viral load (Dwevedi et al., 
2011) and HIV status (Thumbiran et al., 2014) have been associated with an increased risk 
of vertical transmission in HBV-infected pregnant women. However, these variables were 
unknown at the screening , but the fact that vertical transmission occurred suggests that the 
mother could have been positive for HBeAg with a high viral load at the time of birth. 
Although this study only reports few infant HBV infections, five other studies conducted in 
SA have reported the high risk of vertical transmission in HIV-infected pregnant women with 
high HBV viral load (Burnett et al., 2007; Andersson et al., 2012, 2013; Hoffman et al., 
2014; Thumbiran et al., 2014). This calls for the importance of screening pregnant women 
for HBV markers and possibly HBV viral load during their pregnancy with the aim of 
suppressing viral load and reducing the risk of transmitting HBV infection to their infants. 
Moreover, HB vaccination around the time of birth, as recommended by the WHO, reduces 
the risk of acquiring infection. HB vaccination at birth has been shown to reduce HBV 
transmission from in SSA as compared to a 6-week dose of the vaccine (Ekra et al., 2008). 
Longitudinal studies, assessing the impact of screening and treating pregnant women and 
administering birth dose vaccine on HBV perinatal transmission, need to be performed to 
show the reduction of mother to child transmission in Africa. 
 Furthermore, the BCP mutation found in the followed up infant, transmitted from the 
mother, led to the questions of whether these mutations could be transmitted from mothers 
and whether HIV could impact on the evolution of these mutants so they could be at greater 
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risk of HCC. The transmitted mutation, A1762T/G1764A BCP mutation has been shown to 
be a risk factor for liver tumour development in CHB patients in Asia. Other HCC-related 
mutations in the pre-S and pre-core regions were described in antenatal women at high risk of 
perinatal transmission. The combination of these mutations has been established as a higher 
risk of liver malignancy formation as compared to single mutations (Chen et al., 2008). 
Based on the evidence that mutant virus could be transmitted vertically, this leaves the infants 
born from these mothers at high risk of acquiring these mutations hence at a greater risk of 
developing liver tumours. This study provides preliminary results which need to be 
confirmed with further longitudinal studies to determine whether there is an increased risk for 
transmission of these mutant viruses to infants and whether they might increase the risk of 
HCC.  
Perinatal HBV transmission of mutant virus, a problem that has not been well-described in 
HBV infected children in SA, is described in this study.  Furthermore, the higher presence of 
HCC-related mutations in HIV-infected pregnant women as compared to HIV-uninfected 
represents an important public health problem which deserves further study. More work is 
needed to (1) determine why a higher prevalence of HCC-related mutations was shown in 
HIV-infected women as compared to HIV-uninfected and, (2) to determine the risk of HBV 
transmission in infants born from HBV mono-infected as compared to HIV/HBV co-infected 
women. It is also crucial to assess how HBV antenatal screening and a birth dose of the HB 
vaccine could be introduced in SA for a better control and possible eradication of mother to 
child transmission in SSA. 
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